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ABSTRACT 
      Breast cancer is a highly heterogeneous disease classified clinically by expression of 
estrogen receptor alpha ERα, progesterone receptor, and human epidermal growth 
factor receptor. Molecular expression profiling identified a luminal breast cancer sub-type 
that can be sub-divided into luminal A and B. Compared to luminal A, luminal B tumors 
have increased proliferation, poor prognosis, endocrine therapy resistance, and complex 
genomes, including amplification of the 8p11-p12 genomic region. This amplicon occurs 
in 15% of primary breast tumors, correlates with poor prognosis and tamoxifen 
resistance, and harbors several oncogenes. Two of these oncogenes, ASH2L and NSD3 
(WHSC1L1), promote transcription via epigenetic modification of histone proteins. NSD3 
has a long isoform that is associated with di-methylation of lysine 36 on histone 3 
(H3K36me2) and a short isoform that lacks a catalytic SET domain but retains the ability 
to interact with chromatin. ASH2L also lacks a catalytic SET domain yet is tightly and 
specifically linked to tri-methylation of lysine 4 on histone 3 (H3K4me3) in gene 
promoters. In this study, we tested the hypothesis that ASH2L and NSD3 cooperate to 
regulate expression of a suite of genes important in breast cancer, including ESR1, 
which encodes ERα. We discovered that NSD3-short is the major oncogenic isoform of 
NSD3 and its amplification and overexpression leads to overexpression and estrogen-
independent activation of ERα. We also demonstrated that knockdown of ASH2L 
reduces H3K4me3 specifically in promoters of genes important to cell cycle progression. 
ASH2L also regulates promoter H3K4me3 at NSD3 and expression of both NSD3 and 
ERα. Knockdown of ASH2L reduced sensitivity to the cell cycle inhibitor palbociclib in 
the 8p11-p12 amplicon-bearing SUM-44 cell line. Together, the data presented here 
identify a role for ASH2L and NSD3 in cooperative regulation of genes important to cell 
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cycle regulation, including ESR1, and demonstrate that ERα is active in an estrogen-
independent manner in the context of overexpression of these oncogenes. We have 
discovered a novel mechanism of endocrine resistance in luminal B breast cancers and 
provided evidence for the 8p11-p12 amplicon as a biomarker of patients who will 
respond to cell cycle inhibitors and epigenetic therapies against histone 
methyltransferase enzymes. 
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CHAPTER 1: Introduction and Review of Literature 
1.1. Breast Cancer Classification and Treatment 
a. Breast cancer history, classification, and estrogen receptor alpha (ERα) 
 Breast cancer is the most common cancer in women worldwide and accounts for 
more than 40,000 deaths in the United States annually (Morris and Carey 2007, Chang 
2012). As early as 1896, oophorectomy was described by Beatson as providing benefit 
to patients with advanced breast cancer (Cadoo et al. 2013, Mancuso and Massarweh 
2016, Tabarestani et al. 2016), although the mechanism, now known to be estrogen 
deprivation, would not be understood until the discovery of estrogen receptor alpha 
(ERα) by Elwood Jensen et al. in 1958 (Hartman et al. 2009, Pritchard 2013). With this 
discovery, the importance of estrogen signaling in mammary gland ductal development 
and breast cancer genesis and progression was identified and became the focus of 
targeted therapies in breast cancer treatment.  
 Currently, breast cancer is diagnosed and treated based on clinicopathologic 
analysis (Geyer et al. 2012, Cadoo et al. 2013, Netanely et al. 2016). Tumors are 
assessed by immunohistochemistry (IHC) for estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) (Cui et al. 2005, 
Reis-Filho and Pusztai 2011, Eroles et al. 2012). Tumors negative for all three markers 
are known as triple negative breast cancers (TNBC), are treated primarily with 
chemotherapy, and have the worst prognosis (Sorlie et al. 2001, Eroles et al. 2012, 
Cobain and Hayes 2015). HER2-amplified tumors are treated with chemotherapy and 
targeted HER2 antibody therapies (Yang et al. 2009, Cobain and Hayes 2015). Tumors 
expressing ER usually also express PR as its expression is under ER regulation, with 
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loss of PR acting as a marker of poorer prognosis (Margueron et al. 2004, Cui et al. 
2005, Cornen et al. 2014). Tumors expressing both ER and PR are termed “hormone 
receptor-positive” and make up the majority of breast cancer cases (Scott et al. 2011, 
Geyer et al. 2012). Approximately 70-80% of breast cancers express ERα (ER+ breast 
cancer) and have the best prognosis due to the less aggressive nature of the tumors and 
availability of therapies targeting ERα function (Schiff et al. 2003, Cui et al. 2005, Howell 
2006, Robertson 2007, Thomas and Munster 2009, Pathiraja et al. 2010, 2012, Chang 
2012, Geyer et al. 2012, Cadoo et al. 2013, Ignatiadis and Sotiriou 2013, Kerdivel et al. 
2013, Dabydeen and Furth 2014, Lumachi et al. 2015, Nagaraj and Ma 2015, Wang and 
Yin 2015, De Marchi et al. 2016, Selli et al. 2016). 
 ERα is encoded by the ESR1 gene and is a transcription factor that responds to 
estrogens, most predominantly 17β-estradiol (Hartman et al. 2009, Pathiraja et al. 2010, 
Chang 2012). ERα is comprised of two transcriptional activating domains, AF-1 and AF-
2, which flank a central hinge region that includes the ligand-binding and DNA-binding 
domains (Figure 1.1) (Cui et al. 2005, Nicholson and Johnston 2005, Hartman et al. 
2009, Kerdivel et al. 2013, Wang and Yin 2015, Angus et al. 2016). AF-1 is ligand-
independent and is activated by phosphorylation and other post-translational 
modification events while AF-2 is ligand-dependent (Cui et al. 2005, Dowsett et al. 2005, 
Nicholson and Johnston 2005, Hartman et al. 2009, Thomas and Munster 2009, Chang 
2012, Kerdivel et al. 2013, Zhang et al. 2013, Nagaraj and Ma 2015, Wang and Yin 
2015, De Marchi et al. 2016, Steelman et al. 2016, Tabarestani et al. 2016). Binding of 
estradiol at the ligand-binding domain stimulates dimerization and binding to chromatin, 
recruitment of co-regulatory molecules, and gene transcription (Cui et al. 2005, 
Nicholson and Johnston 2005, Howell 2006, Thomas and Munster 2009, Fedele et al. 
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2012, Kerdivel et al. 2013, Zhang et al. 2013, Nagaraj and Ma 2015, Wang and Yin 
2015, De Marchi et al. 2016, Steelman et al. 2016, Tabarestani et al. 2016). The 
resulting effect on gene expression is highly cell- and tissue-type specific and is 
regulated by ligand type, post-translational modifications to ERα, other transcription 
factors, the balance of ERα co-activator versus co-repressor components available, the 
epigenetic state of the chromatin, growth factor signaling pathways, and many other 
factors (Schiff et al. 2003, Margueron et al. 2004, Cui et al. 2005, Kristensen et al. 2005, 
Nicholson and Johnston 2005, Thomas and Munster 2009, Pathiraja et al. 2010, Chang 
2012, Fedele et al. 2012, Hervouet et al. 2013, Kerdivel et al. 2013, Zhang et al. 2013, 
Nagaraj and Ma 2015, Wang and Yin 2015, De Marchi et al. 2016). Transcript variants of 
ERα with non-genomic functions, such as cross-talk with growth factor receptor signaling 
pathways, have also been well-described in the literature but are beyond the scope of 
this review (Howell 2006, Chang 2012, Fedele et al. 2012, Kerdivel et al. 2013, Zhang et 
al. 2013, Wang and Yin 2015, Steelman et al. 2016). Generally, estrogens exert 
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mitogenic effects via ERα-mediated transcriptional activation of genes involved in cell 
cycle and other cellular growth processes (Sorlie et al. 2001, Allred et al. 2004, Kerdivel 
et al. 2013, Wang and Yin 2015). 
b. Treatment of ER+ breast cancer 
 The selective estrogen receptor modulator (SERM) tamoxifen was introduced in 
the 1970s and has since been the most widely used endocrine therapy in advanced 
breast cancer (Morris and Wakeling 2002, Margueron et al. 2004, McKeage et al. 2004, 
Hartman et al. 2009, Huang et al. 2011, Chang 2012, Lumachi et al. 2015, Nagaraj and 
Ma 2015, De Marchi et al. 2016, Selli et al. 2016). The introduction of tamoxifen saw a 
reduction in breast cancer recurrence by 39% and mortality by 30% (Nagaraj and Ma 
2015). Tamoxifen binds to ERα at the ligand-binding domain and prevents signaling 
through the ligand-dependent AF-2 domain but is unable to block the AF-1 domain, 
which is activated through phosphorylation in a ligand-independent manner (McKeage et 
al. 2004, Dowsett et al. 2005, Howell 2006, Hartman et al. 2009, Chang 2012). As a 
result, tamoxifen exerts both antagonist and agonist effects on ERα (Morris and 
Wakeling 2002, Schiff et al. 2003, Allred et al. 2004, Margueron et al. 2004, Dowsett et 
al. 2005, Nicholson and Johnston 2005, Hartman et al. 2009, Chang 2012, Dabydeen 
and Furth 2014, Lumachi et al. 2015, De Marchi et al. 2016, Selli et al. 2016).  
 The benefit of tamoxifen use in breast cancer is centered upon its role as an ERα 
antagonist in breast tissue. The active metabolite of tamoxifen, 4-hydroxytamoxifen 
(4OH-tamoxifen), binds ERα with 25% of the affinity of 17β-estradiol and induces a 
conformational change to prevent recruitment of co-activators and instead favoring co-
repressor recruitment, thereby blocking ERα-mediated transcription of proliferative 
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genes (Morris and Wakeling 2002, Margueron et al. 2004, Cui et al. 2005, Dowsett et al. 
2005, Howell 2006, Chang 2012, De Marchi et al. 2016). Tamoxifen functions as an ERα 
agonist in bone to maintain bone density and blood to reduce serum cholesterol, positive 
effects for patients, but also in liver and uterus, increasing the risk of developing 
endometrial cancer with prolonged use (Morris and Wakeling 2002, Nicholson and 
Johnston 2005, Howell 2006, Hartman et al. 2009, De Marchi et al. 2016). Many adverse 
effects of tamoxifen are due to its agonist activity, including gastrointestinal disturbances 
(e.g. nausea, vomiting), hot flushes, joint pain, and headaches (McKeage et al. 2004, 
Howell 2006). The recommended duration of tamoxifen use is at least 5 years after 
diagnosis and initial treatment and these adverse effects are the primary cause of non-
compliance during adjuvant therapy (Chanrion et al. 2008, Scott et al. 2011, Chang 
2012, Ignatiadis and Sotiriou 2013, Lumachi et al. 2015, Nagaraj and Ma 2015).  
 Due in part to the agonist properties of tamoxifen, recurrence while on therapy 
occurs (Nicholson and Johnston 2005, Robertson 2007, Huang et al. 2011, Bilal et al. 
2012, Chang 2012, Cadoo et al. 2013, Ignatiadis and Sotiriou 2013, Kerdivel et al. 2013, 
Nagaraj and Ma 2015, Kumler et al. 2016, Lim et al. 2016, Mancuso and Massarweh 
2016, Selli et al. 2016, Tabarestani et al. 2016). As such, additional non-steroidal agents 
similar to tamoxifen have been developed, such as toremifene, idoxifene, and 
droloxifene, but none have treatment advantages over tamoxifen (Morris and Wakeling 
2002). To circumvent tamoxifen resistance, another class of anti-estrogen therapies was 
developed to abrogate estrogen-mediated activation of transcription via ERα through a 
reduction in circulating estrogen levels (Morris and Wakeling 2002, Nicholson and 
Johnston 2005, Kerdivel et al. 2013, Robertson et al. 2014, Lumachi et al. 2015). 
Estrogens are derived from androgens by the enzyme aromatase in peripheral tissues, 
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especially adipose tissue in postmenopausal women, as well as within the tumor in the 
context of breast cancer (Morris and Wakeling 2002, Nicholson and Johnston 2005, 
Pritchard 2013, Dabydeen and Furth 2014, Lumachi et al. 2015, Nagaraj and Ma 2015, 
Selli et al. 2016). First-generation aromatase inhibitors (AIs) did not demonstrate 
therapeutic benefit over tamoxifen, but the third-generation non-steroidal AIs anastrozole 
and letrozole and steroidal exemestane surpassed tamoxifen as first-line therapy for 
ER+ breast cancer in postmenopausal women (Morris and Wakeling 2002, Cui et al. 
2005, Nicholson and Johnston 2005, Ariazi et al. 2006, Howell 2006, Robertson 2007, 
Hartman et al. 2009, Robertson et al. 2014). AIs increase gonadotropin releasing 
hormone (GRH) in premenopausal patients, which results in increased estrogen levels, 
therefore these compounds are under investigation in conjunction with GRH-inhibitors to 
extend their use to this patient population (Tabarestani et al. 2016). The introduction of 
AIs as treatment alternatives, both as first-line therapies and for patients who failed to 
respond to tamoxifen, was a major step forward in breast cancer management. 
 Aromatase inhibitors have shown improvement in patient survival and lack the 
increased risk of endometrial cancer of tamoxifen (Chang 2012). AIs have similar 
adverse effects otherwise, including disease recurrence despite initial response (Fedele 
et al. 2012, Ignatiadis and Sotiriou 2013, Nagaraj and Ma 2015, Mancuso and 
Massarweh 2016). More recently, pure ERα antagonists were developed, known as 
selective estrogen receptor degraders (SERDs), such as fulvestrant (ICI-182,780) 
(Dowsett et al. 2005, Howell 2006, Johnston and Cheung 2010). Fulvestrant binds to 
ERα at the ligand-binding domain with 89% the affinity of 17β-estradiol, inducing a 
different conformational change than tamoxifen that results in inhibition of dimerization, 
blocking both the AF-1 and AF-2 domains from participating in transcription (Morris and 
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Wakeling 2002, McKeage et al. 2004, Dowsett et al. 2005, Nicholson and Johnston 
2005, Howell 2006, Scott et al. 2011, Lumachi et al. 2015). This results in complete 
abrogation of transcription of ERα-target genes and destabilization of ERα, prompting 
degradation by the ubiquitin-proteasome complex (Morris and Wakeling 2002, 
Margueron et al. 2004, McKeage et al. 2004, Dowsett et al. 2005, Johnston and Cheung 
2010, Scott et al. 2011). Clinical trials revealed that fulvestrant is at least as effective as 
anastrozole and was thus approved in 2002 for the treatment of hormone receptor-
positive metastatic breast cancer that had failed other endocrine therapies (Dowsett et 
al. 2005). In 2010, fulvestrant was approved as a second-line therapy for 
postmenopausal patients with hormone receptor-positive breast cancer (Scott et al. 
2011, Ignatiadis and Sotiriou 2013). 
 Due to the different mechanism of action of SERDs, cross-resistance to 
tamoxifen and anastrozole is rare (McKeage et al. 2004, Dowsett et al. 2005, Johnston 
et al. 2005, Howell 2006, Johnston and Cheung 2010, De Marchi et al. 2016). Adverse 
effects of fulvestrant are similar to the other endocrine therapies and slightly less 
common, with gastrointestinal disturbances and joint pain being most cited (McKeage et 
al. 2004, Howell 2006, Scott et al. 2011, Lumachi et al. 2015). Clinical trials focused on 
optimal dosing of fulvestrant, however, revealed the dose-dependent nature of this drug 
for reducing ERα levels (Robertson 2007, Scott et al. 2011, Robertson et al. 2014, 
Nagaraj and Ma 2015). The ability to achieve steady-state levels adequate for complete 
inhibition of ERα in patients, especially those with highly ER-positive tumors, without 
reaching the limits of adverse effects is difficult (Robertson 2007). This therapy is also 
given via intramuscular injection as opposed to orally, affecting patient compliance 
(McKeage et al. 2004). A second generation of SERD therapies are under development 
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and testing to attempt to combat these issues (Angus et al. 2016, Mancuso and 
Massarweh 2016). 
 Unfortunately, resistance to endocrine therapy of all types is common (Allred et 
al. 2004, Kerdivel et al. 2013, Pritchard 2013, Nagaraj and Ma 2015). Absence of ERα is 
a very good negative predictor of response to endocrine therapy and its expression is an 
accurate positive predictor of response in approximately 50% of ER+ breast cancers 
(Lonning et al. 2005, Thomas and Munster 2009, Shiu et al. 2010, Cobain and Hayes 
2015, Wang and Yin 2015, Azim et al. 2016). Since half of ER+ breast cancer patients 
do not demonstrate durable response to endocrine therapy, there is a pressing need to 
discover novel biomarkers that will complement ERα in predicting endocrine therapy 
response (Chanrion et al. 2008, Thomas and Munster 2009, Reis-Filho and Pusztai 
2011, Geyer et al. 2012, Habashy et al. 2012, Cobain and Hayes 2015, Mancuso and 
Massarweh 2016, Selli et al. 2016, Rakha and Green 2017). Similarly, many groups are 
investigating parallel processes, such as activation of the PI3K/AKT/mTOR pathway and 
the cyclin D1/CDK4/6-mediated cell cycle pathway, to determine if coupling endocrine 
therapy with inhibitors of these pathways will improve patient outcomes (Caldon et al. 
2012, Ignatiadis and Sotiriou 2013, Dabydeen and Furth 2014, Lumachi et al. 2015, 
Nagaraj and Ma 2015, Azim et al. 2016, Knudsen and Witkiewicz 2016, Kumler et al. 
2016, Lim et al. 2016, Mancuso and Massarweh 2016, Steelman et al. 2016). Indeed, 
these inhibitors have shown promising results in subsets of breast cancer patients in 
combination with endocrine therapy (Cornen et al. 2014, Nagaraj and Ma 2015, Azim et 
al. 2016, Knudsen and Witkiewicz 2016, Mancuso and Massarweh 2016, Steelman et al. 
2016). Some of the mechanisms of endocrine therapy resistance are known, such as 
loss of ERα expression, ESR1 amplifications, point mutations in the ligand binding 
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domain of ERα, and aberrant activation of growth factor signaling pathways, but these 
alterations do not account for all patients with poor response to endocrine therapies (Cui 
et al. 2005, Loi et al. 2009, Pathiraja et al. 2010, Chang 2012, Fedele et al. 2012, 
Kerdivel et al. 2013, De Marchi et al. 2016, Selli et al. 2016, Tabarestani et al. 2016). 
More research is necessary to determine additional mechanisms behind endocrine 
therapy resistance in order to identify biomarkers for which patients will require 
combinatorial treatment strategies and to identify potential targets for novel therapies.  
 Breast cancer has long been described as a highly heterogenetic disease (Carey 
et al. 2006, Morris and Carey 2007, Elsheikh et al. 2009, Kao et al. 2009, Ellis et al. 
2012, Cadoo et al. 2013, Dabydeen and Furth 2014, Cobain and Hayes 2015, Selli et al. 
2016). The current clinical and histopathologic parameters used to classify breast 
cancers are insufficient to capture this diversity and predict treatment response (Sorlie et 
al. 2001, Sorlie et al. 2003, Kao et al. 2009, Habashy et al. 2012, Tang and Tse 2016). 
With expansion of global-scale profiling techniques such as microarrays, next generation 
sequencing, and many others, there has been a paradigm shift toward breast cancer 
classification based on molecular expression profiling. 
c. Molecular profiling of breast cancers 
 In 2000, Perou et al. identified two main types of breast cancer that correlate to 
ERα status of the tumors: those that express genes known to be associated with basal 
cells and those with a more luminal cell-like expression profile (Perou et al. 2000). Many 
groups since have advocated that the delineation of these two cancer types is so robust 
that they should be treated as different diseases and given their own cancer classes in 
large databases such as the cancer genome atlas (TCGA) (Sorlie et al. 2001, Reis-Filho 
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and Pusztai 2011, Geyer et al. 2012, Habashy et al. 2012). The basal tumors then 
subdivide into basal-like, normal-like, and HER2+ subtypes while the luminal group 
divides into luminal A and luminal B (Figure 1.2) (Sorlie et al. 2001). Even within the 
basal and luminal groups, a high degree of heterogeneity remains (Sorlie et al. 2001, 
Morris and Carey 2007, Shiu et al. 2010, Geyer et al. 2012, Ignatiadis and Sotiriou 2013, 
Cornen et al. 2014). Indeed, the luminal group, which are primarily ER+ and express ER-
associated genes such as ESR1, XBP1, CCND1, and GATA3 (Perou et al. 2000, Sorlie 
et al. 2001, Sotiriou et al. 2003, 2012, Habashy et al. 2012, Shan et al. 2014, Tang and 
Tse 2016), has been a topic of controversy in the field. Some advocate for the existence 
of three subtypes, luminal A, B, and C, while others have focused on identifying 
clinically-useful markers to separate luminal A tumors from luminal B, and others still 
have argued that this tumor type actually comprises a continuum rather than individual 
and separable subtypes of breast cancer (Shiu et al. 2010, Geyer et al. 2012, Netanely 
et al. 2016, Tang and Tse 2016). The St Gallen International Consensus on the Primary 
Therapy of Early Breast Cancer 2013 separated this group of tumors into luminal A, 
luminal B HER2-, and luminal B HER2+ (Judes et al. 2016). 
 Regardless of the specific breakdown, it is generally accepted that luminal A 
tumors differ from luminal B tumors in many characteristics (Figure 1.2). Luminal A 
tumors are the most common type of all breast cancers (approximately 55%) and have 
the highest ERα and ERα-target gene expression, including PR, low expression of genes 
associated with proliferation, no HER2 amplifications, low rates of GATA3 mutations, 
simple karyotypes, and higher rates of PIK3CA mutations than luminal B tumors (Raica 
et al. 2009, Shiu et al. 2010, Geyer et al. 2012, Ignatiadis and Sotiriou 2013, Tang and 
Tse 2016). These tumors tend to be well-differentiated and include all cases of lobular 
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carcinoma in situ as well as most cases of invasive lobular carcinoma and multiple other 
histologic subtypes (Shiu et al. 2010, Eroles et al. 2012, Dabydeen and Furth 2014). 
Luminal A tumors tend to be highly responsive to endocrine therapies and have 
significantly better prognosis and relapse rates than luminal B tumors, which comprise 
approximately 12% of all breast cancers and have overall lower expression of ERα and 
associated genes (Raica et al. 2009, Turner et al. 2010, Tang and Tse 2016). Up to 6% 
of luminal B tumors are classified as ER-negative (Eroles et al. 2012). These tumors 
have higher expression of proliferation-associated genes, including MKI67, CCNB1, and 
MYBL2, and indeed these genes are often cited as the major distinction between luminal 
A and B tumors (Cheang et al. 2009, Sircoulomb et al. 2011, Eroles et al. 2012, Ades et 
al. 2014). The luminal B subtype also tends to be more aggressive, higher grade, less 
differentiated, primarily invasive ductal carcinoma of multiple histologic types, usually 
HER2-negative (although half of HER2+ tumors fall under this category), and less 
commonly PR+ than luminal A (Raica et al. 2009, Eroles et al. 2012, Ignatiadis and 
Sotiriou 2013, Tang and Tse 2016). Complex karyotypes with multiple copy number 
aberrations are common with a lower PIK3CA (32% vs 45%) but higher TP53 (32% vs 
13%) mutation rate and more frequent gain of MDM2 and cyclin D1 (Geyer et al. 2012, 
Ades et al. 2014, Tang and Tse 2016). Luminal B tumors also tend to have poorer 
response to endocrine therapy than their luminal A counterpart (Turner et al. 2010, Tang 
and Tse 2016). Although luminal B tumors do respond better to chemotherapy than 
luminal A, response is still much poorer than the other breast cancer subtypes, leaving 
few good therapeutic options for these patients (Sircoulomb et al. 2011, Eroles et al. 
2012, Cadoo et al. 2013, Ignatiadis and Sotiriou 2013, Kerdivel et al. 2013). 
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 Defining molecular subtypes has major implications for identifying and 
developing novel therapeutic strategies for breast cancer management, therefore a 
means by which luminal A and luminal B tumors can be clinically differentiated, both 
from the other intrinsic subtypes as well as from each other, is essential for improving 
therapeutic interventions (Miller et al. 2009, Cornen et al. 2014, Tang and Tse 2016, 
Rakha and Green 2017). Several attempts have been made to identify a genetic 
signature based on the initial intrinsic gene sets that would function as a prognostic and 
predictive clinical assay (van 't Veer et al. 2002, Morris and Carey 2007, Chanrion et al. 
2008, Cheang et al. 2009, Geyer et al. 2012, Ignatiadis and Sotiriou 2013, Luo et al. 
2017). Though there is moderate clinical utility, these attempts have largely been unable 
to capture the biologic complexity and accurately predict tumor classification (Sorlie et al. 
2006, Reis-Filho and Pusztai 2011, Geyer et al. 2012, Ignatiadis and Sotiriou 2013, Selli 
et al. 2016, Tang and Tse 2016). The exception has been Oncotype DX, an RT-PCR-
based test that predicts benefit of chemotherapy and risk of distant recurrence and has 
demonstrated usefulness in predicting patients who will derive minimal benefit from 
chemotherapy (Morris and Carey 2007, Reis-Filho and Pusztai 2011, Bilal et al. 2012, 
Geyer et al. 2012, Cobain and Hayes 2015).  
 Clinicopathologic markers in addition to ER, PR, and HER2 have also been 
proposed to distinguish the intrinsic subtypes. The addition of IHC assessment of basal 
cytokeratin expression, such as CK5, has improved the identification of luminal- versus 
basal-type tumors (Raica et al. 2009, Eroles et al. 2012, Tang and Tse 2016). The two 
major proteins proposed to differentiate luminal A and B by IHC are PR and Ki-67, which 
is a marker of proliferation. Cutoffs of 20% for PR and 14% for Ki-67 have been 
endorsed by the 2011 St. Gallen International Breast Cancer Conference, with luminal A 
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tumors having higher PR expression and luminal B having higher Ki-67 (Eroles et al. 
2012, Geyer et al. 2012, Ignatiadis and Sotiriou 2013, Ades et al. 2014, Tang and Tse 
2016). Due to the lack of true bimodal distribution of these subtypes, these cutoffs are 
subjective, arbitrary, and vary widely based on tumor heterogeneity, even within one 
tumor biopsy (Geyer et al. 2012, Tang and Tse 2016). Additionally, lack of 
standardization of these tests poses another complicating factor in using IHC to define 
tumor subtypes (Eroles et al. 2012, Geyer et al. 2012). Indeed, even IHC assessment of 
ERα expression is highly variable and subjective. ER+ tumors are defined by at least 1% 
of the cells staining positive for nuclear ERα and are treated with endocrine therapy, 
despite studies demonstrating that tumors with 1-10% ERα staining behave much more 
like basal tumors (Allred et al. 2004, Dabydeen and Furth 2014, Lumachi et al. 2015, 
Tang and Tse 2016). Identification of reliable biomarkers that can encompass the vast 
heterogeneity of breast cancers is essential to moving this field forward and improving 
patient outcomes. 
1.2. Breast Cancer Genomics 
a. Genomic alterations in luminal B breast cancer 
 Although breast cancer classification by molecular profiling is complicated, 
evolving, and not yet ready for full clinical use, some of the information obtained from 
these studies can be immediately utilized to inform clinical trial design and spark novel 
scientific studies that will improve understanding of breast cancer pathogenesis and lead 
to identification of potential therapeutic targets. One of the major differences between 
luminal A and B breast cancer subtypes, other than the difference in expression of 
genes associated with proliferation, is the genomic instability associated with luminal B 
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tumors (Kristensen et al. 2005, Geyer et al. 2012, Cornen et al. 2014). As previously 
mentioned, luminal A tumors tend to have relatively simple karyotypes (Kao et al. 2009, 
Geyer et al. 2012). They are often diploid with infrequent translocations and copy 
number alterations (CNAs), although low-level gains of 1q and 16p and deletions of 16q 
are not uncommon, especially as the tumors become higher grade and ERα and 
proliferation gene expression patterns move more toward the luminal B profile 
(Bergamaschi et al. 2006, Shiu et al. 2010, Geyer et al. 2012, Reynisdottir et al. 2013, 
Ades et al. 2014, Cornen et al. 2014). This tendency again highlights the continuum 
pattern rather than bimodal distribution of these two luminal breast cancer subtypes.  
 Three major genomic phenotypes have been described in breast cancer (Shiu et 
al. 2010). In contrast to the “simplex” phenotype of luminal A, luminal B tumors have 
much greater genomic instability and frequency of high-level CNAs and aneuploidy (Shiu 
et al. 2010, Cornen et al. 2014). These tumors fall into a “firestorm” or “amplifier” pattern 
characterized by multiple recurrent amplifications (Shiu et al. 2010, Sircoulomb et al. 
2011). The third breast cancer genomic phenotype is termed “sawtooth” or “complex” 
pattern, which demonstrates alternating low-level gains and deletions that affect multiple 
chromosomes in the same tumor type (Shiu et al. 2010). These three phenotypes are 
highly correlated with tumor grade (Shiu et al. 2010, Geyer et al. 2012, Habashy et al. 
2012, Cornen et al. 2014). Luminal B tumors often have losses of Xp, 22q, 18p, 16q, 
17q, 14q, 13q, 11q, 10q, 9p, 8p, 6q, 4p, and 1p and gains of 20q, 17q, 16p, 11q, 10p, 
8q, and 1q (Garcia et al. 2005, Reis-Filho et al. 2006, Bernard-Pierrot et al. 2008, 
Haverty et al. 2008, Shiu et al. 2010, Sircoulomb et al. 2011, Geyer et al. 2012, Habashy 
et al. 2012).  
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 In addition to large areas of chromosomal gains and losses, luminal B tumors 
often have more focal CNAs (Yang et al. 2006, Sircoulomb et al. 2011, Geyer et al. 
2012, Ades et al. 2014, Cornen et al. 2014). High level amplification of specific genomic 
regions known as amplicons is a common mechanism of overexpression of the 
oncogenes found in that location (Ray et al. 2004, Bergamaschi et al. 2006, Ellis et al. 
2007, Shiu et al. 2010, Yang et al. 2010, Bilal et al. 2012). Since amplicons frequently 
harbor multiple candidate oncogenes, identifying the “drivers” from the “passengers” is 
key to elucidating drug targets (Garcia et al. 2005, Haverty et al. 2008, Shiu et al. 2010, 
Mahmood et al. 2013, Chen et al. 2014, Irish et al. 2016). For example, amplification of 
17q12 is well-known to induce overexpression of the HER2 oncogene and is associated 
with poor endocrine response and outcome (Still et al. 1999, Sorlie et al. 2001, Yang et 
al. 2004, Bilal et al. 2012). As HER2 is a driving oncogene, targeted therapies such as 
trastuzumab, a monoclonal antibody directed toward HER2, has been a highly 
successful intervention (Yang et al. 2010). Similarly, other amplicons are known to 
harbor driver oncogenes. C-MYC is found on the 8q24 amplicon (Still et al. 1999, Ray et 
al. 2004, Yang et al. 2004, Yang et al. 2006, Bernard-Pierrot et al. 2008, Yang et al. 
2010). The 11q12-q14 amplicon, which harbors CCND1, an ERα-target gene associated 
with cell cycle progression, is found in up to 30% of breast cancers and is commonly 
associated with endocrine resistance and poorer outcome in ER+ tumors (Still et al. 
1999, Ray et al. 2004, Yang et al. 2004, Yang et al. 2006, Bernard-Pierrot et al. 2008, 
Kwek et al. 2009, Shiu et al. 2010, Yang et al. 2010, Sircoulomb et al. 2011, Bilal et al. 
2012, Ignatiadis and Sotiriou 2013, Lim et al. 2016). Despite frequent losses of 8p in 
luminal B breast cancers, a small region near the centromere is commonly amplified, 
known as the 8p11-p12 amplicon (Figure 1.3) (Ray et al. 2004, Garcia et al. 2005, Gelsi-
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Boyer et al. 2005, Cooke et al. 2008, Shiu et al. 2010, Turner et al. 2010, Sircoulomb et 
al. 2011, Geyer et al. 2012, Ades et al. 2014, Cornen et al. 2014). This amplicon is fairly 
prevalent, found in 15% of all breast cancers but up to 32% of luminal B breast cancers, 
and is associated with worse outcome in these cancers (Ray et al. 2004, Yang et al. 
2004, Gelsi-Boyer et al. 2005, Shiu et al. 2010, Sircoulomb et al. 2011, Reynisdottir et al. 
2013, Zhang et al. 2013). 
 
b. The 8p11-p12 amplicon and candidate oncogenes 
 Several groups have identified and validated oncogenes from the 8p11-p12 
region and linked this amplicon to luminal B, ER+ tumors with poor metastasis-free 
survival, high histologic grade and Ki-67 proliferation indices, and resistance to 
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endocrine therapy (Ray et al. 2004, Garcia et al. 2005, Streicher et al. 2007, Bernard-
Pierrot et al. 2008, Elsheikh et al. 2009, Shiu et al. 2010, Yang et al. 2010, Sircoulomb et 
al. 2011, Bilal et al. 2012, Geyer et al. 2012, Wu et al. 2012, Mahmood et al. 2013, 
Cornen et al. 2014). The 8p11-p12 amplicon ranges in size from 1 to 11 Mb but is most 
commonly approximately 5 Mb in length (Garcia et al. 2005, Yang et al. 2006, Melchor et 
al. 2007). Although there is variation in the specific start and end sites among tumors 
and cell lines that have been mapped, the NRG1 gene is the most common telomeric 
breakpoint site and usually includes loss of the remaining p arm of chromosome 8 (Ray 
et al. 2004, Garcia et al. 2005, Gelsi-Boyer et al. 2005, Melchor et al. 2007, Cooke et al. 
2008), which harbors important tumor suppressor genes such as DLC1, SGCZ, and 
TUSC3 (Reis-Filho et al. 2006, Cooke et al. 2008) . The amplicon has four sub-regions 
of amplification, named A1-A4 from telomere to centromere (Gelsi-Boyer et al. 2005, 
Melchor et al. 2007, Sircoulomb et al. 2011, Reynisdottir et al. 2013, Turner-Ivey et al. 
2014), with up to 21 genes demonstrating coordinated amplification and overexpression 
in breast cancer, depending on the technique used, thereby identified as candidate 
oncogenes (Ray et al. 2004, Yang et al. 2004, Garcia et al. 2005, Yang et al. 2006, 
Bernard-Pierrot et al. 2008, Cooke et al. 2008, Kwek et al. 2009, Yang et al. 2010, 
Holland et al. 2011, Bilal et al. 2012, Cornen et al. 2014, Turner-Ivey et al. 2014, Irish et 
al. 2016). Additionally, this amplicon is not unique to breast cancer, but has also been 
implicated in lung, bladder, pancreatic, and ovarian cancers (Figure 1.4) (Bernard-Pierrot 
et al. 2008, Yang et al. 2010, Dutt et al. 2011, Mahmood et al. 2013, Luo et al. 2017).  
 Many amplicons are well-known to play major roles in breast tumorigenesis and 
amplification is a common mechanism of overexpression on oncogenes. For example, 
the 17q12 amplicon contains HER2 (ERBB2) and identification and characterization of 
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this oncogene has led to the development of targeted therapies, such as trastuzumab 
(Still et al. 1999, Sorlie et al. 2001, Yang et al. 2004, Yang et al. 2010, Bilal et al. 2012). 
This oncogene has been considered the only driving oncogene from the 17q12 locus, 
but more recent studies have identified other genes, once thought of as passengers, to 
have driving roles in a subset of breast cancers with this amplicon, including GRB7 and 
STARD3 (Sorlie et al. 2001, Ray et al. 2004, Bernard-Pierrot et al. 2008, Haverty et al. 
2008, Mahmood et al. 2013). Similarly, the 8q24 amplicon is common in breast tumors 
and harbors C-MYC, a well-known breast cancer oncogene (Still et al. 1999, Ray et al. 
2004, Yang et al. 2004, Yang et al. 2006, Bernard-Pierrot et al. 2008). The 11q12-q14 
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amplicon, which contains CCND1, the gene encoding the cell cycle protein cyclin D1, 
has been shown in numerous studies to enhance breast cancer progression (Still et al. 
1999, Ray et al. 2004, Yang et al. 2004, Yang et al. 2006, Bernard-Pierrot et al. 2008, 
Kwek et al. 2009, Shiu et al. 2010, Yang et al. 2010, Sircoulomb et al. 2011, Bilal et al. 
2012, Ignatiadis and Sotiriou 2013, Lim et al. 2016). This amplicon also harbors CTTN 
(EMS1), GAB2, and other suspected oncogenes. Interestingly, the 11q12-q14 amplicon 
is commonly associated with the 8p11-p12 amplicon and cross-talk between these two 
genomic regions has been suggested, discussed in more detail below (Reis-Filho et al. 
2006, Kwek et al. 2009, Sircoulomb et al. 2011, Bilal et al. 2012, Cornen et al. 2014). 
 Following discovery of the 8p11-p12 amplicon in breast cancer, several groups 
set out to map the region and identify the driver and passenger oncogenes (Still et al. 
1999, Ray et al. 2004, Yang et al. 2004, Garcia et al. 2005, Gelsi-Boyer et al. 2005, 
Yang et al. 2006). Profiling of 8p11-p12 amplicon-bearing tumors and cell lines revealed 
incredible complexity and heterogeneity in this region, with multiple amplicon peaks 
observed (Yang et al. 2004, Reis-Filho et al. 2006, Melchor et al. 2007, Kwek et al. 
2009, Wu et al. 2012, Luo et al. 2017). Several strong candidate oncogenes were 
identified based on commonality of amplification and coordinated overexpression, 
including: FGFR1, ZNF703, BRF2, RAB11FIP1, LSM1, PPAPDC1B, ASH2L, DDHD2, 
EIF4EBP1, KAT6A, TC-1, WHSC1L1, TACC1, ERLIN2, and PROSC (Ray et al. 2004, 
Garcia et al. 2005, Gelsi-Boyer et al. 2005, Yang et al. 2006, Bernard-Pierrot et al. 2008, 
Haverty et al. 2008, Elsheikh et al. 2009, Kwek et al. 2009, Yang et al. 2009, 
Reynisdottir et al. 2013, Zhang et al. 2013, Cornen et al. 2014). Indeed, many of these 
genes have been investigated further and their transforming properties validated. For 
example, TACC1 was implicated by Still et al. (1999) in cell transformation, anchorage-
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independent growth, and proliferation. Similarly, LSM1 has been implicated by Streicher 
et al. (2007) as involved in grow-factor independent growth and soft agar colony-forming 
ability, both properties of transformed cells, when overexpressed in the non-transformed 
MCF10A breast cancer cell line. DDHD2 has also been implicated in regulating insulin-
independent growth and disorganized acini formation in MCF10A cells grown in Matrigel 
when its overexpression is induced (Yang et al. 2010). PPAPDC1B was described by 
Bernard-Pierrot and colleagues as displaying transforming properties when 
overexpressed in a fibroblast cell line and having a negative regulatory effect on ERα 
while also promoting survival, proliferation, anchorage-independent growth in breast, 
lung, and pancreatic cancers (Bernard-Pierrot et al. 2008, Mahmood et al. 2013). This 
group also identified WHSC1L1, a histone methyltransferase, as a significant oncogene 
from the 8p11-p12 genomic region, but suggested it not to be the best avenue of 
investigation due to other oncogenes having greater potential as druggable targets 
(Bernard-Pierrot et al. 2008). They later pursued this gene further and cited its potential 
and importance as a drug target for epigenetic therapies, also mentioning ASH2L, 
another factor involved in histone methylation from the 8p11-p12 amplicon, as potentially 
interesting as well (Mahmood et al. 2013). These two oncogenes will be discussed in 
more detail in subsequent sections. Similarly, our group has also established KAT6A 
(MYST3), a histone acetyltransferase (HAT) discovered as an important gene via RNA-
interference screening, to be essential for proliferation, colony formation, and 
anchorage-independent growth in the amplicon-bearing SUM-52 breast cancer cell line 
(Turner-Ivey et al. 2014). This study also identified several important cancer-related 
genes and biological pathways under control of this chromatin-modifying oncogene.  
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 One hypothesis regarding amplicons is that the smallest area commonly 
amplified will contain the driving oncogene(s). To investigate this concept, a 1 Mb region 
in sub-region A1 was identified as the most conserved area of amplification (Garcia et al. 
2005). Several groups identified five candidate oncogenes from this 1 Mb region based 
on coordinate amplification and overexpression: PROSC, ZNF703 (FLJ14299), ERLIN2 
(C8orf2, SPFH2), BRF2, and RAB11FIP1 (ROC) (Garcia et al. 2005, Melchor et al. 
2007, Haverty et al. 2008, Holland et al. 2011, Reynisdottir et al. 2013). Subsequent 
studies confirmed the transforming potential of several of these genes. ERLIN2 
overexpression in the non-transformed MCF10A cell line resulted in cell proliferation in 
the absence of insulin and insulin-like growth factors, anchorage-independent growth, 
and highly proliferative colony formation (Yang et al. 2010). This gene has been shown 
to act as a “non-classical” oncogene, indirectly promoting cell survival via modulation of 
the stress response by the endoplasmic reticulum, an important adaptation in 
transformed cells (Wang et al. 2012). Little work has been done on BRF2 in 8p11-p12 
amplicon-bearing cells. Our group demonstrated its overexpression can induce insulin-
independent growth in MCF10A cells (Yang et al. 2010) but another group cited its 
elimination from consideration as a potential oncogene due to high expression in 
MCF10A cells at baseline (Kwek et al. 2009). Similarly, PROSC is often identified as a 
strong candidate oncogene (Reis-Filho et al. 2006, Haverty et al. 2008, Kwek et al. 
2009, Yang et al. 2010, Holland et al. 2011, Reis-Filho and Pusztai 2011, Reynisdottir et 
al. 2013, Luo et al. 2017), but is understudied in the context of the 8p11-p12 amplicon. 
RAB11FIP1 is also understudied in this context, but has been implicated in 
PI3K/AKT/mTOR pathway activation in luminal B breast cancer and may play a role in 
protein trafficking (Yang et al. 2010, Cornen et al. 2014). Sircoulomb et al. (2011) and 
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Holland et al. (2011) simultaneously described ZNF703 (FLJ14299) as the only 
candidate oncogene of these five that is commonly and coordinately amplified and 
overexpressed across breast tumors harboring this site of focal amplification. These 
groups identified ZNF703 as a co-factor for a nuclear repressor complex that may 
contribute to transcriptional regulation and control of cell proliferation and clonogenicity 
via regulation of ERα and TGF-β, respectively, and both studies linked the 8p11-p12 
amplicon to endocrine resistance.  
 Although not contained in this 1 Mb region, one of the more well-known 
oncogenes from this amplicon is fibroblast growth factor receptor-1 (FGFR1), which is 
located more proximally in sub-region A2 and amplified in 16-27% of breast cancers 
(Shiu et al. 2010, Turner et al. 2010, Ades et al. 2014). One study linked amplification 
and overexpression of FGFR1 to anchorage-independent proliferation, endocrine 
therapy resistance, and poor prognosis (Ignatiadis and Sotiriou 2013). Interestingly, 
FGFR1 is not always amplified, amplification does not always correlate with 
overexpression, its knockdown does not always result in decreased proliferation, and 
treatment with ligands FGF1 and FGF2 have been shown to actually inhibit proliferation 
of some 8p11-p12 amplicon-bearing breast cancer cells (Still et al. 1999, Ray et al. 
2004, Yang et al. 2004, Haverty et al. 2008, Elsheikh et al. 2009, Turner et al. 2010, 
Mahmood et al. 2013). Therefore, FGFR1 is not universally accepted as a driver of all 
cancers with 8p11-p12 amplification and these tumors are more likely driven by 
oncogenes in close proximity to this gene (Melchor et al. 2007, Elsheikh et al. 2009, 
Turner et al. 2010, Bilal et al. 2012). More recent studies investigating the role of FGFR1 
as a driving oncogene from this genomic region actually identified eight other amplicon 
genes as better predictors of FGFR1 amplification than FGFR1 itself, including ASH2L, 
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BAG4, BRF2, DDHD2, LSM1, PROSC, RAB11FIP1, and WHSC1L1 (NSD3) (Luo et al. 
2017). Two of these genes, ASH2L and NSD3, also mentioned above, are the focus of 
the work presented here and are discussed in detail below. 
 As investigation of the oncogenes from the 8p11-p12 amplicon has progressed, 
new insight has been gained into the function of this genetic change in breast cancer. 
This has led to the development of new hypotheses regarding the potential cooperation 
of the multiple driving oncogenes that have been identified and described. As mentioned 
previously, the 11q12-q14 amplicon has been hypothesized to cooperate with the 8p11-
p12 amplicon due to their coordinated amplification, where amplification of 8p11-12 
occurs in 40% of 11q12-14 amplified cases (Reis-Filho et al. 2006, Kwek et al. 2009, 
Shiu et al. 2010, Yang et al. 2010, Sircoulomb et al. 2011, Bilal et al. 2012, Ignatiadis 
and Sotiriou 2013, Lim et al. 2016). CCND1 (11q13) induces expression of ZNF703 
(8p12) via the RB/E2F pathway  and expression of ZNF703, BAG4, RAB11FIP1, and 
WHSC1L1 (NSD3), all 8p11-p12 amplicon genes, is increased when 11q12-q14 is 
amplified, independent of concomitant 8p11-p12 amplification (Kwek et al. 2009). 
Overexpression of CCND1 in the SUM-44 cell line, which harbors both amplicons, 
resulted in upregulation of these 8p11-p12 amplicon genes. Although not fully explored, 
this study also indicated evidence that FGFR1 and DDHD2 from the 8p11-p12 amplicon 
may interact with C-MYC, a commonly amplified oncogene from the 8q24 region (Kwek 
et al. 2009). Together, this study provides evidence that the complex genomic structures 
of luminal B tumors may be due in part to interactions between driving oncogenes from 
multiple amplicons. 
 It was suggested that oncogenes from the 8p11-p12 amplicon cooperate to 
promote tumorigenesis, a concept that is supported by groups studying this amplicon 
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(Gelsi-Boyer et al. 2005, Yang et al. 2006, Sircoulomb et al. 2011, Wu et al. 2012, Luo et 
al. 2017). This hypothesis of cooperation partially explains the complexity of this 
amplicon and the plethora of oncogenes in this “hot spot” of genomic activity (Ray et al. 
2004). The candidate oncogenes from this region can often be grouped by similar 
function, such as regulation of RNA metabolism, vesicle trafficking, tyrosine kinase 
activity, chromatin maintenance, and regulation of ERα (Gelsi-Boyer et al. 2005, Yang et 
al. 2010, Turner-Ivey et al. 2014, Irish et al. 2016). The latter two functions are of 
particular interest to our group since all three of the 8p11-p12 oncogenes implicated in 
epigenetic regulation of chromatin structure, KAT6A (MYST3), WHSC1L1 (NSD3), and 
ASH2L, are also implicated in regulation of ERα and/or ESR1, the gene which encodes 
ERα (Ades et al. 2014, Qi et al. 2014, Turner-Ivey et al. 2014, Irish et al. 2016). Indeed, 
genetic abnormalities, such as amplifications, are increasingly linked to epigenetic 
dysregulation in cancers, leading to enhanced focus on understanding the role of 
chromatin modification in tumorigenesis and key players and processes that can 
become therapeutic targets in breast and other cancers. 
1.3. Breast Cancer Epigenomics 
a. Epigenetics overview 
 Epigenetics is emerging as an important mechanism of transcriptional 
dysregulation in cancer and understanding the effects of various chromatin-modifying 
enzymes on gene expression patterns related to cell proliferation, survival, DNA repair, 
and other carcinogenic processes is essential to prevention, diagnosis, and treatment of 
cancer. Epigenetics is defined as changes to the expression profile of a cell not 
accounted for by alterations to the DNA sequence (Miyamoto and Ushijima 2005, 
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Kristensen et al. 2009, Lustberg and Ramaswamy 2009, Jovanovic et al. 2010, Pathiraja 
et al. 2010, Grzenda et al. 2011, Lustberg and Ramaswamy 2011). It includes DNA 
methylation, histone post-translational modifications (hPTM), non-coding RNA, and 
nucleosome remodeling and is a multi-layer regulation system that is complex by its 
nature (Margueron et al. 2004, Jovanovic et al. 2010, Rijnkels et al. 2010, Lustberg and 
Ramaswamy 2011, Abdel-Hafiz and Horwitz 2015, Noberini and Bonaldi 2017).  
 The first and best-characterized epigenetic modification investigated is DNA 
methylation at CpG islands in promoter regions by DNA methyltransferase (DNMT) 
enzymes (Lustberg and Ramaswamy 2009). In general, DNA methylation results in gene 
silencing and cancers tend to have global hypermethylation (suppression) with 
hypomethylation (expression) of specific genes, such as those involved in cell cycle 
progression (Lo and Sukumar 2008, Jovanovic et al. 2010, Pathiraja et al. 2010, Huang 
et al. 2011). For this reason, inhibitors of the methyltransferase enzymes responsible for 
these events have proven clinically successful at re-expression of heavily methylated 
genes and have a positive influence on patient survival (Cai et al. 2011, Falahi et al. 
2014). One such example is the re-expression of ERα and subsequent re-sensitization 
of ER-negative breast cancers to endocrine therapy (Kristensen et al. 2009, Falahi et al. 
2014, Abdel-Hafiz and Horwitz 2015). 
 In addition to methylation of the DNA, modifications to the chromatin structure 
and regulation of access to the genetic information contained therein is emerging as an 
essential component of tumor initiation and progression in breast and other types of 
cancer (Lo and Sukumar 2008, Grzenda et al. 2011, Kim et al. 2016). Chromatin is 
composed of nucleosomes, units of 147 base pair segments of DNA wrapped around 
octamers of histone proteins, made up of two each of histone proteins H2A, H2B, H3, 
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and H4 (Lo and Sukumar 2008, Kristensen et al. 2009, Souza et al. 2009, Jovanovic et 
al. 2010, Grzenda et al. 2011, Kumar et al. 2016). These nucleosomes are linked via 
histone H1 and complexed with additional proteins into areas of highly condensed, 
transcriptionally inactive heterochromatin and open, transcriptionally active euchromatin 
(Lo and Sukumar 2008, Kristensen et al. 2009, Shan et al. 2014, Kumar et al. 2016). 
Within nucleosomes, the N-terminal tails of the histone proteins are left exposed, 
rendering them susceptible to post-translational modification by epigenetic enzymes (Liu 
et al. 2009, Jovanovic et al. 2010, Kim et al. 2016). Known hPTMs include acetylation, 
methylation, sumoylation, ubiquitination, phosphorylation, and ADP-ribosylation (Lo and 
Sukumar 2008, Souza et al. 2009, Jovanovic et al. 2010, Grzenda et al. 2011, Huang et 
al. 2011). Different modifications on different histone tail amino acid residues in different 
regions of the genome produce a variety of effects on the transcriptional program of the 
cell (Figure 1.5) (Liu et al. 2009, Kuo et al. 2011, Kim et al. 2014, Osmanbeyoglu et al. 
2014, Kumar et al. 2016). These modifications have such a profound effect on gene 
expression that they account for much of the cellular programming during 
embryogenesis that produces a vast number of functionally differentiated cell and tissue 
types from a single set of genetic information, and conversely their dysregulation can 
aberrantly revert differentiated cells back to a pluripotent state, which has major 
implications in tumorigenesis (Lo and Sukumar 2008, Liu et al. 2009, Sircoulomb et al. 
2011, Nagamatsu et al. 2012, Osmanbeyoglu et al. 2014). 
 Since epigenetic factors play a major role in altering the expression of large sets 
of genes simultaneously, it is no surprise that aberrant expression of these enzymes can 
lead to cancer (Lo and Sukumar 2008, Demircan et al. 2009, Liu et al. 2009, Yang et al. 
2009, Kim et al. 2014, De Marchi et al. 2016, Kim et al. 2016). Global studies of hPTMs 
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demonstrate that early stage tumors have a different epigenomic profile than late stage 
tumors and the different molecular subtypes of breast cancer can be further clarified by 
analyzing their epigenomic states (Garapaty et al. 2009, Messier et al. 2016). An 
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important aspect of epigenetics is the ability of the modifications to chromatin structure 
to be both stable, with heritability of the epigenetic state of cells being an essential 
component of development and maintenance of phenotype, and dynamic, with different 
patterns of gene expression required throughout the life of a cell and the mitotic process 
(Miyamoto and Ushijima 2005, Lustberg and Ramaswamy 2009, Pathiraja et al. 2010, 
Allali-Hassani et al. 2014). As such, most epigenetic modifications, unlike genetic 
changes, are reversible (Lo and Sukumar 2008, Simon and Lange 2008, Kristensen et 
al. 2009, Lustberg and Ramaswamy 2009, Pathiraja et al. 2010, Cai et al. 2011, 
Morishita and di Luccio 2011, Liu et al. 2014, Michalak and Visvader 2016). These 
features make epigenetic enzymes and the chromatin alterations they generate key drug 
targets in cancer and other diseases.  
b. Histone acetylation and methylation 
 The best-studied hPTM thus far is acetylation. Histone acetylation usually occurs 
on lysine (K) residues in the exposed histone tails, especially K4, K9, and K27 of H3 and 
K5, K8, K12, and K16 of H4 (Figure 1.5) (Lo and Sukumar 2008, Kristensen et al. 2009, 
Lustberg and Ramaswamy 2009, Huang et al. 2011, Judes et al. 2016, Messier et al. 
2016). Histone acetylation weakens the charge interaction between DNA and histones, 
relaxing the chromatin, and therefore is generally associated with transcriptionally active 
genes (Lo and Sukumar 2008, Lustberg and Ramaswamy 2009, Pathiraja et al. 2010, 
Zhang et al. 2013). In normal cells, histone acetylation is regulated by opposing activity 
of histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes 
(Margueron et al. 2004, Lo and Sukumar 2008, Huang et al. 2011). Acetylated histones 
also interact with other epigenetic changes, such as DNA methylation, to contribute to 
overall transcriptional balance (Lustberg and Ramaswamy 2009, Pathiraja et al. 2010). 
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Some cancer types have high levels of global histone acetylation associated with 
aberrant transcription of cell cycle progression programs while others have low levels, 
correlating to overactivity of HDACs that shut down transcription of tumor suppressors 
(Lo and Sukumar 2008, Elsheikh et al. 2009, Judes et al. 2016, Messier et al. 2016). 
HDAC inhibitors have been studied for their potential to promote hyperacetylation and 
transcription of pro-apoptotic genes and show promising results in clinical trials, 
especially in combination with DNMT inhibitors and endocrine therapies (Margueron et 
al. 2004, Lo and Sukumar 2008, Kristensen et al. 2009, Lustberg and Ramaswamy 
2009, Cai et al. 2011, Connolly and Stearns 2012, Abdel-Hafiz and Horwitz 2015, 
Borbely et al. 2015, Connolly et al. 2016, Walsh et al. 2016). HDAC inhibitors can also 
promote acetylation of proteins such as HSP90, a chaperone protein for clients such as 
ERα, AKT, HER2, cRAF, and others, which are then destabilized and degraded (Lo and 
Sukumar 2008, Lustberg and Ramaswamy 2009). Depending on the tumor type and 
subtype, this can be beneficial in cancer treatment. HDAC inhibitors have shown 
success in several hematologic malignancies but have yet to demonstrate much benefit 
in breast cancer (Kerdivel et al. 2013, Falahi et al. 2014).  
 Histone methylation is less understood and more complex than histone 
acetylation (Lo and Sukumar 2008, Huang et al. 2011). Histone methylation occurs at K 
and arginine (R) residues, though is almost exclusively found on K, and can be both 
activating and repressive depending on the specific residue, location within a gene and 
how many methyl groups are added (Lo and Sukumar 2008, Elsheikh et al. 2009, 
Morishita and di Luccio 2011). K residues can accept up to three methyl groups in a 
stepwise fashion, and different enzymes are involved in catalyzing mono-, di-, and tri-
methylation as well as de-methylation events (Li et al. 2009, Liu et al. 2009, Huang et al. 
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2011, Kim et al. 2014, Kim et al. 2016). In general, the most common activating 
methylation marks include H3K4me3, H3K36me3, and H3K79me3 and repressive marks 
include H3K9me3, H3K27me3, and H4K20me3 (Lo and Sukumar 2008, Elsheikh et al. 
2009, Souza et al. 2009, Fang et al. 2010, Jovanovic et al. 2010, Huang et al. 2011, 
Morishita et al. 2014). Similarly, arginine residues can be methylated by protein-arginine 
methyltransferase family proteins, and H4R3me3 is associated with activated 
transcription (Elsheikh et al. 2009, Butler et al. 2011). Although the exact specificity of 
different histone methyltransferase (HMT) enzymes responsible for placing these marks 
is still controversial, some general patterns have emerged. 
 The first HMTs, though not yet known to function as such, were identified in the 
1940s in Drosophila melanogaster when it was observed that loss of homeobox (HOX) 
gene expression in male flies produced extra sex combs, and the phenomenon was 
termed “polycomb” (Grzenda et al. 2011). These polycomb group (PcG) enzymes that 
negatively regulate HOX gene expression have since been identified as the SET 
(Suppressor of variegation 3-9, Enhancer of zeste and Trithorax) domain-containing 
HMTs EZH1 and EZH2 and their complex partners (Angrand et al. 2001, Lo and 
Sukumar 2008, Simon and Lange 2008, Grzenda et al. 2011). The SET domain provides 
the catalytic activity for the 4 subgroups, PRC1 (polycomb repressive complex), which is 
associated with transcriptional maintenance, and PRC2, PRC3, and PRC4 that are 
associated with transcriptional initiation (Grzenda et al. 2011, Huang et al. 2011, Yuan et 
al. 2011, Garapaty-Rao et al. 2013). PcG factors exert their repressive function primarily 
via tri-methylation of H3K27 and H3K9 and are critical for embryonic development, stem 
cell maintenance, differentiation, proliferation, and invasion (Rampalli et al. 2007, Simon 
and Lange 2008, Pathiraja et al. 2010, Grzenda et al. 2011, Yuan et al. 2011, Judes et 
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al. 2016). EZH2 is one of the most studied HMTs to date and EZH2 inhibitors are now in 
clinical trials (Garapaty-Rao et al. 2013, Sato et al. 2017). Activity of PcG enzymes is 
found at both active and inactive genes and transcriptional repression and chromatin 
compaction is thought to be the “default” setting of cells, with activation of transcription 
occurring through “de-repression” in a tightly controlled fashion (Rampalli et al. 2007, 
Yuan et al. 2011). 
 Until the 1980s, it was unclear how PcG enzyme activity was counterbalanced 
(Grzenda et al. 2011). Also in Drosophila melanogaster, the trithorax group (trxG) of 
chromatin modifiers was discovered (Ikegawa et al. 1999, Luscher-Firzlaff et al. 2008, 
Grzenda et al. 2011, Yuan et al. 2011). This family of proteins is made up of HMT 
enzymes that also contain SET domains, which possesses the catalytic HMT function 
(Ikegawa et al. 1999, Angrand et al. 2001, Cao et al. 2010, Judes et al. 2016). TrxG 
enzymes counteract PcG repression primarily by H3K4 tri-methylation, mediated by MLL 
(mixed lineage leukemia) and other ASH2L-containing complexes, leading to active 
transcription (Guertin et al. 2006, Rampalli et al. 2007, Grzenda et al. 2011). Many 
promoters possess both H3K27me3 and H3K4me3 at high levels and are termed 
“poised” chromatin regions, though the “switch” that determines which direction gene 
transcription ultimately favors is unclear and may depend on cross-talk with other layers 
of epigenetic regulation, such as DNA methylation and histone acetylation (Grzenda et 
al. 2011, Wan et al. 2013, Ullius et al. 2014, Katoh 2016). MYC may be involved in 
recruitment of other enzymes, such as p300, that de-methylate and acetylate H3K27 for 
transcriptional activation in an ASH2L-dependent manner (Hervouet et al. 2013, Ullius et 
al. 2014, Erfani et al. 2015). SET domain-containing proteins also di-methylate H3K36, 
another marker of active gene transcription (Li et al. 2009, Liu et al. 2009, Kuo et al. 
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2011, Yuan et al. 2011, French et al. 2014, Liu et al. 2014, Zhu et al. 2016). These 
enzymes include ASH1L and the NSD family of HMTs, discussed in more detail along 
with ASH2L and the MLL complexes in subsequent sections (Figure 1.6).   
 Although chromatin-modifying enzymes are often studied individually, the reality 
is that many of these enzymes are found in complexes together, and activation of one 
tends to facilitate recruitment of others (Wang et al. 2007, Nguyen et al. 2008, Simon 
and Lange 2008, Li et al. 2009, Yates et al. 2010, Huang et al. 2011, Kumar et al. 2016). 
This is exemplified in the SWI/SNF and similar complexes that have been well-
characterized and are known to have a vast selection of subunits that contribute to 
chromatin architecture in a plethora of biological contexts (Yates et al. 2010, Kumar et 
al. 2016). Similarly, transcription factors such as ERα rely on several epigenetic proteins 
for local remodeling of nucleosomes to facilitate transcription, create positive feedback 
loops to maintain transcription, and auto-regulate shutting down of these pathways to 
prevent aberrant gene expression (Margueron et al. 2004, Lo and Sukumar 2008, Li et 
al. 2009, Fang et al. 2010, Jacques-Fricke and Gammill 2014, Locke et al. 2015). Some 
of the better-characterized binding partners of ERα include the HATs p300/CBP, PCAF, 
and SRC1 (NCoA1, nuclear co-activator 1), which function as co-activators to destabilize 
the nucleosomes and open the chromatin for transcription (Margueron et al. 2004, 
Garapaty et al. 2009, Hervouet et al. 2013, Zhang et al. 2013). Various HMT, 
demethylase, and DNMT enzymes, including HMTs MLL1 and MLL2, also complex with 
ERα to close the chromatin once the transcriptional pattern is complete (Cui et al. 2005, 
Huang et al. 2011, Hervouet et al. 2013, Zhang et al. 2013, Ades et al. 2014). In addition 
to histones, epigenetic factors can modify non-histone proteins. For example, SMYD2, a 
HMT, methylates K266 in the hinge region of the ERα protein itself in the absence of 
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17β-estradiol and LSD1, a demethylase, must first remove this inhibitory K266me prior to 
acetylation at the same residue by p300/CBP, which contributes to ERα activation upon 
stimulation with 17β-estradiol (Zhang et al. 2013). Many other enzymes are also 
implicated in direct modification of ERα, particularly related to the hinge-region ligand-
binding and ligand-independent AF-1 domains (Margueron et al. 2004, Kerdivel et al. 
2013). When any of the mechanisms contributing to transcriptional access are disrupted, 
tumorigenesis can result.  
 An essential feature of epigenetics is the ability for precise interpretation of the 
combinatorial nature of histone modifications and translation to transcriptional signals 
(Grzenda et al. 2011, Hervouet et al. 2013). This is accomplished by the various “reader” 
domains possessed by epigenetic enzymes. Bromodomains recognize acetylated 
histones and recruit additional factors to the chromatin (Lo and Sukumar 2008, Grzenda 
et al. 2011, Rahman et al. 2011, Wagner and Carpenter 2012). The bromodomain and 
extraterminal domain (BET) family of proteins, BRDT, BRD2, BRD3, and BRD4, have 
been implicated as “linker” or “bridge” proteins in various cancer types between 
acetylated histones and other epigenetic factors and have been the focus of drug 
development leading to clinical trials in recent years (Morishita and di Luccio 2011, 
Rahman et al. 2011, Feng et al. 2014, Zou et al. 2014, Nagarajan et al. 2015, Shen et al. 
2015, Crowe et al. 2016, Kumar et al. 2016, Zhang et al. 2016). Other common domains 
include WD40, ADD, and chromodomains (CHD), which recognize methylated lysine 
residues (Guccione et al. 2007, Lo and Sukumar 2008, Grzenda et al. 2011, Kim et al. 
2016). Plant homeodomains (PHD) are zinc finger motifs that recognize methylated 
lysines and arginine residues, preferentially H3K4me3 and H3K9me3 (Huang et al. 
1998, Grzenda et al. 2011, Wagner and Carpenter 2012, He et al. 2013, Allali-Hassani 
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et al. 2014, Morishita et al. 2014, Kim et al. 2016). PWWP (Pro-Trp-Trp-Pro) domains 
are highly conserved and preferentially recognize H3K36me1 and H3K36me2 (Yang et 
al. 2010, Grzenda et al. 2011, Wagner and Carpenter 2012, Allali-Hassani et al. 2014, 
Morishita et al. 2014, Wen et al. 2014, Shen et al. 2015, Kim et al. 2016). The PHD5-
C5HCH domain unique to the NSD family of HMTs also plays an important role in 
directing these enzymes to chromatin, preferentially binding H3K4me0 and H3K9me3 
(He et al. 2013). These reader domains generally bind multiple histone and non-histone 
PTMs with substrate affinities dependent upon the three-dimensional structures of the 
domains, presence of coregulatory factors that cause conformational changes to those 
binding pockets, nearby histone and DNA modifications that can have allosteric effects 
on HMTs, and other factors, increasing the complexity of the rich language of the histone 
code. 
 As the field of epigenetics has expanded exponentially over the past two 
decades (Huang et al. 2011), it has become clear that the complexity and interaction 
between all the chromatin regulatory marks, together termed the “histone code” 
(Grzenda et al. 2011, Hervouet et al. 2013), needs further evaluation. There is a clear 
link between aberrant expression of epigenetic modifiers of chromatin and pathology, 
especially tumorigenesis (Miyamoto and Ushijima 2005, Lo and Sukumar 2008, 
Demircan et al. 2009, Li et al. 2009, Kim et al. 2014, Paska and Hudler 2015, Kim et al. 
2016, Zhu et al. 2016). Globally-targeted inhibition of some of these enzymes, such as 
the DNMT, HDAC, and bromodomain inhibitors, have proven that this pathway of 
investigation is worthwhile and has highlighted the need to fine-tune pharmacologic 
control of epigenetic editing in a cancer subtype-specific manner (Lo and Sukumar 2008, 
Falahi et al. 2014, French et al. 2014). For a more detailed discussion of the topics 
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briefly addressed in this section, interested readers are referred to several 
comprehensive review articles (Lo and Sukumar 2008, Lustberg and Ramaswamy 2009, 
Jovanovic et al. 2010, Rijnkels et al. 2010, Veeck and Esteller 2010, Cai et al. 2011, 
Connolly and Stearns 2012, Falahi et al. 2014, Lin et al. 2015, Paska and Hudler 2015, 
Michalak and Visvader 2016, Walsh et al. 2016, Damaskos et al. 2017). Only the 
implications of histone methylation on lysine residues 4 and 36 of histone 3 will be 
discussed further as these groups are regulated by the two 8p11-p12 amplicon factors 
involved in histone methylation, ASH2L and NSD3, respectively.  
1.4. Histone Methyltransferases from the 8p11-p12 Amplicon 
a. NSD3 (WHSC1L1) and H3K36me2 
 The Nuclear-receptor binding SET Domain-containing (NSD) family of proteins is 
part of the trithorax (trx) group of chromatin-modifying enzymes and has three main 
members: NSD1, NSD2 (WHSC1/MMSET), and NSD3 (WHSC1L1 for Wolf-Hirschhorn 
Syndrome Candidate 1-Like 1) (Huang et al. 1998, Yang et al. 2010). These enzymes 
are HMTs and share a large degree of homology with one another as well as with other 
SET domain-containing proteins conserved throughout evolution (Angrand et al. 2001, Li 
et al. 2009, Wu et al. 2010, Yang et al. 2010, Zhou et al. 2010, Morishita and di Luccio 
2011, Katoh 2016). All three family members are dysregulated in a number of benign 
and malignant disease states and they have all been established as oncogenes 
(Douglas et al. 2005, Yang et al. 2010, Morishita and di Luccio 2011, He et al. 2013). 
Much of the work on these enzymes has been done in hematological malignancies, 
primarily acute myeloid leukemia (AML) for NSD1 and NSD3 and multiple myeloma for 
NSD2, but they have also been implicated in lung, pancreatic, colorectal, liver, bladder, 
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glioblastoma, neuroblastoma, head and neck carcinoma, and breast cancers (Stec et al. 
2001, Li et al. 2009, Taketani et al. 2009, Zhou et al. 2010, Morishita and di Luccio 2011, 
Morishita and di Luccio 2011, He et al. 2013, Morishita et al. 2014, Suzuki et al. 2015, 
Saloura et al. 2016). Though there has been much debate over the specificity of these 
HMTs and some controversy remains, it has been established that they all possess 
H3K36 methylation ability and NSD3 is unambiguously implicated in di-methylation of 
this lysine residue, which is generally associated with active transcription (Li et al. 2009, 
Kuo et al. 2011, Morishita and di Luccio 2011, Rahman et al. 2011, Wagner and 
Carpenter 2012, He et al. 2013, Allali-Hassani et al. 2014, Feng et al. 2014, French et al. 
2014, Jacques-Fricke and Gammill 2014, Morishita et al. 2014, Saloura et al. 2016, 
Bennett et al. 2017). NSD2 is implicated in the greatest number of histone methylation 
events (Li et al. 2009, Morishita and di Luccio 2011, Morishita et al. 2014). In addition to 
histone methylation, NSD1 has demonstrated methylation of NF-κb and NSD3 has been 
shown to methylate the epidermal growth factor receptor (EGFR), activating downstream 
events in the absence of EGF that lead to DNA replication in squamous cell carcinomas 
of the head and neck (Morishita and di Luccio 2011, Saloura et al. 2017). NSD2 and 
NSD3 share the highest degree of homology compared to NSD1, and all three have 
highly conserved sequences (Angrand et al. 2001, Yang et al. 2010, Zhou et al. 2010, 
Morishita and di Luccio 2011). Knockout mouse models confirm that the functions of 
these three enzymes are non-redundant and they likely perform unique roles in 
development and, then, in tumorigenesis as well (He et al. 2013, Allali-Hassani et al. 
2014, Bennett et al. 2017).  
 NSD3 has three isoforms (Figure 1.7). The longest isoform, dictated NSD3-L, is 
1437 amino acids from 24 exons located at 8p11.23 and contains an N-terminal PWWP 
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domain followed by 4 sequential PHD fingers, a second PWWP domain, a SAC (SET-
associated cysteine-rich) domain, SET domain (catalytic HMT domain), and a final PHD 
finger linked to a C5HCH (cys-his-rich) domain that is unique to the NSD family 
(Angrand et al. 2001, Stec et al. 2001, Yang et al. 2010, Zhou et al. 2010, Morishita and 
di Luccio 2011, Morishita and di Luccio 2011, He et al. 2013, Saloura et al. 2016). 
WHISTLE is a shorter, C-terminal version of this protein generated by a downstream 
promoter that is specific to testes and bone marrow (Kim et al. 2007, Zhou et al. 2010, 
Bennett et al. 2017). It recruits HDAC1 with its PWWP domain and methylates H3K4 and 
H3K27 to repress transcription and may also induce apoptotic cell death through 
activation of caspase-3 (Kim et al. 2007, Zhou et al. 2010). This isoform has not been 
shown to have a role in tumorigenesis (Bennett et al. 2017). Alternative splicing of the 
NSD3 gene at exon 9 produces a truncated 645 amino-acid protein, NSD3-S, that 
contains only the first PWWP chromatin-binding domain and lacks the catalytic SET and 
other binding domains (Angrand et al. 2001, Stec et al. 2001, Yang et al. 2010, Zhou et 
al. 2010, Saloura et al. 2017). While both the long and short isoforms of NSD3 
demonstrate overexpression at the transcript and protein levels in tumor versus normal 
tissues in multiple cancer types, NSD3-S is consistently identified as expressed to a 
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higher degree than NSD3-L (Stec et al. 2001, Yang et al. 2010, Shen et al. 2015, Irish et 
al. 2016).  
 There is mounting evidence to indicate that NSD3-S is more transforming than 
NSD3-L despite lacking the catalytic SET domain. The 8p11-p12 amplicon often 
contains breakpoints and deletions in the 3’ end of the NSD3 sequence, originally 
leading to the conclusion that it was not a driving oncogene from this amplicon (Yang et 
al. 2010, Dutt et al. 2011). Several studies have alternatively suggested that the short 
isoform actually is the dominant oncogenic form of this protein and is under selective 
pressure during the amplification process to preserve the 5’ end of the transcript 
(Nagamatsu et al. 2012). Shen et al. (2015) demonstrated NSD3-S as the essential 
oncogenic isoform in AML by serving as an adaptor protein to link BRD4 to other 
chromatin-modifying enzymes such as CHD8, and the PWWP domain was necessary 
for this function. This group also identified a new domain on NSD3-S, a transcription 
activating domain (TAD) comprised of the highly acidic first 100 amino acids, suggesting 
that NSD3 can exert oncogenic function and transcriptional activation independent of 
HMT activity. This is consistent with other studies that have demonstrated the necessity 
of NSD3 in regulating gene transcription but with obvious disconnect between 
transcriptional outcome and H3K36me2 alterations (Jacques-Fricke and Gammill 2014). 
Others have postulated that NSD3-S acts by binding to chromatin through its PWWP 
domain and preventing the methyltransferase function of NSD3-L by occupying the 
binding sites (Stec et al. 2001, Irish et al. 2016). It is important to note that, although 
NSD3-S somewhat unexpectedly has been shown to play a more transforming role than 
NSD3-L in some studies, there is also evidence to indicate that the enzymatic activity of 
NSD3-L that generates H3K36me2 is also important in some tumors (Chen et al. 2014, 
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Liu et al. 2014, Suzuki et al. 2015). While the distinction between the two main isoforms 
of NSD3 remains to be fully understood, it has become clear that NSD3 is an important 
oncogene in many cancer types.  
 Although one study demonstrated that knockdown of NSD3-L in non-NSD3-
amplified cell lines resulted in increased cell cycle progression and proliferation, 
suggesting that NSD3-L may be a tumor suppressor gene (Zhou et al. 2010), all others 
have confirmed it is a bona fide oncogene (Morishita and di Luccio 2011, He et al. 2013, 
Chen et al. 2014). This study also demonstrated increased NSD3-L transcript levels 
compared to NSD3-S (Zhou et al. 2010), a finding that is challenged by the body of 
literature on this gene as well as findings from our laboratory in the same MCF7 breast 
cancer cell line (Stec et al. 2001, Yang et al. 2010, Shen et al. 2015, Irish et al. 2016). 
NSD3, like NSD1, has been shown to create an oncogenic fusion protein with NUP98 in 
AML and is associated with poor prognosis and increased aggressiveness, possibly by 
competing with EZH2-mediated repression of HOX-A gene expression (Rosati et al. 
2002, Wang et al. 2007, Li et al. 2009, Taketani et al. 2009). Similarly, a fusion protein of 
the first 7 exons of NSD3 with the NUT gene in NUT midline carcinomas of the lung and 
mediastinum produced a phenotype of high proliferation and lack of differentiation 
(French et al. 2014). This cancer is highly aggressive with few treatment options and 
poor patient survival and would benefit from inhibition of NSD3, which induced 
differentiation and reduced proliferation in a NUT midline carcinoma model cell line 
(French et al. 2014, Suzuki et al. 2015). Increased NSD3 expression is associated with 
reversion of cell phenotype toward pluripotency in other models as well (Yang et al. 
2010, Nagamatsu et al. 2012), consistent with a role in tumorigenesis. NSD3 has been 
implicated in pancreatic cancer and non-small cell lung cancer progression through its 
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chromatin modifying behavior (Zhou et al. 2010, Morishita and di Luccio 2011, Mann et 
al. 2012, Kang et al. 2013, Mahmood et al. 2013, Jacques-Fricke and Gammill 2014, 
Suzuki et al. 2015).  
 NSD3 has been shown to bind several other proteins. BRD4, whose 
bromodomain recognizes acetylated histones, also possesses an extraterminal (ET) 
domain that binds NSD3 and other chromatin-modifying enzymes (Rahman et al. 2011, 
Wagner and Carpenter 2012, Feng et al. 2014, Shen et al. 2015, Crowe et al. 2016, 
Zhang et al. 2016). The BRD4-NSD3 unit participates in activating transcription at 
several important target genes, including CCND1 (Rahman et al. 2011, Wagner and 
Carpenter 2012). This complex is found primarily in the gene body and is associated 
with H3K36me2, the histone mark for which NSD3 is responsible (Rahman et al. 2011). 
Rahman et al. (2011) also identified BRD2 as an NSD3-binding partner. The unique 
PHD5-C5HCH domain of the NSD family members has been extensively studied by He 
et al. (2013) and, though each member has different binding affinity, this motif in NSD3 
was demonstrated to prefer H3K4me0 and H3K9me3, both markers of repressed 
chromatin. This is consistent with previous studies demonstrating that NSD3 complexes 
with LSD2, a H3K4 demethylase, and G9a, another SET enzyme responsible for the 
repressive H3K9me3 mark (Morishita and di Luccio 2011, Wagner and Carpenter 2012, 
He et al. 2013, Feng et al. 2014). It has been proposed that these proteins coordinate 
the precise dynamic balance of H3 modifications that facilitate optimal transcriptional 
elongation while simultaneously preventing unwanted initiation of intragenic transcription 
at target genes (Feng et al. 2014). 
 Methylation of H3K36 is generally associated with transcriptional activity. 
H3K36me2, the major histone-methyl mark of NSD3, is an important hPTM for the 
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recruitment of other enzymes involved in transcriptional activation (Li et al. 2009, 
Wagner and Carpenter 2012). Methylated H3K36 tends to shift from me2 at the 
promoter to me3 at the 3’ end (Li et al. 2009, Rahman et al. 2011, Wagner and 
Carpenter 2012, Zhu et al. 2016). There is only one human enzyme known to tri-
methylate H3K36: SETD2 (Wagner and Carpenter 2012, Michalak and Visvader 2016, 
Zhu et al. 2016). Knockdown of NSD3 or its binding partner BRD4 often indirectly 
decreases H3K36me3 levels by preventing the di-methylation step upon which SETD2 
builds and these two factors have been shown to form a complex together with RNA 
polymerase II to keep tight regulation on chromatin structure and prevent transcriptional 
initiation outside the transcriptional start site (Li et al. 2009, Fang et al. 2010, Rahman et 
al. 2011, Wagner and Carpenter 2012, Jacques-Fricke and Gammill 2014, Katoh 2016). 
Increased levels of H3K36 methylation are associated with cancers such as AML 
(Morishita et al. 2014, Shen et al. 2015). H3K36me3 recruits corepressors, such as 
HDAC complexes and LSD2, to aid in this regulation (Fang et al. 2010, Zhu et al. 2016). 
H3K36 methylation is important early step in activation of transcription by antagonizing 
repressive marks, such as H3K27me3, and these hPTMs rarely coexist (Yuan et al. 
2011). Additionally, H3K36 methylation is implicated in alternative splicing events, X-
inactivation, and DNA repair and recombination (Wagner and Carpenter 2012). Due to 
the dynamic nature of chromatin regulation and complexity of the histone code, 
H3K36me2 has also been implicated in transcriptional repression (Morishita and di 
Luccio 2011, Wagner and Carpenter 2012). The PWWP domains of the NSD family 
members are able to read H3K36me0 and H3K36me1 to recruit these enzymes for 
further methylation by the catalytic SET domain, which all HMT proteins possess, 
including non-NSD family members such as ASH1L, which shares similarities with NSD1 
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(Wagner and Carpenter 2012, Liu et al. 2014, Katoh 2016). With the tightly coordinated 
balance associated with H3K36me2 in regulating transcription, it is no surprise that 
aberrant expression of the enzymes that alter this control have vast implications in 
disease state such as cancer. 
 In breast cancer, NSD3 has been identified as one of the top most important 
HMTs in tumorigenesis. One study analyzed a dataset of 958 breast tumors using TCGA 
copy number and expression data and GISTIC analysis and determined that, of the 51 
known human HMTs, NSD3 has the highest correlation between copy number 
amplification and coordinate overexpression, thus emphasizing the importance of 
understanding this oncogene in breast cancer (Liu et al. 2014). NSD3 was found 
amplified in 19% of luminal B breast cancers and was expressed to a higher degree in 
luminal versus other breast cancer subtypes (Liu et al. 2014). Overexpression of NSD3 
in the non-transformed MCF10A resulted in a transformed phenotype while knockdown 
in NSD3-overexpressing breast cancer cell lines reduced proliferation (Yang et al. 2010, 
Liu et al. 2014, Irish et al. 2016). Knockdown of NSD3 in the amplicon-bearing luminal B 
breast cancer cell line SUM-44 by our group resulted in decreased expression of ESR1 
by microarray, and chromatin immunoprecipitation followed by high throughput 
sequencing (ChIP-seq) with an ERα antibody cocktail demonstrated ERα actively bound 
to chromatin without estrogen in a FOXA1-dependent manner, which was then 
abrogated by knockdown of NSD3 (Irish et al. 2016). Together, these data provided the 
foundation for further exploration of the role of NSD3 in luminal B breast cancer as 
described in this work.  
 Although there has been much progress in elucidating the function of NSD3 and 
its role in tumorigenesis over the past decade, there remains much to be determined 
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about this driving oncogene. Due to the highly conserved SET domain and mounting 
evidence that inhibition of this enzyme would be beneficial in multiple cancer types, 
several groups have suggested NSD3 and its family members as an excellent model for 
drug development that would revolutionize the field of epigenetic therapies in cancer 
(Chen et al. 2014, Katoh 2016, Michalak and Visvader 2016, Saloura et al. 2016). In 
addition to the catalytic SET domain, drug targets that would inhibit the PWWP domain 
common to both NSD3-S and NSD3-L would be highly beneficial for blocking non-
enzymatic effects as well (Shen et al. 2015). This study seeks to identify the role of 
NSD3 amplification and overexpression in 8p11-p12 amplicon-bearing breast cancer cell 
lines and to extend the work previously done in our laboratory linking knockdown of 
NSD3 to a reduction in ERα expression in this context. 
b. ASH2L and MLL complexes 
 The human ASH2L (Absent, Small, or Homeotic disc 2-Like) gene was first 
discovered by Ikegawa et al. in 1999 by large scale genome sequencing and computer-
based gene prediction methods as being homologous to the Drosophila melanogaster 
trithorax group (trxG) gene ash2. This group of proteins antagonizes transcriptional 
silencing by the polycomb group (PcG) of epigenetic factors as discussed in previous 
sections. ASH2L has two isoforms: a 628-amino acid ASH2L1 and a 501-amino acid 
ASH2L2 protein (Wang et al. 2001). ASH2L has a PHD finger motif and thus has been 
implicated in transcriptional regulation since its discovery (Ikegawa et al. 1999). It also 
has a WH (winged helix) motif for DNA binding, a SPRY domain, and a DPY-30 binding 
motif, but it lacks the SET domain characteristic of the trxG family and related ASH1L 
protein (Ikegawa et al. 1999, Chen et al. 2012). ASH2L is implicated in tight regulation of 
H3K4 methylation, which is associated with activated transcription (Dou et al. 2006, 
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Guccione et al. 2007, Luscher-Firzlaff et al. 2008, Wan et al. 2013, Judes et al. 2016). 
Specifically, ASH2L knockdown primarily affects H3K4me3 levels as opposed to mono- 
or di-methylation (Steward et al. 2006, Demers et al. 2007, Fossati et al. 2011). 
 H3K4 tri-methylation was originally thought to be irreversible, barring histone 
protein turnover, and its regulation in cells of utmost importance to transcriptional 
regulation in differentiation and development (Steward et al. 2006). While the latter is still 
true, H3K4me3 is now known to be de-methylated by LSD1 (Blobel et al. 2009, Fang et 
al. 2010, Huang et al. 2011, Hervouet et al. 2013, Kim et al. 2014, Abdel-Hafiz and 
Horwitz 2015). The primary H3K4 HMT family in mammalian cells is the SET1 family, 
which includes MLL proteins 1-4, SET1A, and SET1B, and is named for their highly 
conserved SET domain that is also found in other HMT groups, such as the NSD family 
as previously described (Dou et al. 2006, Steward et al. 2006, Tan et al. 2009, Cao et al. 
2010, Wu et al. 2010, Xiao et al. 2011, Chen et al. 2012, Kim et al. 2014, Qi et al. 2014, 
Katoh 2016). MLL proteins actually have very weak enzymatic activity and require 
binding partners, one of which is ASH2L (Southall et al. 2009, Chen et al. 2012). In 
contrast to H3K4me1 and H3K4me2, H3K4me3 is strictly associated with active gene 
transcription and its distribution closely overlaps that of elongating RNA polymerase II 
(Demers et al. 2007, Guccione et al. 2007, Luscher-Firzlaff et al. 2008). H3K4me3 is 
often localized to the 5’ (proximal promoter) end of target genes and ASH2L is also 
confined to this region, though MLL may spread further along the gene (Demers et al. 
2007, Luscher-Firzlaff et al. 2008). In contrast, H3K4me2 has a greater distribution, 
suggesting a major role for ASH2L as the primary activator of H3K4 tri-methylation in 
promoter regions (Guccione et al. 2007).  
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 Since ASH2L does not possess a SET domain like other trxG proteins, it is 
known to form complexes with the MLL family of SET domain proteins and is a 
component of all H3K4 HMTs characterized to date (Ikegawa et al. 1999, Butler et al. 
2011, Ernst and Vakoc 2012, Wan et al. 2013, Qi et al. 2014, Butler et al. 2017). MLL 
proteins are preferentially H3K4 mono-methylases with weak enzymatic activity and 
ASH2L is critical for enhancement of HMT function and regulation of MLL-mediated 
catalysis of H3K4me3 (Patel et al. 2009, Chen et al. 2012). RbBP5, another MLL 
complex member, is implicated in activating MLL-mediated catalysis of the intermediate 
H3K4me2 state (Dou et al. 2006, Ernst and Vakoc 2012). The third critical MLL complex 
participant is WDR5, which is important for the stability of the protein-protein interactions 
and recruitment to chromatin (Dou et al. 2006, Steward et al. 2006). Menin, encoded by 
the MEN1 gene, is also often found together with the WDR5-ASH2L-RbBP5 (WAR) 
subunit and has demonstrated properties of tumor suppression as well as the ability to 
directly bind RNA polymerase II (Guertin et al. 2006, Guccione et al. 2007, Luscher-
Firzlaff et al. 2008). DPY-30 is also commonly associated with WAR and ASH2L has a 
DPY-30 binding domain on its C-terminal end (Patel et al. 2011, Chen et al. 2012, Ali 
and Tyagi 2017). The sub-complex containing all 4 subunits, known as WRAD, can exist 
independent of MLL, with and without additional binding partners, implying that these 
genes may coordinate to recruit other chromatin-modifying enzymes or may have 
actions outside of hPTM (Patel et al. 2011, Ernst and Vakoc 2012, Ali et al. 2014, Ali and 
Tyagi 2017). Interestingly, although knockdown of ASH2L usually reduces global levels 
of H3K4me3, MLL-dependent H3K4 mono- and di-methylation at some genes is 
maintained, suggesting it may still interact with the chromatin and act as an HMT, but 
cannot perform tri-methylation without ASH2L (Guertin et al. 2006, Tan et al. 2009, 
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Butler et al. 2011, Fossati et al. 2011, Chen et al. 2012). Knockdown of MLL, however, 
does not alter methylated H3K4 levels, implying that ASH2L may be responsible for 
H3K4me3 catalysis by other HMT enzymes as well, perhaps by interaction with other 
SET domain-containing enzymes, and emphasizing the essential role that ASH2L plays 
in this histone methyl mark (Steward et al. 2006, Demers et al. 2007, Blobel et al. 2009, 
Butler et al. 2011, Wan et al. 2013). 
 The requirement of the non-SET binding partners ASH2L, RbBP5, and WDR5 for 
HMT activity at H3K4me3 is unique (Patel et al. 2011). As such, several studies have 
attempted to understand the biological role of the WRAD sub-complex without a SET 
domain-containing component (Steward et al. 2006, Patel et al. 2009, Ernst and Vakoc 
2012, Ali and Tyagi 2017). One study demonstrated that the sub-complex interacts with 
nuclear hormone transcription factor coregulatory proteins NRC and NIF-1 and 
maintained affinity for H3 in this context (Garapaty et al. 2009), but the role of ASH2L in 
promoting HMT activity outside SET domain-containing proteins remained undefined. 
Patel et al. (2009) suggested that the sub-complex itself may possess H3K4-specific 
methylation ability when MLL is not present, although this activity is not through a SET 
domain and the mechanism is unknown. This finding was confirmed by their 2011 
description of this phenomenon as well (Patel et al. 2011). Later, Cao et al. (2010) 
demonstrated that HMT activity is intrinsic to the ASH2L-RbBP5 heterodimer and 
requires the highly conserved SPRY domain of ASH2L. This group also suggested that 
ASH2L and the SET domain of MLL1 form a joint catalytic subunit for promoting H3K4 
methylation and that overall activity of the MLL complex is dependent upon binding of 
the methyl-donor SAM to ASH2L (Cao et al. 2010). The WRAD sub-complex HMT 
activity has also been suggested as a second active site in the MLL complex, one 
Chapter 1: Introduction  Page | 50  
 
contributing factor to enhanced H3K4 methylation when the entire complex is assembled 
(Ernst and Vakoc 2012, Patel et al. 2014). These findings provided the foundation for the 
“two-step” hypothesis of MLL complex activation whereby a minimal association 
between ASH2L and RbBP5 is required to provide a second catalytic pocket in the 
three-dimensional structure of the complex, thus enhancing the overall methylation 
ability of the MLL family of proteins (Ernst and Vakoc 2012, Patel et al. 2014, Li et al. 
2016, Ali and Tyagi 2017). This hypothesis explains the ability of ASH2L to act as an 
HMT even in the absence of a SET domain. 
 MLL complexes are known to interact with a plethora of proteins, including other 
epigenetic factors, transcription factors, and basal transcription machinery (Dou et al. 
2006, Demers et al. 2007). ASH2L has similarly been shown to directly bind transcription 
factors such as AP2δ, as well as the basal transcriptional machinery (Tan et al. 2008). 
This study suggested that the critical role of ASH2L is as a mediator between chromatin-
modifying enzymes and factors involved in transcription. Yates et al. (2010) 
demonstrated binding of the WAR sub-complex, and specifically ASH2L, to CHD8, an 
APT-dependent chromatin remodeler that alters H3 methylation patterns of HOX genes. 
Additionally, MLL complexes have been shown by several groups to interact directly with 
ERα, modifying the histone code near ERα-target genes to promote transcription via 
promotion of catalysis of H3K4me3 by ASH2L (Hervouet et al. 2013, Zhang et al. 2013, 
Bhan et al. 2014, Qi et al. 2014). ASH2L and the complexes in which it participates have 
major effects on gene expression during embryogenesis and beyond (Dou et al. 2006, 
Butler et al. 2011). Tight regulation of ASH2L is therefore required but poorly 
understood. One study identified arginine residues on ASH2L that can be di-methylated 
by PRMT1, but the biological effect of this modification is unknown (Butler et al. 2011). 
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Similarly, MLL1 can auto-methylate ASH2L in the MLL-WRAD complex and, although 
the function of this methylation is unknown, one possibility is that it acts as a mechanism 
of autoregulation (Patel et al. 2014). WDR5 binds acetylated H3 tails with high affinity, 
preventing the HMT activity of ASH2L-containing MLL complexes (Guccione et al. 2007, 
Avdic et al. 2011). Of course, the actions of PcG proteins are well-known to antagonize 
H3K4 methylation by these trxG enzymes as well (Grzenda et al. 2011). The balance of 
other epigenetic marks, transcription factors, and protein-protein interactions could also 
play a role in keeping ASH2L and associated complexes in check, but these events 
currently remain unclear and are understudied to date (Dou et al. 2006, Butler et al. 
2011, Vedadi et al. 2017).  
 Clearly, ASH2L plays a major role in regulation of gene expression. It is 
especially implicated in transcription of genes associated with development, stem cell 
divisions, and mitotic regulation (Ikegawa et al. 1999, Demers et al. 2007, Butler et al. 
2011, Kawabe et al. 2012, Ali et al. 2014). Knockdown of ASH2L results in decreased 
expression of genes associated with cell cycle, proliferation, and survival in a range of 
tissue types, including hematologic cells, breast tumors, skeletal muscle, 
osteosarcomas, and gliomas (Wang et al. 2001, Rampalli et al. 2007, Luscher-Firzlaff et 
al. 2008, Pullirsch et al. 2010, Schram et al. 2013, Ali et al. 2014, Erfani et al. 2015, Zhu 
et al. 2016). Knockdown of ASH2L in embryonic stem cells results in reduced 
pluripotency due to globally decreased H3K4me3 and increased H3K9me3 levels, a 
mark of silenced chromatin (Wan et al. 2013). Similarly, MLL and the WRAD sub-
complex is linked to cell cycle progression through S and M phases (Ali et al. 2014). 
Given the link to stem cell potential and cell cycle regulation, dysregulation of ASH2L 
can be linked to tumorigenesis.  
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 Similar to NSD3, much of the work on ASH2L in cancer has been done in 
hematologic models. It was first identified as an oncogene by Lüscher-Firzlaff et al. 
(2008) where they demonstrated that ASH2L cooperates with MYC and RAS, is 
overexpressed in human tumor samples, and results in decreased tumor growth upon 
knockdown. The interaction of ASH2L with MYC was later confirmed and implicated in 
regulation of bivalent chromatin with high levels of both activating marks H3K4me3 and 
H3K27ac (Ullius et al. 2014). ASH2L is important for differentiation of erythroid cell 
lineages and its aberrant expression is implicated in hematologic malignancies (Wang et 
al. 2001, Cao et al. 2010). MLL is often involved in translocations or is mutated or 
deleted in these cancers (Luscher-Firzlaff et al. 2008, Southall et al. 2009, Ali et al. 
2014), thus raising questions about ASH2L function outside of MLL complexes in this 
context. Additionally, ASH2L has been described as transforming in some 
osteosarcomas and recently was implicated in regulation of EGFR expression via 
H3K4me3 in gliomas (Schram et al. 2013, Erfani et al. 2015). Interestingly, ASH2L 
demonstrated tumor suppressor characteristics in cell lines from several cancer types 
with enriched H3K4me3 at p53 pro-apoptotic gene promoters (Mungamuri et al. 2015). 
The authors implicated ASH2L in promoting stability of the initiation complex, though the 
specific role of ASH2L in this setting was not clearly defined. A dataset of 511 AML 
patient samples analyzed by reverse phase protein array (RPPA) revealed that ASH2L 
expression is inversely correlated with patient survival and expression of cell adhesion 
and cell cycle inhibition genes (Butler et al. 2017). 
 ASH2L is not well-characterized in breast cancer. Along with other 8p11-p12 
amplicon genes, ASH2L was identified as one of the core luminal B genes associated 
with cell cycle and proliferation (Cornen et al. 2014). Multiple analyses attempting to 
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identify the driver oncogene(s) from the 8p11-p12 amplicon called out the potential of 
ASH2L as such (Garcia et al. 2005, Yang et al. 2006, Kwek et al. 2009, Yang et al. 
2010, Cornen et al. 2014, Turner-Ivey et al. 2014), but investigation into its biological 
function has not yet been fully explored in a luminal B breast cancer model. One group 
demonstrated recruitment of ASH2L to the promoter of ESR1 by GATA3, where ASH2L 
potentiated the effects of the GATA3 transcription factor to induce ERα overexpression 
in breast cancer cell lines and primary tumors (Qi et al. 2014). Since ASH2L is one of the 
most coordinately overexpressed 8p11-p12 amplicon genes when it is amplified 
(Sircoulomb et al. 2011), and given the link between this amplicon and ERα as reported 
by our work on NSD3 (see Chapter 2) and its prevalence in the ER+ luminal subtype of 
breast cancer, understanding the link between ASH2L, ERα, and other amplicon genes 
such as NSD3 could provide exciting new insight into an understudied oncogene and 
lead to new therapeutic opportunities in this patient subset. This study seeks to explore 
the role of ASH2L in epigenetic regulation of gene expression in luminal B breast cancer 
cells with the goal of understanding another step in the mechanism of breast 
tumorigenesis. 
1.5. Significance 
 ER+ breast cancer, once thought to be a relatively straightforward disease 
dependent upon estrogen, has since proven to be an incredibly heterogeneous set of 
diseases with varying degrees of ERα expression and activity that makes reliable 
prediction of response to endocrine therapy nearly impossible. The call to discover 
oncogenic signatures that will inform individualized therapy for breast cancer patients is 
urgent. At the cross-roads of cancer genomics and epigenomics is amplification-induced 
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overexpression of chromatin-remodeling enzymes. The 8p11-p12 amplicon harbors two 
histone methyltransferases, NSD3 and ASH2L, which are capable of exerting a vast 
array of aberrations in the expression profiles of the tumors in which they are 
overexpressed, and therefore are the focus of the remainder of this work. HMTs have 
been cited as promising candidates for suppression in the treatment of various cancers 
(Chen et al. 2014, Liu et al. 2014, Michalak and Visvader 2016), and understanding how 
these enzymes function in the amplified and overexpressed state often observed in 
breast cancer will facilitate drug development in this field. Indeed, recent studies utilizing 
large-scale databases have identified several HMTs as compelling targets for drug 
development in cancer therapeutics and suggested that the NSD family of HMTs will 
provide the optimal starting place for structure-based design (Chen et al. 2014, Bennett 
et al. 2017). These studies have called for an improved understanding of chromatin-
modifying enzymes as a whole and NSD3 and ASH2L and the complexes in which they 
function specifically. These oncogenic enzymes have the potential to serve both as 
biomarkers for therapy response and as novel therapeutic targets themselves and 
represent an exciting new arm of investigation in breast cancer research and treatment. 
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CHAPTER 2: NSD3 amplification and overexpression results in overexpression 
and estrogen-independent activation of the estrogen receptor in human breast 
cancer. 
 
2.1. NSD3 is overexpressed in 8p11-p12 amplicon-bearing cell lines and is a 
verified oncogene. 
 Nuclear Receptor Binding SET Domain protein 3 (NSD3; formerly known as 
WHSC1L1) was verified as an oncogene by our laboratory (Yang et al. 2006, Yang et al. 
2010, Irish et al. 2016). We surveyed a panel of normal breast, breast cancer, and lung 
squamous cell carcinoma cell lines for expression of NSD3 and discovered that NSD3 is 
overexpressed at both the message and protein levels in amplicon-bearing cell lines 
compared to control and that expression is highest in the luminal B breast cancer cell 
line SUM-44 (Figure 2.1-A). Additionally, we noted that the short isoform of NSD3 
(NSD3-S) is expressed to a higher degree than the long isoform (NSD3-L), a finding 
consistent with data from our lab and others that have demonstrated a role for NSD3-S 
as the primary transforming isoform of this oncogene (Yang et al. 2010, Shen et al. 
2015). These data correlate with the Cancer Genome Atlas (TCGA), which also showed 
that, for a group of 964 breast cancer tumors, NSD3-S was overexpressed compared to 
NSD3-L in the context of NSD3 amplification (Figure 2.1-B) (Gao et al. 2013).  
 Since the effects of the two isoforms of NSD3 on cell proliferation had not been 
previously differentiated, we performed growth assays following knockdown of NSD3-S 
or total (NSD3-T) using shRNA that targeted either a unique sequence in the 3’UTR of 
the NSD3-S transcript or a sequence common to the coding region of both isoforms, 
respectively. Knockdown with either construct did not affect cell proliferation compared 
to LacZ control in the amplicon-null MCF7 breast cancer cell line or amplicon-bearing 
DMS-114 lung squamous cell cancer (LSCC) cell line (Figure 2.1-C and Figure 2.1-D). 
Knockdown of NSD3 with both constructs in the amplicon-bearing SUM-44 breast 
Chapter 2: NSD3  Page | 56  
 
Chapter 2: NSD3  Page | 57  
 
cancer cell line, however, did reduce cell proliferation (Figure 2.1-E). Interestingly, the 
inhibitory effect on growth was greater with knockdown of NSD3-S compared to NSD3-T 
(Irish et al. 2016), again underscoring the oncogenic role of the short isoform in 
particular. These proliferation assays were repeated using IPTG-inducible shRNA 
constructs and, although these constructs were able to achieve similar levels of NSD3 
knockdown as the constitutive vectors in SUM-44 and DMS-114 cells (Figure 2.1-F), the 
effects on cell growth were not recapitulated in either cell line (Figure 2.1-G). This and 
other data (Figure 2.2-A and Figure 2.2-B) prompted our lab to discontinue the use of 
the IPTG-inducible shRNA system. 
 To investigate the role of this oncogene further, our lab generated a transgenic 
FVB mouse model with targeted overexpression of NSD3 to the mammary epithelium 
(Turner-Ivey et al. 2017). NSD3 transgenic females exhibited morphological 
abnormalities during mammary gland development that resulted in a lactation defect due 
to the inability of alveoli to undergo full functional differentiation. By 40 weeks of age, 
these NSD3 transgenic females also developed mammary gland dysplasias, 
hyperplasias, carcinomas in situ, and invasive carcinomas. Together, these data validate 
previous work demonstrating the transforming ability of NSD3 and confirm its role as an 
important driving oncogene in human breast cancer. 
2.2. NSD3 knockdown results in reduced expression of estrogen receptor alpha 
(ERα). 
 To investigate further the role of NSD3 in breast cancer, we performed 
microarray analysis following NSD3-S knockdown in SUM-44 cells and noted decreased 
expression of multiple important genes, including ESR1, which encodes ERα (Table 
2.1). To confirm and explore this relationship, SUM-44 cells were infected with LacZ 
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control or IPTG-inducible 
NSD3-S or NSD3-T shRNA 
constructs and harvested at 
12 hour intervals following 
initiation of IPTG-treatment 
to assess NSD3 and ERα 
levels by western blotting 
and ESR1 levels by RT-
PCR. This system 
demonstrated very poor 
knockdown of either NSD3 
isoform and relatively little 
change in ERα or ESR1 levels (Figure 2.2-A). A second attempt at this experiment 
demonstrated similar results (Figure 2.2-B). Coupled with the inconsistent results 
observed on growth patterns using this inducible shRNA system (Figure 2.1-F and 2.1-
G), we concluded this system was unreliable and switched to the constitutive shRNA 
system exclusively. Knockdown of NSD3-S and NSD3-T reduced ERα levels compared 
to control beginning at 72 hours post-infection (Figure 2.2-C). ERα expression 
consistently reached peak knockdown at 7 days post-infection with shNSD3-S or NSD3-
T virus (Figure 2.2-D). This elucidation of the timing of NSD3-induced reduction in ERα 
levels was essential to begin to understand the mechanism and implications of this 
relationship. 




2.3. NSD3 overexpression results in overexpression of estrogen receptor alpha 
(ERα). 
 To explore further the effect of NSD3 amplification and overexpression on ERα 
expression, we assessed ERα levels by immunoblot in a panel of breast and LSCC cell 
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lines and determined that that SUM-44 cells express extremely high levels of ERα 
protein (Figure 2.3-A, upper). This finding was especially interesting considering that 
MCF7 cells are held as the benchmark ER+ cell line for ERα expression in vitro and ZR-
75-1, CAMA-1, and T47D are also described as ER+ and widely used to study ERα 
biology in breast cancer cell lines. SUM-44 cells have markedly increased ERα 
expression compared to all of these lines. RT-PCR for ESR1 expression in this panel of 
cell lines revealed that message level expression followed the same pattern as protein 
expression (Figure 2.3-A, lower). 
 To assess the biological relevance of the dramatic overexpression of ERα in 
SUM-44 cells in relation to ERα levels observed in patients, we performed RT-PCR to 
determine message level expression of NSD3 and ESR1 in a group of patient tumor 
specimens compared to the panel of cell lines (Figure 2.3-B). While we noted 7 cases of 
high ESR1 expression without corresponding overexpression of NSD3, indicating that 
ESR1 can be overexpressed without NSD3, we discovered that every case of NSD3 
overexpression also displayed high levels of ESR1. TCGA also demonstrates this link 
between NSD3 and ESR1 overexpression (Figure 2.3-C). We obtained a pleural effusion 
sample from a breast cancer patient at MUSC with metastatic ER+ breast cancer 
resistant to endocrine therapy and performed immunoblots for NSD3 and ERα (Figure 
2.3-D). While we were unable to isolate a homogeneous population of cells from this 
specimen, even this heterogeneous sample demonstrated NSD3 expression greater 
than MCF7 and CAMA-1 cells and ERα expression comparable to the ER+ CAMA-1 line. 
From these data we concluded that ESR1 can be overexpressed without NSD3 
overexpression, suggesting that there are multiple mechanisms for ERα upregulation in 
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human breast cancer, but not vice versa, demonstrating an important link between the 
NSD3 oncogene and the transcription factor ERα. Importantly, we found that only the 
SUM-44 cell line recapitulated the expression levels of these two genes in patient tumors 
(Figure 2.3-B). SUM-44 is the only in vitro model that represents this important subgroup 
of breast cancer patients and serves as a means by which to study the biology of tumors 
with NSD3-induced overexpression of ERα.  
 Since we previously demonstrated that knockdown of NSD3-S reduced ERα 
expression in SUM-44 cells (Figure 2.2), we next tested whether overexpression of 
NSD3-S in amplicon-null MCF7 (ER+) cells or amplicon-bearing CAMA-1 (ER+) and 
SUM-52 (ER-negative) cells would induce overexpression of ERα as detected by 
immunoblot. NSD3-S overexpression did not alter ERα levels in MCF7 cells but did 
increase ERα protein levels in both of the amplicon-bearing cell lines (Figure 2.3-E, 
upper). Message level expression of ERα downstream target genes in CAMA-1 cells 
also increased, suggesting that the upregulated ERα by NSD3-S overexpression is 
transcriptionally active (Figure 2.3-E, lower). This suggests that NSD3 is necessary but 
not sufficient to overexpress ERα and requires one or more additional factors present on 
the 8p11-p12 amplicon. Since NSD3 is an epigenetic modifier of chromatin, we 
assessed a panel of cell lines for expression of the two other chromatin modifiers 
present in the 8p11-p12 genomic region: KAT6A and ASH2L. RT-PCR revealed that, of 
the breast cancer cell lines, CAMA-1, SUM-52, and SUM-44 have the highest levels of 
KAT6A (Figure 2.3-F) and SUM-44 expresses the highest ASH2L protein levels, 
followed by SUM-52, CAMA-1, and MCF7 (Figure 3.1-A). Together, these data led to our 
hypothesis that these three 8p11-p12 amplicon oncogenes, ASH2L, KAT6A, and NSD3, 
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work cooperatively to promote tumorigenesis in luminal B breast cancer. This work 
discovered a clear link between NSD3 amplification and overexpression and 
overexpression of ERα in human breast cancer and identified SUM-44 as a unique 
model by which this patient group can be studied further. 
2.4. SUM-44 cells are estrogen-independent despite high-level ERα expression. 
 Since SUM-44 cells have extremely high levels of ERα expression, we 
hypothesized that this line would be highly responsive to its mitogenic ligand, 17β-
estradiol, and highly sensitive to the SERM tamoxifen as this drug is used clinically to 
treat ER+ breast cancers. To test this hypothesis, we measured the proliferation of SUM-
44 cells grown in phenol red-free media and treated with increasing doses of estrogen 
over 12 days and observed no difference in growth across these concentrations (Figure 
2.4-A). Since SUM-44 cells are routinely grown in serum free, low phenol red media, we 
tested the effect of phenol red, often cited as having a stimulatory effect on ERα 
(Wesierska-Gadek et al. 2006), in this cell line using “white” phenol red-free, “red” 
phenol red-supplemented, and “regular” low phenol red Ham’s F-12 media. We 
observed no difference in cell growth due to the phenol red content of the media (Figure 
2.4-B).  
 We next tested the effect of the SERM Tamoxifen on SUM-44 cells and, while 
higher concentrations of the drug did inhibit the growth of these cells, they were still able 
to proliferate and reached a plateau where increasing the amount of drug did not have a 
corresponding increase in response (Figure 2.4-C). We repeated this assay, performed 
in phenol red-free media, using 4OH-tamoxifen, the active metabolite of tamoxifen, and 
again observed a plateau in the proliferation response of this cell line (Figure 2.4-D). To 
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assess how this observation compared to other cell lines, we treated the 8p11-p12 
amplicon-bearing lines SUM-52, SUM-44, and CAMA-1 as well as the amplicon-null 
MCF7 line with 4OH-tamoxifen and observed that SUM-44 cells had little response up to 
the 1 nM treatment dose, mirroring the ER-negative SUM-52 line rather than the 
tamoxifen-sensitive ER+ CAMA-1 line (Figure 2.4-E). Interestingly, 4OH-tamoxifen 
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elicited an agonistic effect on the ER+ MCF7 cell line before achieving antagonistic 
concentrations (Figure 2.4-E). These results are an important step toward understanding 
patients with highly ER+ tumors that do not respond to traditional endocrine therapies.  
 In addition to these findings, ERα chromatin immunoprecipitation and high-
throughput sequencing (ChIP-seq) was performed in our laboratory (Irish et al. 2016). 
These data demonstrated that ERα maintained the ability to bind to chromatin without 
estrogen in SUM-44 cells. This work also showed that treatment with estrogen increased 
the number of peaks per gene and size of those peaks, indicating that these cells are 
capable of responding to estrogen, but no significant alterations of the interaction of ERα 
with the chromatin were observed in this context. Knockdown of NSD3-S abrogated the 
ability of ERα to bind to chromatin without estrogen, suggesting that the estrogen-
independent activity of ERα is dependent upon NSD3. Based on these observations, we 
concluded that, despite high-level ERα expression, the SUM-44 cell line is independent 
of estrogen signaling for growth and survival.  
2.5. SUM-44 cells are ERα-dependent. 
 One explanation for the estrogen-independent state of ERα in this model is that 
the receptor is no longer functional. Indeed, loss of ERα or its function is a known 
mechanism of endocrine resistance in ER+ human breast tumors (Kerdivel et al. 2013). 
Since we clearly demonstrate here that SUM-44 cells maintain ERα expression and 
previous characterization of this cell line detected wild-type ERα (Ethier 1996), we next 
sought to determine whether the receptor was functional in SUM-44 cells. Previously 
performed ChIP-seq experiments demonstrated that ERα is indeed capable of binding to 
chromatin without estrogen and ChIP-PCR validated enrichment of several important 
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ERα-target genes (Figure 2.5-A). Enrichment was enhanced by treatment with estrogen, 
again underscoring that this receptor maintains its normal structure and function. In 
MCF7 cells, there was no enrichment of target genes over negative control until 
estrogen was added. Interestingly, enrichment of the gene encoding the progesterone 
receptor (PR), an ERα pioneer factor associated with good prognosis genes that is lost 
in SUM-44 cells, was dramatically increased with estrogen treatment in MCF7 cells but 
not in SUM-44, further confirming that ERα is active in these cells but is behaving 
differently than in MCF7 cells (Mohammed et al. 2015). Indeed, ERα ChIP-seq in SUM-
44 cells identified FOXA1 binding motifs in addition to estrogen response elements 
(ERE) (Irish et al. 2016), consistent with reports that alternative pioneer factors are 
involved in ERα-mediated gene transcription upon loss of PR (Ross-Innes et al. 2012). 
 To test the ability of ERα to alter the expression of target genes, we performed 
RT-PCR following siRNA-mediated knockdown of ESR1 or FOXA1. ERα target gene 
expression decreased with knockdown of both ESR1 and FOXA1 (Figure 2.5-C). When 
ESR1 was knocked down using three different shRNA constructs, MCF7 cells 
demonstrated reduced proliferation while SUM-44 cells were unable to survive or 
proliferate (Figure 2.5-D), suggesting that SUM-44 cells are highly dependent on ERα for 
growth and survival. Array analysis following knockdown of either NSD3-S or ESR1 
revealed that the top-scoring biological processes of the genes affected by knockdown 
of both ESR1 and NSD3-S are related to cell cycle regulation and DNA replication 
(Table 2.2; Appendix A). Together, these data demonstrate that SUM-44 cells are highly 
dependent on ERα signaling for growth, survival, and gene transcription. We conclude 
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that ERα is active in an estrogen-independent manner in the 8p11-p12-amplified SUM-
44 cell line. 
 Since the SUM-44 cell line represents the group of patients who respond poorly 
to AIs and SERMs yet maintain high-level ERα expression, we tested the sensitivity of 
this cell line to the SERD Fulvestrant. At increasing doses of drug, we observed 
corresponding decreasing levels of ERα expression and proliferation of the cells (Figure 
2.5-E). When this response was compared to other cell lines, we noted that SUM-44 
cells are not as sensitive as the other ER+ MCF7 and CAMA-1 cell lines (Figure 2.5-F). 
Since the mechanism of action of the SERD compounds is dose-dependent and directly 
proportional to the ability of the drug to degrade the receptor, it is expected that a cell 
line such as 
SUM-44, which 
has the highest 
ERα expression 
of the cell lines 
tested (Figure 
2.3-A), would 
appear to be 
resistant to 
fulvestrant due 
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Figure 2.5. SUM-44 cells are ERα-dependent. A ERα ChIP-PCR in SUM-44 cells after 
treatment with 17β-estradiol for 6 hours. B ERα ChIP-PCR in MCF7 cells after treatment with 
17β-estradiol for 6 hours. C Immunoblot (inset) for protein expression and RT-PCR for 
transcript expression of selected ERα-target genes following siRNA-mediated knockdown of 
ESR1 (left) or FOXA1 (right) in SUM-44 cells. D Immunoblot for ERα expression (upper) and 
corresponding cell photographs (lower) following shRNA-mediated knockdown of LacZ control 
or ESR1 by three different shRNA constructs in MCF7 (left) and SUM-44 (right) cells. E 
Proliferation assay in SUM-44 cells treated with indicated concentrations of fulvestrant for 12 
days with corresponding immunoblot demonstrating dose-dependent degradation of ERα 
(inset). F Proliferation assay in SUM-44, SUM-52, CAMA-1, and MCF7 cells treated with 
indicated concentrations of fulvestrant for 12 days. (Figure on page 69). 
This is an important finding for breast cancer patients who fall into this subtype of cancer 
and provides foundational evidence for the 8p11-p12 amplicon as a marker for those 
patients who would benefit from addition of a SERD therapy to their AI/SERM regimen. 
These findings also underscore the need for development of additional SERD 
compounds that can achieve adequate degradation of ERα without subjecting patients to 
intolerable adverse effects.  
2.6. Summary 
 Together, these data demonstrate that amplification and subsequent 
overexpression of the NSD3 oncogene results in overexpression of the transcription 
factor ERα. Under these circumstances, the receptor is activated in an estrogen-
independent manner, rendering traditionally-used endocrine therapies, such as 
Tamoxifen, ineffective. These cells do, however, respond to the SERD Fulvestrant, but 
require high-dose treatment for adequate degradation of ERα. These data provide 
rationale for continued SERD development and offer a foundation for implementation of 
these types of therapies in patients using the 8p11-p12 amplicon and NSD3 
overexpression as a biomarker. Further investigation is required to elucidate the 
mechanism of NSD3-induced overexpression and activation of ERα, which could provide 
additional therapeutic strategies to combat endocrine-resistant breast cancer.  
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CHAPTER 3: ASH2L regulates gene expression via H3K4me3 in promoters and 
knockdown of ASH2L reduces expression of NSD3, ERα, and other genes 
important in cell proliferation processes. 
3.1. ASH2L is overexpressed in ER+, 8p11-p12 amplicon-bearing breast cancer. 
 ASH2L (Absent, Small, or Homeotic disc 2-Like) is a chromatin-modifying factor 
located in the 8p11-p12 genomic region and is amplified in approximately 12% of breast 
cancers (TCGA). In a panel of breast cancer cell lines, ASH2L is overexpressed to 
varying degrees compared to the non-transformed MCF10A breast cell line (Figure 3.1-
A). Of note, ASH2L is known to have two isoforms expressed in human tissues and 
multiple bands observed in ASH2L immunoblots suggest the presence of at least one 
other ASH2L isoform expressed in the amplicon-bearing SUM-44, CAMA-1, and SUM-
52 cell lines (Figure 3.1-A). This possibility was not explored further and only the highest 
molecular weight ASH2L isoform was pursued in this study as this is the major isoform. 
 According to TCGA, ASH2L mRNA expression is higher in clinically-defined ER+ 
breast tumors compared to ER-negative tumors (Figure 3.1-B). Similarly, mRNA 
expression is greatest in the TCGA-defined highly proliferative subgroup of ER+ breast 
tumors as compared to low proliferation ER+, ER-negative, and HER2-amplified tumors 
(Figure 3.1-C). Amplification of ASH2L is highly correlated with overexpression at the 
message level (Figure 3.1-D), consistent with our observations at the protein level by 
immunoblot in cell lines with ASH2L amplification (Figure 3.1-A), as well as several 
large-scale studies of the 8p11-p12 amplicon which identified ASH2L as one of the 
candidate oncogenes where amplification is well-correlated with overexpression. These 
studies suggest ASH2L as a potential driving oncogene from this genomic region, but it 
remains understudied in breast cancer. 
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 ASH2L is implicated in the tumorigenesis of osteosarcoma, glioma, and leukemia 
and is known to be primarily involved in tri-methylation of lysine (K) 4 on histone H3 
(H3K4me3) by interacting with binding partners, such as WDR5, RbBP5, DPY-30, and 
MLL proteins, which are SET domain-containing histone methyltransferases (HMTs) 
(Dou et al. 2006). ASH2L has demonstrated HMT activity on H3K4 as a heterodimer with 
RbBP5 even without a SET domain-containing collaborator and is part of all known 
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H3K4 HMT complexes characterized to date (Butler et al. 2017). As such, we sought to 
determine the influence of ASH2L on the H3K4me3 status in a luminal B breast cancer 
model. We selected the SUM-44 cell line, in which ASH2L is amplified and 
overexpressed to the highest degree of the cell lines tested (Figure 3.1-A). 
3.2. Overall H3K4 tri-methylation patterns in SUM-44 cells are similar between 
control and ASH2L knockdown on a global scale. 
 To assess the influence of ASH2L overexpression on H3K4 tri-methylation, we 
performed chromatin immunoprecipitation and high throughput sequencing (ChIP-seq) 
utilizing an H3K4me3 antibody following shRNA-mediated knockdown of ASH2L or LacZ 
control in SUM-44 cells. Three biological replicates for each of shLacZ control and 
shASH2L were performed, designated A, B, and C. Quality control measures can be 
found in Appendix B and complete gene lists and peak data can be found in Appendix C. 
Sequences were aligned and annotated and the overlap between these annotated gene 
names corresponding to peaks called for the replicates was analyzed by Venn Diagram 
comparison (Figure 3.2-A). Similar numbers of peaks were called across the three LacZ 
control replicates with near complete overlap, corresponding to 15,341 genes with 
H3K4me3 enrichment in common. Overlap between ASH2L knockdown replicates A and 
C was also nearly identical with peaks called in a similar number of genes, both to each 
other as well as the shLacZ samples. Replicate B of the ASH2L knockdown group 
demonstrated overall poor enrichment for H3K4me3 in the paired ChIP versus input 
samples (Appendix B), and thus a much smaller number of genes were called in this 
sample. Nevertheless, the degree of overlap of this gene set with the other two ASH2L 
knockdown replicates was high. Due to the discrepancy in enrichment in this ChIP 
compared to the other two, accepting only the genes enriched in all three replicates 
would erroneously suggest that overall H3K4me3 levels were reduced by ASH2L 
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knockdown. However, western blot analysis of whole cell lysates isolated in parallel with 
these ChIP samples indeed showed that global levels of H3K4me3 were not reduced by 
knockdown of ASH2L (Figure 3.2-B). Principal component analysis also demonstrated 
the very close similarity between the LacZ control replicates and relative variability in the 
ASH2L knockdown replicates, confirming the observations by the Venn Diagram-style 
comparisons of annotated gene names (Figure 3.2-C). Based on these data, the genes 
were summed across the three replicates within each shRNA type for further analysis. 
 To determine the set of genes with reduced H3K4me3 enrichment due to 
knockdown of ASH2L, the LacZ control gene set was compared to that of the ASH2L 
knockdown group (Figure 3.2-D; Appendix D). We had hypothesized that there would be 
a significant proportion of genes with decreased enrichment of H3K4me3 upon 
knockdown of ASH2L, corresponding to the far left segment of the Venn Diagram in 
Figure 3.2-D, which represents the genes with peaks called in the LacZ control but not 
ASH2L knockdown group. While 2,251 genes do indeed fall into this category, the vast 
majority (13,090) of genes demonstrated enrichment in common between LacZ control 
and ASH2L knockdown. Since this Venn Diagram strategy of comparison employed a 
binary, presence or absence assessment of the two gene sets, differences in peak 
concentration between the two conditions were not taken into account. Analysis of the 
log2 fold change between the ASH2L knockdown and LacZ groups as a function of the 
log2 concentration of each sequence represented did indeed show that overall H3K4me3 
enrichment was reduced following knockdown of ASH2L (Figure 3.2-E). These data 
demonstrate that knockdown of ASH2L does reduce the robustness of H3K4me3 peaks, 
but does not cause them to completely disappear. This is likely due to residual 
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expression of ASH2L in the knockdown samples (Figure 3.2-B). The implications of this 
scenario on gene transcription are unknown.  
 Together, the results of the ChIP analysis demonstrated that knockdown of 
ASH2L reduced the size of H3K4me3 peaks in SUM-44 cells, but the number of peaks 
and the overall distribution of H3K4 tri-methylation between control and ASH2L 
knockdown groups was largely unchanged. This observation was in contrast to our 
original hypothesis that knockdown of ASH2L would reduce global patterns of H3K4me3 
in SUM-44 cells. Instead, we discovered that H3K4me3 peaks are similar between 
control and ASH2L knockdown, which then led us to the hypothesis that ASH2L may 
play a role in H3K4 tri-methylation in a more specific set of genes. 
3.3. ASH2L is responsible for H3K4me3 in the promoters of genes involved in 
breast cancer tumorigenesis. 
 H3K4me3 is known to be most abundant in the 5’ proximal promoter regions of 
actively transcribed genes (Demers et al. 2007, Luscher-Firzlaff et al. 2008). Similarly, 
ASH2L has been shown to be confined to these regions as well (Demers et al. 2007). In 
order to identify the specific gene set with ASH2L-regulated H3K4me3 peaks, we sorted 
the overall peak data sets by detailed annotation and isolated the peaks with promoter 
annotations only. Promoter H3K4me3 peaks were found in 3,317 genes from the LacZ 
group and 2,522 genes from the ASH2L knockdown group. Comparison between the 
two gene sets identified 2,035 genes that lose H3K4 tri-methylation following knockdown 
of ASH2L and are therefore found uniquely in the LacZ control gene set (Figure 3.3-A). 
These genes annotate primarily to cell cycle processes by ToppFun analysis (Figure 3.3-
B and Appendix E). Somewhat unexpectedly, there were also a significant number of 
genes (1,240) with promotor H3K4 tri-methylation that demonstrated enrichment upon 
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ASH2L knockdown only. This is especially interesting since ASH2L is tightly and 
specifically linked to H3K4me3 and may indicate that another HMT gains H3K4 tri-
methylation ability in the context of 8p11-p12 amplification in breast cancer. 
 Several interesting patterns emerged upon closer inspection of the 2,035 genes 
that lost H3K4me3 enrichment following ASH2L knockdown. Twelve of the 21 candidate 
oncogenes from the 8p11-p12 amplicon region are contained in this 2,035 gene set, 
including ADAM9, ASH2L, DDHD2, DUSP4, FGFR1, IKBKB, LSM1, PLEKHA2, POMK, 
SMIM19, UBXN8, and WHSC1L1 (NSD3), and thus we predict have increased 
H3K4me3 in their promotor regions due to ASH2L overexpression when the amplicon is 
present. These genes have some of the strongest peak scores and most have multiple 
peaks called in their promoter region in the shLacZ control group but do not have any 
peaks called in the ASH2L knockdown group (Table 3.1). Examination of the peaks in 
the integrated genome viewer (IGV) demonstrated the robust nature of the promoter 
H3K4me3 peaks in these genes, including WHSC1L1 (NSD3) and ASH2L itself, as 
opposed to other significant genes identified in this dataset, such as EZH2 and WDR5 
(Figure 3.3-C). RSF1 was included here to illustrate the dramatic decrease in peak size 
in the promoter peaks of NSD3 and ASH2L upon ASH2L knockdown since RSF1 was 
not identified as differentially regulated between control and ASH2L knockdown 
datasets. ESR1 was included here to demonstrate negative ChIP data as neither the 
control nor ASH2L knockdown samples identified H3K4me3 peaks at the ESR1 gene 
promoter. These data highlight the cooperative nature of this amplicon and suggest that 
ASH2L may be involved in generating a positive feedback loop of active transcription of 
amplicon genes. 
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 In addition to the 8p11-p12 amplicon genes listed above, several important 
epigenetic regulators were identified in this 2,035 gene set (Table 3.1). As mentioned, 
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the other oncogenic 8p11-p12 amplicon HMT NSD3 was found in this set, as was EZH2, 
the major HMT of the polycomb group complexes that are antagonized by trithorax 
group proteins such as ASH2L. The ASH2L sub-complex member WDR5 appeared 
here, as did KMT2B (MLL4), one of the SET domain-containing enzyme family that is 
activated by ASH2L to generate H3K4me3. These data again suggest that knockdown of 
ASH2L breaks several positive feedback loops in which it participates to maintain active 
transcription via chromatin remodeling. While the loss of H3K4me3 peaks upon ASH2L 
knockdown provides some insight into the genes that may be under epigenetic control of 
this oncogene, this dataset does not provide information regarding the transcriptional 
effect that loss of this histone modification induces. Therefore, additional exploration of 
the effects of ASH2L knockdown on the transcriptome was carried out. 
3.4 ASH2L knockdown reduces expression of genes with decreased promoter 
H3K4me3 levels. 
 To determine the influence of ASH2L knockdown on gene expression, total RNA 
was harvested and sequenced in triplicate following ASH2L knockdown using two 
different shRNA constructs in SUM-44 cells.  The resulting datasets (Appendix F) were 
compared to RNA-seq from shLacZ control triplicate samples run in parallel. We 
identified 6,473 genes downregulated in common between control and ASH2L 
knockdown with the ASH2L 275. We similarly identified 5,766 genes downregulated in 
common between control and knockdown with the ASH2L 276 construct. We used a 
false discovery rate (FDR) cutoff of 0.4 for this analysis, a measure of the probability of 
type I error, in this case the assumption that these genes were significantly differently 
expressed from control when they actually were not. To increase statistical stringency, 
we next compared the differentially expressed genes from the two ASH2L shRNA 
constructs compared to control and identified 3,278 genes that were downregulated in 
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common between them (Figure 3.4-A; Table 3.2; Appendix G). In order to assess the 
biological processes affected by this suite of genes, we performed ToppFun analysis on 
the 3,278 genes and discovered that they are involved in cell cycle regulation, DNA 
replication, and chromatin organization (Figure 3.4-B). These results are consistent with 
previously implicated functions of ASH2L. We validated knockdown of several of these 
genes by immunoblot, including Ki-67, PI3K, and FOXA1 (Figure 3.4-C). Expression of 
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these genes did decrease upon knockdown of ASH2L in SUM-44 cells but had varied 
changes in expression in MCF7 cells, in which ASH2L is not amplified and its expression 
is much lower than in SUM-44 cells. These data validate the RNA-seq results and 
confirm that knockdown of ASH2L reduces gene expression. Interestingly, several of the 
genes with reduced transcript expression following ASH2L knockdown RNA-seq 
analysis did not demonstrate reduced protein levels (Figure 3.4-C), suggesting a 
disconnect between transcript- and protein-level expression for a subset of ASH2L-
regulated genes. 
 In order to determine which of the genes with decreased H3K4me3 promoter 
peaks in ASH2L knockdown cells also demonstrated decreased expression upon 
knockdown of ASH2L, the 3,278 genes downregulated in common between both ASH2L 
knockdown constructs compared to control were then cross-referenced with the 2,035 
genes that lost H3K4me3 peaks after knockdown of ASH2L. This strategy identified 438 
genes with coordinated decreased expression and H3K4me3 peak loss (Figure 3.4-D). 
ToppFun analysis of this set of genes assigned many of the same processes and 
pathways as the RNA-seq gene set alone, including palbociclib response, cell cycle 
processes, and chromosome organization (Figure 3.4-E and Appendix H). This gene set, 
however, was also assigned to several additional processes and pathways, such as 
genes that are upregulated in MCF7 cells upon treatment with estradiol, proteins that 
interact with ESR1/ERα, DNA and RNA binding, and histone methyltransferase activity. 
Together, these results demonstrate that ASH2L regulates H3K4me3 in the promoter 
regions of important genes related to breast cancer, primarily related to cell cycle and 
chromatin modification, and some of these genes are downregulated at the transcript 
and protein level as a result.  
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3.5 ASH2L, NSD3, and ERα influence the expression of similar suites of genes 
related to cell cycle progression. 
 The 438 genes identified in the previous section as downregulated upon loss of 
promoter H3K4me3 due to ASH2L knockdown were also implicated in ESR1 interactions 
and response to estradiol (Figures 3.4-D and 3.4-E; Appendix H). Given these results, 
the inclusion of NSD3 in this group of 438 ASH2L-regulated genes, and the link between 
NSD3 overexpression and estrogen-independent activation of ERα (see Chapter 2), we 
hypothesized that ASH2L is responsible for promoter H3K4me3-mediated NSD3 
overexpression in the context of amplification of these two oncogenes, thus influencing 
ERα expression and activity and perpetuating the alterations to the transcriptome in the 
setting of 8p11-p12 amplified breast cancer. Knockdown of ASH2L resulted in reduced 
protein expression of NSD3 and ERα in SUM-44 cells (Figure 3.5-A), supporting the 
hypothesis that these three factors are cooperating to alter transcription in luminal B 
breast cancer models. Additionally, preliminary evidence in support of this hypothesis 
from TCGA demonstrates that ASH2L and NSD3 overexpression at the transcript level is 
highly correlated in a cohort of 2,509 primary breast tumors, with a Pearson correlation 
score of 0.81 and Spearman rank of 0.65 (Figure 3.5-B).  
 To test this hypothesis further, we compared the 438 genes with reduced 
H3K4me3 and expression upon ASH2L knockdown with genes that were downregulated 
upon ESR1 or NSD3-S knockdown using a p-value cutoff of 0.1 (Figure 3.5-C). In this 
analysis, 320 genes were unique to the ASH2L knockdown H3K4me4 ChIP-seq/RNA-
seq downregulated group. We ran ToppFun analysis on this set of 320 genes and 
discovered they align with processes primarily involved in DNA repair and chromosome 
organization. (Figure 3.5-D and Appendix I). Interestingly, “ESR1 interactions” was 
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identified as a significant process ascribed to the 320 genes regulated by ASH2L, 
indicating that the group of genes under ASH2L transcriptional regulation are ERα -
interacting proteins. As expected, these genes include chromatin remodeling enzymes 
and factors associated with transcription, such as TOPBP1, ZNF131, SMARCE1, 
TADA3, and several ribosomal proteins. PIK3CA also appears in this set of 320 genes, 
and the PI3K/AKT/mTOR pathway is known to play a role in activation of ERα via 
phosphorylation of S167 of the ERα protein. Treatment of LacZ control or ASH2L 
knockdown SUM-44 cells with 1 μM of the mTOR inhibitor KU-0063794 for 24 hours did 
not reduce ERα-pS167 levels in SUM-44 or MCF7 cells, however (Figure 3.5-E). ASH2L 
and its sub-complex binding partner WDR5 are included in the list of genes that annotate 
in ToppFun to ESR1 interactions, suggesting that these proteins themselves may 
cooperate with ERα. ASH2L immunoprecipitation (IP) followed by ERα blotting identified 
a possible interaction between these two proteins (Figure 3.5-F). Although the MLL 
proteins are known to bind to ERα, this is the first study to provide evidence that ASH2L 
and ERα may directly interact and this possibility should be explored further.  
 From the overlapping gene sets in Figure 3.5-C, the 58 genes commonly 
downregulated by ASH2L and ESR1 knockdown were primarily involved in the cell cycle 
and estradiol-regulated processes. The 16 genes commonly downregulated by ASH2L 
and NSD3 knockdown were involved in processes having to do with transcription and 
chromatin/DNA interactions (data not shown). We have previously analyzed the overlap 
between ESR1 and NSD3 function (Chapter 2; (Irish et al. 2016)). Since the set of genes 
here is specifically those which were found to be downregulated by microarray analysis 
(p<0.1), we analyzed these genes by ToppFun and found that they annotate to 
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processes similar to what we previously reported, including cell cycle and estradiol-
mediated processes (data not shown).  
3.6 Knockdown of ASH2L results in decreased proliferation and clonogenicity in 
luminal B breast cancer and reduces sensitivity to palbociclib. 
 Since ASH2L knockdown reduces expression of NSD3 and ERα, we 
hypothesized that ASH2L indirectly mediates the expression of the genes regulated by 
these two factors. The H3K4me3 ChIP-seq data indicated that ASH2L directly affects 
epigenetic regulation of NSD3 but not ESR1 (Figure 3.3-C) and we already validated the 
causal relationship between knockdown of NSD3 and decreased ERα expression 
(Chapter 2), so it is possible that the downregulation of these two factors occurs 
sequentially following knockdown of ASH2L. To test this hypothesis, whole cell lysate 
was harvested from SUM-44 cells at 5, 7, 11, and 14 days following infection with 
ASH2L-specific or LacZ control shRNA vectors and probed for ASH2L, NSD3, and ERα 
protein expression (Figure 3.6-A). Although previous immunoblots for these proteins 
performed as knockdown validation steps for other experiments indicated that the 
reduction in NSD3 expression may precede that of ERα, and that shRNA-mediated 
NSD3 knockdown-induced reduction in ERα expression takes approximately seven 
days, this more controlled test did not reproduce the temporal aspect of ASH2L 
knockdown-mediated reduction of NSD3 and ERα expression. 
 Some of the 44 genes shown in Figure 3.5-C derived by comparison of the 
ASH2L knockdown H3K4me3 ChIP-seq, ASH2L knockdown RNA-seq, and ESR1 and 
NSD3-S knockdown arrays gene sets appear in Table 3.3. This gene set is associated 
with several interesting processes by ToppFun analysis (Figure 3.6-B and Appendix I). 
Many of these processes are associated with the cell cycle. Since this is a common 
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theme associated with ASH2L-mediated transcriptomic alterations and high proliferation 
rates are associated with luminal B breast cancer and poor prognosis, we measured cell 
growth following shRNA-mediated knockdown of ASH2L in several cell lines (Figure 3.6-
C). In both amplicon-bearing (SUM-44, CAMA-1, and SUM-52) and amplicon-null 
(MCF7) cell lines, knockdown of ASH2L by two different shRNA constructs reduced cell 
proliferation compared to shLacZ control. Knockdown levels were reported by 
immunoblot analysis for ASH2L expression in the four cell lines (Figure 3.6-C). Similarly, 
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knockdown of ASH2L was performed in SUM-44 and MCF7 cells and clonogenicity 
measured by colony forming assay (Figure 3.6-D). Knockdown of ASH2L reduced 
clonogenicity in both cell lines to approximately the same degree, and the 276 ASH2L 
shRNA construct demonstrated a much greater effect than the 275 construct in both cell 
lines, although both achieved statistical significance (Figure 3.6-D, upper). Together, 
these data demonstrate that knockdown of ASH2L decreases cell proliferation and 
clonogenic potential in luminal breast cancer cell lines regardless of 8p11-p12 
amplification status. 
 In addition to cell cycle processes, analysis of ASH2L-regulated genes 
consistently identified palbociclib response as a significant process to which they are 
annotated (Figure 3.4-B, Figure 3.4-E, Figure 3.6-B). Palbociclib selectively inhibits 
cyclin dependent kinases (CDK) 4 and CDK6, which bind cyclin D1 (CCND1) to advance 
cell cycle progression from G1 to S phase (Nagaraj and Ma 2015). CCND1 is found on 
the 11q14 amplicon, which SUM-44 cells harbor in addition to the 8p11-p12 amplicon 
(Kwek et al. 2009). CDK6 is also amplified in this cell line and was identified by siRNA-
based screening technique performed in our lab as essential for growth and survival of 
these cells. Palbociclib is approved for use in postmenopausal women with ER+/HER2-
negative breast cancer and clinical trials are in progress for several similar compounds 
(Knudsen and Witkiewicz 2016). To determine the sensitivity of ASH2L-overexpressing 
cell lines to palbociclib, we treated a panel of cell lines with increasing doses of 
palbociclib and assessed cell number on day seven (Figure 3.7-A). We observed that 
the ASH2L-low MCF7 and CAMA-1 cell lines were more sensitive to palbociclib than the 
SUM-44 and SUM-52 cells. To validate the bioinformatic assignment of ASH2L-
regulated genes to palbociclib response, we knocked down ASH2L in SUM-44 and 
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MCF7 cells with increasing doses of palbociclib and measured their growth (Figure 3.7-
B). Knockdown of ASH2L reduced sensitivity of SUM-44 cells to palbociclib but had no 
effect on MCF7 sensitivity to this compound. Of note, MCF7 had greater overall 
sensitivity to palbociclib than SUM-44 cells. MCF7 cells do not have amplification of 
8p11-p12 or 11q14. 
 To further examine the relationship between genes regulated in expression by 
ASH2L, NSD3, and ESR1, and genes associated with response to palbociclib, a sub-set 
of genes was identified and expression level assessed by qRT-PCR. The set of 44 
genes regulated by ASH2L, NSD3, and ESR1 included 10% (17 of 172) of the genes 
annotated as involved in response to palbociclib in ToppFun according to the 
comparative toxicogenomics database (CTD) (Table 3.4). From this set of 17 genes that 
lost promoter H3K4me3 upon ASH2L knockdown and were downregulated in response 
to knockdown of ASH2L, NSD3, and ESR1, we selected a sub-set of five genes that 
were downregulated in response to treatment with palbociclib according to CTD data, 
including FBXO5, EZH2, TTK, CCNE2, and BUB1 (Table 3.4). To determine if treatment 
with palbociclib reduced expression of these genes in the context of ASH2L 
overexpression, we treated SUM-44 and MCF7 cells with palbociclib and harvested RNA 
24 hours after treatment with 100 nM palbociclib for analysis of relative transcript 
expression by RT-PCR (Figure 3.7-C). Expression of FBXO5, EZH2, TTK, CCNE2, and 
BUB1 was reduced in the palbociclib-sensitive MCF7 cell line, as predicted by the CTD 
data, however SUM-44 cells did not demonstrated a reduction in transcript level for 
these genes. ASH2L and ESR1 transcript levels were not significantly affected by 
palbociclib treatment (Figure 3.7-C). RNA was also harvested 2 and 96 hours following 
treatment with 100 nM palbociclib, demonstrating a recovery in gene expression at 96 
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hours post-palbociclib in the MCF7 cell line and an increase in transcript expression in 
the SUM-44 line for the five genes assessed (Figure 3.7-D). These data indicate that 
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palbociclib resistance in the SUM-44 cells may be due to ASH2L-mediated 
transcriptional upregulation of genes that must be downregulated for response to 
palbociclib, thus preventing the cytostatic effects of this compound. This hypothesized 
mechanism should be investigated further. 
 The smallest set of genes analyzed in ToppFun, the 44 in common to ASH2L 
knockdown H3K4me3 ChIP-seq, ASH2L knockdown RNA-seq, NSD3-S and ESR1 
knockdown microarrays (Figure 3.5-C), annotated to palbociclib response with the 
strongest p-value (Figure 3.6-B; Table 3.4), indicating that ASH2L, NSD3, and ERα all 
have a role in mediating expression of the suite of genes responsible for sensitivity to 
palbociclib and highlighting again the cooperative potential of these oncogenes in 8p11-
p12-amplified breast cancer. This set of 44 overlapping genes (Appendix H) likely 
regulated by ASH2L, NSD3, and ESR1 requires further validation of their expression and 
investigation of the biological processes to which they connect that is beyond the scope 
of this study. 
3.7 Summary 
 Little was known about ASH2L in breast cancer prior to these studies. Here, we 
demonstrated that ASH2L is involved in H3K4 tri-methylation specifically at the 
promoters of target genes without altering global H3K4me3 levels. Knockdown of ASH2L 
results in decreased expression of a subset of these genes with ASH2L-mediated 
promoter H3K4me3 marks, and these genes are implicated in cell cycle regulation and 
chromosome organization. ASH2L potentially exerts downstream effects by modulating 
several proteins important to cell signaling pathways, such as the PI3K/AKT1/mTOR 
pathway, and through expression of cell cycle proteins such as cyclin D1. Additionally, 
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ASH2L may be responsible for H3K4me3-mediated transcriptional regulation of itself as 
well as the co-amplified HMT NSD3, which has been shown to overexpress and activate 
ERα in an estrogen-independent manner (Chapter 2). Together, these data implicate 
ASH2L in the regulation of a large suite of genes, both directly and indirectly, when 
amplified and overexpressed in luminal B breast cancers. These studies identify ASH2L 
as an upstream regulator of many targetable pathways in breast cancer, and therefore 
this oncogene has the potential to inform drug discovery. Further investigation into the 
ASH2L complex composition in this setting and confirmation of the factors and pathways 
under control of this oncogene will be essential to extend these studies, ultimately 
leading to therapies that will benefit the breast cancer patient population with ASH2L 
amplification and overexpression. 
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CHAPTER 4: Discussion and Future Directions 
4.1. 8p11-p12 Amplified Breast Cancer 
a. Breast cancer in vitro models 
 Due to the incredible heterogeneity of breast cancer, a major challenge in 
research is acquiring laboratory models able to encompass the multiple patient 
subpopulations observed clinically (Benjamini and Hochberg 1995, Kao et al. 2009, 
Dabydeen and Furth 2014). The MCF7 cell line is considered the gold standard by which 
ER+ breast cancers are studied in vitro and in vivo, however this luminal A cell line does 
not sufficiently capture the complexity of the luminal type tumors as a whole (Comsa et 
al. 2015). This cell line has a simplex genomic pattern and is sensitive to endocrine 
therapies such as tamoxifen (Shiu et al. 2010, Comsa et al. 2015). While attempts have 
been made to induce tamoxifen resistance in MCF7 cells and these altered cell lines 
have been thoroughly investigated, this artificial representation of endocrine resistance 
does not translate to patient tumors and the genomic profiles of these modified MCF7 
cell lines do not resemble patient-derived luminal B cell lines (Ross-Innes et al. 2012).  
 Model cell lines with intrinsic tamoxifen resistance have been reported but 
generally have lost ERα expression or dependence in culture, such as the SUM-52 cell 
line. While it is well-known that a significant number of patient tumors retain ERα 
expression even in the context of resistance to endocrine therapy, an in vitro model 
accurately representing this patient population has not previously been available (Cui et 
al. 2005). Similarly, although cell lines with amplification of the 8p11-p12 amplicon have 
been reported, these models have varying degrees of expression of the oncogenes 
contained in this region (Ray et al. 2004, Garcia et al. 2005, Gelsi-Boyer et al. 2005). 
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Approximately 15% of primary breast tumors have 8p11-p12 amplification and this 
number increases in metastatic samples, correlating with poor prognosis and ERα 
expression (Bernard-Pierrot et al. 2008, Tabarestani et al. 2016). Several groups have 
linked the 8p11-p12 amplicon with endocrine resistance (Shiu et al. 2010, Luo et al. 
2017). Amplification is a major mechanism of oncogene overexpression and activation 
(Ray et al. 2004, Yang et al. 2006, Streicher et al. 2007, Bernard-Pierrot et al. 2008), 
and thus there is a need for more model cell lines by which to study the highly 
heterogenic 8p11-p12 amplicon.   
 The SUM-44 cell line, originating from metastatic cells in the pleural effusion fluid 
from a breast cancer patient with ER+ disease (Ethier et al. 1993), reflects the 
characteristics of a subset of breast cancer patients not previously represented in vitro, 
including intrinsic tamoxifen resistance and amplification of the 8p11-p12 genomic region 
(Ray et al. 2004, Irish et al. 2016). This cell line expresses ESR1/ERα to a higher degree 
than other ER+ cell lines, even MCF7 cells, a biologically relevant observation when 
compared to patient tumor sample ESR1 expression (Figure 2.3-B). SUM-44 cells have 
amplification of 8p11-p12 with abundant overexpression of the amplicon genes, even 
compared to other amplicon-bearing cell lines such as CAMA-1 and SUM-52 (Figure 
2.3-A). Interestingly, the SUM-52 cell line, originally ER+, has lost ERα expression in 
culture and although the CAMA-1 cell line retains ERα expression, the level is very low 
compared to MCF7 and SUM-44. Together, the data presented in this work establish a 
model by which endocrine resistant, highly ER+ breast tumors can be investigated. Due 
to the heterogeneity of breast cancer patients, establishment of additional models is 
necessary, but here we offer an important advancement in the ability to understand the 
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8p11-p12 amplicon in luminal B breast cancer and the effects of the amplicon genes on 
constitutive activation of ERα as well as the transcriptome as it relates to tumorigenesis. 
b. NSD3 
 NSD3 (WHSC1L1) was identified and validated as an 8p11-p12 amplicon 
oncogene in breast and other cancers (Yang et al. 2010, Bilal et al. 2012, He et al. 2013, 
Mahmood et al. 2013, Chen et al. 2014, French et al. 2014). We and others have 
demonstrated that the catalytic, SET domain-containing NSD3-L isoform is not the major 
oncogenic isoform (Shen et al. 2015, Irish et al. 2016). Instead, NSD3-S, produced by 
alternative splicing at exon 10 of the NSD3 (WHSC1L1) gene, is more highly expressed 
than NSD3-L (Figure 2.1-A) and has greater transforming ability when overexpressed in 
the MCF10A breast cell line (Yang et al. 2010). Knockdown of this isoform reduced cell 
proliferation and expression of ESR1, the gene that encodes ERα (Figure 2.2). Further 
investigation of this relationship identified that NSD3-mediated overexpression of ERα 
resulted in estrogen-independent activity of this receptor (Figure 2.5) and tamoxifen 
resistance (Figure 2.4). In the context of the 8p11-p12 amplicon, ERα is targeted to 
FOXA1 binding sites in addition to EREs (Irish et al. 2016), resulting in downstream 
transcription of a suite of genes correlating with poor prognosis in breast cancer (Figure 
2.5-C). Knockdown of NSD3 and ESR1 identified altered expression of genes 
associated with cell cycle processes (Table 2.2), suggesting that one of the roles of 
NSD3-S is to mediate ERα activity and estrogen dependence.  
 The mechanism of NSD3-induced overexpression and estrogen-independent 
activation of ERα is poorly understood. Since the effect is mediated primarily by NSD3-
S, investigation of the role of NSD3-S in general will elucidate possible effects on ERα. 
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Shen et al. (2015) identified NSD3-S as an adaptor protein between BRD4, a member of 
the bromodomain and extraterminal domain (BET) family of chromatin readers, and 
CHD8, a chromodomain helicase DNA binding protein involved in transcriptional 
regulation via nucleosome remodeling. BRD4 is tethered to chromatin by acetylated 
histones and is essential for maintenance of leukemia through interactions with other 
proteins. Identification of NSD3-S as an adaptor protein that aides BRD4 interactions 
with these other factors is a novel finding that has implications for breast cancer 
treatment. Preliminary studies in our laboratory indicate that SUM-44 cells may be 
sensitive to the BRD4 inhibitor JQ1 and that NSD3 binds BRD4 by co-IP (data not 
shown). BET inhibitors are currently under investigation in several cancer types (French 
et al. 2014), and inclusion of NSD-S as a potential biomarker for patient response would 
be an exciting arm of investigation. 
 In addition to its role as a linker protein, NSD3-S has been hypothesized to inhibit 
histone and non-histone protein methylation. NSD3-S retains the N-terminal PWWP 
domain and maintains the ability to read methylated H3K36 residues, thereby occupying 
potential binding sites of the NSD3-L isoform (Stec et al. 2001). In addition to the 
implications of such a role for NSD3-S on gene transcription, this hypothesis is 
applicable to ERα activation. In estradiol-mediated activation of ERα, the protein is de-
methylated and acetylated at the K266 residue (Zhang et al. 2013). In the context of 
NSD3-S amplification and overexpression, NSD3-S may bind ERα-K266 and prevent 
methylation, thereby leaving the protein susceptible to activation by acetylation, perhaps 
by another amplified and overexpressed 8p11-p12 amplicon oncogene, KAT6A, a HAT 
enzyme. The potential influence of NSD3-S on ERα PTM could be investigated by ERα 
proteomic analysis following knockdown of NSD3-S. Similarly, ERα is activated by 
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several phosphorylation events and any potential effects of NSD3-S on ERα 
phosphorylation could be identified by the same technique. 
 Since ERα is a receptor that is activated by ligand-stimulated dimerization, it is 
possible that NSD3-S does not affect the ERα protein itself and, instead, ERα is 
activated in an estrogen-independent manner by NSD3-induced overexpression leading 
to spontaneous dimerization. ERα is known to have a ligand-independent AF-1 domain 
(Cui et al. 2005), therefore abundant expression of the receptor as is observed with 
NSD3 amplification and overexpression may be sufficient to result in estrogen-
independent ERα activity. AF-1 is known to be involved in transcription of a suite of 
genes different from those mediated by the ligand-dependent AF-2 domain (Wang and 
Yin 2015), consistent with ERα ChIP-seq and microarray results that demonstrated 
differential binding and expression profiles in 8p11-p12 amplicon-bearing SUM-44 cells 
compared to amplicon-null MCF7 cells (Irish et al. 2016). Testing the hypothesis that 
abundant overexpression of ERα is sufficient to induce estrogen-independent activation 
would require overexpression of the receptor in MCF7 cells and assessing ERα activity 
by reporter assay and RT-PCR for ERα target genes in the absence of estrogen. If these 
experiments indeed demonstrate estrogen-independent ERα activity, we would then 
predict that these MCF7 cells induced to recapitulate the ERα expression levels 
observed in SUM-44 cells would show tamoxifen resistance in vitro but would retain their 
sensitivity to fulvestrant. 
 If the estrogen-independent activation of ERα is due to its overexpression rather 
than PTM, then we would hypothesize that the effect of NSD3 overexpression to induce 
ERα overexpression reported here is due to epigenetic modifications by NSD3 that lead 
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to increased transcription of ESR1. Since NSD3-S is implicated in chromatin 
modification as an adaptor protein and NSD3-L is implicated in H3K36me3 in gene 
bodies of actively transcribed genes, analysis of the epigenetic landscape at the ESR1 
gene with knockdown of NSD3-S and NSD3-T would identify the relationship between 
these two isoforms of NSD3 and their transcriptional effects on ESR1. Indeed we have 
shown that knockdown of NSD3 reduced ESR1 transcript and ERα protein levels (Figure 
2.2), but the precise temporal relationship between this events has yet to be determined, 
therefore it remains unclear whether NSD3 knockdown first affects ESR1 transcription or 
ERα protein stability/activity/PTM that then results in a positive feedback loop whereby 
activated ERα is able to increase its own expression by its actions as a transcription 
factor. Other ERα co-factors and modifying proteins that may be involved in this process 
also remain yet unknown. Clearly, there is still a great deal of investigation necessary to 
elucidate the mechanism of ERα overexpression in the context of NSD3 amplification 
and overexpression. 
 The discovery of the relationship between overexpression of the 8p11-p12 
amplicon oncogene NSD3 and overexpression and estrogen-independent activation of 
ERα has exciting implications for the treatment of amplicon-bearing luminal B breast 
cancers. We have demonstrated that these cells, though tamoxifen resistant (Figure 2.4-
E), respond to the SERD fulvestrant (Figure 2.5-E and Figure 2.5-F) and treatment with 
fulvestrant recapitulates the cytotoxic effects of ESR1 knockdown in this cell line. The 
link between NSD3 and ERα described here is a novel mechanism of endocrine 
resistance in ER+ breast cancer.  
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 In addition to breast cancer, the 8p11-p12 amplicon is present in several other 
cancer types (Gao et al. 2013, Mahmood et al. 2013). NSD3 is a validated oncogene in 
lung squamous cell carcinoma (LSCC), bladder carcinoma, and AML (Mahmood et al. 
2013, Shen et al. 2015). These cancers are not ERα-dependent as is the case in breast 
cancer, and we demonstrated that two LSCC cell lines with high expression of NSD3 
have undetectable levels of ERα expression (Figure 2.1-A and Figure 2.3-A). As such, 
we hypothesize that NSD3 has an important role in tumorigenesis outside of its effects 
on ERα. NSD3 is the least studied member of the NSD family of SET domain HMT 
proteins and the effects of NSD3 and its substrate, H3K36me2, remain understudied in 
cancer. In order to investigate the genes under epigenetic regulation by NSD3, we 
attempted to perform ChIP-seq analysis in SUM-44 cells utilizing an NSD3 antibody 
developed by the Vakoc group at the Cold Spring Harbor Laboratory (Shen et al. 2015), 
but were unsuccessful. The H3K4me3 ChIP-seq performed in this study in the context of 
ASH2L knockdown demonstrated the potential efficacy of employing a similar strategy to 
investigate the effects of NSD3 on H3K36me2 in the SUM-44 cell line as a future 
direction of this project. 
 Figure 4.1 illustrates the three proposed mechanisms of NSD3 oncogenesis. 
Panel A depicts the epigenetic role of NSD3-L, which catalyzes H3K4me2 in gene 
bodies to promote active transcription. We hypothesize that, in addition to a suite of 
genes involved in regulation of the cell cycle, NSD3 promotes transcription of ESR1, 
thereby inducing ERα overexpression. Since NSD3-S lacks the catalytic SET domain, its 
mechanism for promoting tumorigenesis remains largely unknown. Figure 4.1-B depicts 
a possible role for NSD3-S based on the model proposed by Shen et al. (2015). Here, 
NSD3-S acts as an adaptor protein for recruitment of additional chromatin-modifying 
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enzymes and transcription factors, thus affecting the transcriptome. This mechanism 
relies on chromatin binding by BRD protein family, which recognize acetylated histones 
(Lo and Sukumar 2008). We have previously hypothesized that the 8p11-p12 amplicon 
oncogene KAT6A is responsible for histone acetylation in this context. Alternatively, 
anchoring of NSD3-S to the chromatin by the BRD family proteins may act to prevent 
binding by NSD3-L, thus preventing H3K36me2 in those gene bodies. The exact 
mechanism and downstream implications of possible NSD3-S inhibition of NSD3-L 
remain to be elucidated. Finally, we have also hypothesized that NSD3-S binds K 
residues on the ERα protein itself, preventing its methylation and rendering it susceptible 
to activation by acetylation (Figure 4.1-C). These different mechanisms of action are not 
mutually exclusive and all potentially influence cell cycle progression, tumorigenesis, and 
endocrine resistance and therefore extension of the work reported here should explore 
each of these hypotheses. 
c. ASH2L 
 ASH2L is understudied in breast cancer despite having been identified by several 
groups as a potential driving oncogene from the 8p11-p12 amplicon region (Garcia et al. 
2005, Kwek et al. 2009, Cornen et al. 2014). Here, we identified a role for ASH2L in the 
regulation of H3K4me3 in promoter regions and expression of genes associated with cell 
cycle (Chapter 3). Knockdown of ASH2L resulted in decreased expression of an 
important set of genes, reduced proliferation and clonogenicity, and reduced sensitivity 
to the cell cycle inhibitor palbociclib. Together, the results of this study identify ASH2L as 
a driving oncogene in ER+ breast cancer and as a potential biomarker for palbociclib 
sensitivity in endocrine resistant tumors, a therapy currently in clinical trials for the 
treatment of ER+ breast cancer. Further investigation of ASH2L as a biomarker for drug 
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response and as a potential drug target itself could identify new therapeutic strategies to 
increase survival in patients with the 8p11-p12 amplicon. 
 ASH2L lacks the catalytic SET domain characteristic of HMT enzymes (Ikegawa 
et al. 1999). While this oncogene does possess methyltransferase activity when coupled 
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with its binding partner RbBP5 (Tan et al. 2009), ASH2L commonly relies on the 
formation of complexes with SET domain-containing proteins, such as the MLL family of 
HMTs, where the role of ASH2L lies primarily in promoting catalysis of H3K4me3 
(Steward et al. 2006). ASH2L is present in all known complexes responsible for 
H3K4me3 and is tightly and specifically linked to this histone methyl mark (Butler et al. 
2017). Here, we demonstrated that knockdown of ASH2L reduced the robustness of 
global H3K4me3 peaks across the genome in SUM-44 cells (Figure 3.2-E). Remaining 
H3K4me3 is likely a result of incomplete knockdown of ASH2L, which was not achieved 
due to the extreme level of ASH2L overexpression in the context of its amplification 
(Figure 3.2-B). Despite the reduction in robustness, ASH2L knockdown had little effect 
on the overall distribution of H3K4me3 peaks (Figure 3.2-D). We were, however, able to 
identify a major role for ASH2L in the elimination of H3K4me3 peaks specifically in the 
promotor regions of genes (Figure 3.3-A), a function in agreement with the previous 
studies on ASH2L-directed H3K4 tri-methylation (Demers et al. 2007).  
 The complex in which ASH2L functions in the context of the 8p11-p12 amplicon 
is yet unknown and investigation of the protein(s) assisting ASH2L would be an 
interesting future direction of this project. It is possible that ASH2L is forming a complex 
with the MLL family as is well-documented, but with the extremely high level of 
amplification-induced overexpression of ASH2L it is also possible that novel binding 
partners are favorable in this context. Since ASH2L lacks a catalytic SET domain, the 
direct versus indirect role of ASH2L on histone methylation is unclear. The effects of 
ASH2L on H3K4me3 elucidated in this study may be a reflection of indirect effects via 
the influence of ASH2L on binding partners. Indeed, we demonstrated here that the 
ASH2L binding partner WDR5 has reduced promoter H3K4me3 peaks and transcript 
Chapter 4: Discussion  Page | 104  
 
expression upon ASH2L knockdown (Tables 3.1 and 3.2). WDR5 is responsible for 
chromatin binding, recruitment of ASH2L and other MLL complex proteins, and stability 
of the ASH2L-MLL complex (Steward et al. 2006, Guccione et al. 2007, Ali and Tyagi 
2017). Identification of regulation of WDR5 expression by ASH2L reveals a feedback 
loop by which ASH2L may increase its chromatin-binding ability. Lack of corresponding 
evidence of ASH2L-mediated regulation of MLL family members suggests that ASH2L is 
relying on alternative binding partners for its function in the context of amplification-
induced overexpression in breast cancer. Suspected ASH2L binding partners, such as 
other SET domain-containing proteins, could be identified by ASH2L IP followed by 
immunoblotting for such factors, although novel ASH2L binding proteins would not be 
identified by this method and would require additional techniques such as proteomic 
analysis. 
 According to the ChIP-seq and RNA-seq analyses presented in Chapter 3, 
ASH2L mediates H3K4me3 at its own promoter as well as several other chromatin-
modifying enzymes such as NSD3 and EZH2, suggesting that ASH2L amplification 
establishes a positive feedback loop whereby amplified ASH2L drives expression of 
itself, leading to increased transcription of cell cycle genes and chromatin-modifying 
enzymes that also alter downstream gene expression. Similarly, ASH2L knockdown 
abolished H3K4me3 in the promoter regions of over half of the candidate oncogenes 
from the 8p11-p12 amplicon region (Table 3.1), suggesting that ASH2L may have a role 
in modulating the expression of these amplified genes. Of these amplicon genes, 
however, RNA-seq analysis identified only POMK and NSD3 as transcriptionally 
downregulated upon knockdown of ASH2L but also identified the 8p11-p12 amplicon 
gene KAT6A, another epigenetic factor, as being under ASH2L transcriptional regulation 
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without corresponding modification of the H3K4me3 status of its promoter region (Table 
3.2). Further investigation of the relationship between promoter H3K4me3 and 
transcription is required. Epigenetic regulation is complex and other chromatin-modifying 
or epigenetic reader enzymes may be altered in the context of ASH2L knockdown to 
modify the histone code, accounting for the discrepancy between H3K4me3 and 
transcription.  
 The ChIP-seq and RNA-seq datasets provide a plethora of avenues for further 
investigation of the role of this oncogene in cell and tumor biology. Importantly, the 
analysis presented in Chapter 3 focused solely on genes which lost H3K4me3 promoter 
tri-methylation with a corresponding reduction in gene expression upon ASH2L 
knockdown. Genes with increased expression following ASH2L knockdown may 
represent tumor suppressors that are reduced when ASH2L is amplified and 
overexpressed. Genes that gained H3K4me3 following knockdown of ASH2L may 
represent an interesting group of factors, especially considering other groups have 
reported ASH2L knockdown abolishes H3K4 tri-methylation as ASH2L is required to 
promote catalysis of this reaction. Of note, we did not recapitulate the global reduction in 
H3K4me3 upon ASH2L knockdown that other studies have demonstrated, indicating that 
either ASH2L is overexpressed to such a degree in SUM-44 cells that residual levels are 
sufficient to maintain H3K4me3 methyltransferase activity or that another factor is 
compensating for ASH2L reduction in the context of 8p11-p12 amplification. 
Identification of an HMT with H3K4 tri-methylation capabilities independent of ASH2L 
would be a novel finding in the field. 
 Finally, immunoblots designed to validate the ASH2L RNA-seq knockdown 
results identified several proteins with unchanged expression despite message-level 
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downregulation (Figure 3.4-C), suggesting a disconnect between transcriptional 
regulation and ultimate expression of several key factors. The complex nature of 
epigenetic alterations, transcriptional effects, and protein expression and stability leave 
several questions unanswered from these studies. The data indicate ASH2L influences 
H3K4me3 in the promoter of NSD3 and knockdown of ASH2L reduces NSD3 expression 
(Figure 3.3-C, Figure 3.5-A, and Table 3.2), therefore we hypothesize that amplification 
of ASH2L leads to overexpression of co-amplified NSD3, which then influences ESR1 
and ERα expression and activity (Chapter 2), as well as cell cycle genes and ASH2L 
itself, establishing a positive feedback loop. This hypothesis is illustrated by Figure 4.2-
A. More investigation into the complex biology of 8p11-p12 amplified breast tumors is 
required to fully understand the implications of ASH2L and its direct and indirect impact 
on breast cancer progression and therapy resistance. 
d. Cooperating oncogenes and ERα 
 One hypothesis generated from this study is that ASH2L and NSD3 cooperate to 
alter epigenetic regulation of gene transcription and expression and activity of ERα in the 
context of 8p11-p12 amplified breast cancer. We demonstrated that knockdown of 
ASH2L abolished H3K4me3 in the promoter of NSD3 (Figure 3.3-C and Table 3.3), 
reduced NSD3 and ESR1 transcript levels (Table 3.2), and decreased NSD3 and ERα 
protein expression (Figure 3.5-A and Figure 3.6-A) in SUM-44 cells. Knockdown of 
NSD3 reduced ESR1 and ERα expression (Figure 2.2). From these data we conclude 
that ASH2L regulates NSD3 expression via promoter H3K4me3 and NSD3 then 
regulates expression and estrogen-independent activation of ERα. Further study is 
necessary to determine if ASH2L is directly involved in overexpression and/or activation 
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of ERα and whether these two oncogenes, ASH2L and NSD3, cooperate to modify the 
chromatin state in breast tumors in which they are amplified and overexpressed. 
 As discussed above, the complex in which ASH2L is found is essential to its 
function. Since ASH2L lacks the catalytic SET domain of other HMT enzymes, 
recruitment of SET proteins is essential to ASH2L function (Dou et al. 2006). NSD3-L 
possesses a SET domain that primarily catalyzes H3K36me2 in gene bodies and is 
associated with active transcription (Li et al. 2009). NSD3-L has also been implicated in 
H3K4 methylation, but this histone mark has not been well-characterized for this enzyme 
(Jacques-Fricke and Gammill 2014). IP of ASH2L followed by immunoblot for NSD3 
would determine whether ASH2L and NSD3 form a complex and, if so, which isoform of 
NSD3 is involved. These proteins do not necessarily need to bind one another, however, 
in order to coordinately regulate gene expression (Figure 4.2-C). ASH2L NSD3-S lacks a 
catalytic SET domain like ASH2L yet displays oncogenic characteristics when 
overexpressed in non-transformed breast cells (Yang et al. 2010). These two oncogenes 
may therefore provide similar functions in breast cancer cells outside of histone 
methylation. Since the stability and activity of several important proteins, ERα included, 
depends on PTM such as methylation (Zhang et al. 2013), global proteomic analysis of 
the methylome in breast cancer cell lines following knockdown of either ASH2L or 
NSD3-S would be an interesting future direction of this project. 
 In order to interact with chromatin, NSD3 requires the assistance of chromatin 
reader proteins such as those of the BET family (Wagner and Carpenter 2012). Other 
studies have identified BRD4 as an NSD3 binding partner, but other BRD family proteins 
may also be involved (Shen et al. 2015). BRD2 was identified here by H3K4me3 ChIP-
seq and RNA-seq with ASH2L knockdown, NSD3-S knockdown array, and ESR1 
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knockdown array (Table 3.3). Immunoblot analysis following knockdown of ASH2L in 
SUM-44 and MCF7 cells did not reveal a change in BRD2 expression, however (Figure 
3.4-C). Whole cell lysate was harvested for the blots shown in Figure 3.4-C seven days 
post infection with ASH2L shRNA constructs, therefore longer incubation may be 
required to detect changes in protein expression. Alternatively, a disconnect between 
promoter H3K4me3, transcription, and protein expression may be present in these cells 
and investigation of factors involved in translational regulation would be an interesting 
future direction of this project. One such factor, EIF4EBP1, is found on the 8p11-p12 
amplicon, is amplified and overexpressed in SUM-44 cells, and is implicated in 
translational dysregulation in cancer (Karlsson et al. 2011). This factor may mediate the 
proteomic effects of transcriptional dysregulation by ASH2L, NSD3, and ERα. 
 While we discovered a direct link between knockdown of NSD3-S and reduced 
expression of ESR1 and ERα (Figure 2.2), we were not able to induce overexpression of 
ERα in the amplicon-null MCF7 cell line simply by overexpression if NSD3-S (Figure 2.3-
E). Successful induction of ERα overexpression in the amplicon-positive cell lines 
CAMA-1 and SUM-52 suggests that other amplicon components are required for 
overexpression and activity of ERα in this setting. IP followed by immunoblot for ERα 
identified a potential interaction between these two proteins (Figure 3.5-F). The MLL 
complex, which includes ASH2L, is known to interact directly with ERα and ERα relies 
on histone- and chromatin-modifying enzymes to promote transcription at ERα-target 
genes (Cui et al. 2005, Turner-Ivey et al. 2014). Therefore, we hypothesize that ASH2L 
and ERα cooperate to alter gene transcription in the context of 8p11-p12 amplification, 
including increased transcription of ESR1 (Figure 4.2-B). Additional co-IP assays are 
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required to validate the interaction between ASH2L and ERα and close study of the 
transcriptional effects of these two factors would be necessary to explore this 
hypothesis. 
 The complex nature of amplification-induced overexpression and subsequent 
activation of oncogenes, epigenetic modifications, transcriptional regulation, and ERα-
Chapter 4: Discussion  Page | 110  
 
signaling renders study of individual genomic alterations difficult. This study attempted to 
elucidate the roles of two important oncogenes, ASH2L and NSD3, and characterize the 
transcriptional effects of these two epigenetic factors. There are a multitude of pathways 
to investigate stemming from these studies, some of which are discussed here. 
Ultimately, the goal of these in vitro studies is to identify novel mechanisms of drug 
treatments for patients with 8p11-p12 amplicon-bearing ER+ breast cancer. The 
implications of these studies on breast cancer management are discussed below. 
4.2. ER+ Breast Cancer Treatment 
a. Endocrine therapies 
 While tamoxifen and the aromatase inhibitors have made great strides in the 
treatment of ER+ breast cancer, not all patients with ER+ disease respond to these 
drugs. Mechanisms of endocrine resistance have long been the subject of investigation, 
and several have been identified. First, loss of ERα expression can occur (Cui et al. 
2005). These cells are no longer dependent upon the receptor for growth and survival, 
therefore endocrine therapies are irrelevant to these processes, much like tumors that 
are ER-negative upon diagnosis. Second, point mutations in the ligand-binding domain 
of ERα can abrogate the ability of tamoxifen to bind and activate the ligand-independent 
AF-1 domain of ERα (Chang 2012, Angus et al. 2016). This mechanism renders AIs 
ineffective as well since ERα is no longer dependent upon estrogen for activation and is 
capable of signaling through the ligand-independent AF-1 domain. Third, amplification of 
ESR1, though rare, does occur (Tabarestani et al. 2016). This mechanism is not yet 
well-characterized, but does correlate with endocrine resistance. Finally, we 
demonstrate here a novel mechanism of endocrine resistance: overexpression and 
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estrogen-independent activation of ERα by the 8p11-p12 amplicon oncogene NSD3, 
perhaps in cooperation with other amplicon-oncogenes (Chapter 2). This mechanism 
also requires further investigation, as discussed above, but highlights again the diversity 
of breast tumors and the genomic alterations that can have vast effects on drug 
sensitivities, underscoring the need to better characterize luminal B breast cancers to 
identify novel treatment strategies to overcome endocrine resistance. 
 Several drugs have undergone clinical trials for the treatment of endocrine-
resistant, ER+ breast cancer. Fulvestrant was developed in an attempt to expand the 
SERM repertoire to pure ERα antagonists (Howell 2006). Fulvestrant (ICI 182,780; 
Faslodex) binds ERα and induces a conformational change different than that of 
tamoxifen, preventing dimerization and targeting the receptor for degradation by the 
proteasome system (Dowsett et al. 2005). Fulvestrant binding also inactivates both the 
AF-1 and AF-2 domains of ERα, unlike tamoxifen, completely abolishing ERα-mediated 
gene transcription (McKeage et al. 2004). Since the mechanism of action of Fulvestrant 
is primarily due to degradation of ERα, cross-resistance with tamoxifen and anastrozole 
is minimal (De Marchi et al. 2016). Several clinical trials assessing efficacy and dosing of 
Fulvestrant led to its approval in 2010 for the treatment of post-menopausal women with 
ER+ breast cancer nonresponsive to other endocrine therapy (Ignatiadis and Sotiriou 
2013).  
 While Fulvestrant has been a major step forward in breast cancer treatment, the 
ability of this drug to degrade ERα is dose-dependent and achieving steady-state doses 
adequate for tumors with high-level ERα expression is a major clinical challenge 
(Robertson 2007). Several other SERDs are under development and testing, but interest 
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in this drug class has diminished due to apparent resistance in patients. This so-called 
resistance, however, may be due the dose-dependent nature of Fulvestrant, reflecting 
inadequate bioavailability. The work presented here is an important step toward shifting 
the paradigm regarding ERα expression and endocrine therapy resistance. Most luminal 
B tumors have relatively low ERα expression and it has long been thought that these 
tumors are not dependent upon the receptor for growth and survival, thereby accounting 
for the overall poor response to endocrine therapies (Ades et al. 2014). Here, we 
demonstrate that high-level ERα expression does occur in patient tumors with endocrine 
resistance, this receptor is a driving oncogene in this setting, and abolishing ERα 
expression is detrimental to these cancer cells (Chapter 2). The data presented in this 
work support continued development of the SERD drug class and underscore the need 
for such a drug that can effectively eliminate high ERα overexpression in patients. 
b. Signaling pathway therapies 
 In addition to therapies targeting ERα signaling, several other pathways have 
been implicated in ER+ breast tumors. The “non-genomic” effects of ERα have been 
described in detail in several review articles, all concluding that cytoplasmic and/or 
membrane-bound ERα cross-talks with growth factor receptor pathways such as EGFR 
(McKeage et al. 2004, Dowsett et al. 2005, Johnston et al. 2005, Kristensen et al. 2005, 
Nicholson and Johnston 2005, Ariazi et al. 2006, Howell 2006, Chang 2012, Fedele et 
al. 2012, Ignatiadis and Sotiriou 2013, Kerdivel et al. 2013, Nagaraj and Ma 2015, Wang 
and Yin 2015, Tabarestani et al. 2016). In breast cancer, ERα expression (ERα-66) is 
essentially exclusively nuclear, as demonstrated by IHC staining of patient biopsies and 
ERα ChIP experiments identifying chromatin-bound ERα prior to treatment with 17β-
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estradiol (Cui et al. 2005, Howell 2006, Angus et al. 2016, Irish et al. 2016). Smaller ERα 
isoforms, most commonly ERα-36 and ERα-46, have been described as mediating these 
non-genomic ERα activities and the sensitivity of these isoforms to endocrine therapy is 
unknown, though both retain the DNA-binding and ligand-binding domains (Wang and 
Yin 2015). Additionally, the role of ERβ in breast cancer is not fully characterized 
(Hartman et al. 2009). Despite the questions that still remain surrounding non-genomic 
ERα signaling, it is known that cross-talk with cell signaling pathways does occur in the 
form of post-translational modifications. 
 The PI3K/AKT/mTOR pathway is known to activate ERα by phosphorylation of 
several serine residues, including S118, S167, and S305 (Kerdivel et al. 2013, Zhang et 
al. 2013, Steelman et al. 2016). The EGFR pathway can phosphorylate ERα tyrosine 
residue Y537 and p38/MAPK is implicated in threonine phosphorylation on ERα-T311 
(Cui et al. 2005, Kerdivel et al. 2013). Several drugs targeting these pathways have 
been tested in ER+ breast cancer, but success is limited and biomarkers of response are 
unknown (Morris and Wakeling 2002, Fedele et al. 2012). Since the PI3K/AKT/mTOR 
pathway was identified as possibly regulated by ASH2L (Chapter 3), we hypothesized 
that inhibition of mTOR would alter ERα phosphorylation, possibly identifying the 
mechanism behind estrogen-independent activation of ERα in the SUM-44 cell line. 
Reduced PI3K expression by ASH2L knockdown was confirmed by immunoblot but 
AKT1 was unchanged (Figure 3.4-C) and immunoblot for ERα-pS167 following treatment 
with the mTOR inhibitor KU-00063794 did not identify reduction of phosphorylation at 
this site (Figure 3.5-E), therefore the mechanism of estrogen-independent ERα 
activation remains unknown.  
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 Another strategy for overcoming endocrine resistance is to target genes 
downstream of ERα (Mancuso and Massarweh 2016). ERα drives cell cycle progression 
from G1 to S phase through activation of its transcriptional program (Wang and Yin 
2015). CCND1 (cyclin D1) is an ERα-target gene that mediates G1 to S phase transition 
by binding to CDK4 or CDK6 and stimulating transcription (Dabydeen and Furth 2014). 
Cyclin D1 is associated with several types of cancer, including breast, and is correlated 
with endocrine resistance (Dabydeen and Furth 2014, Nagaraj and Ma 2015). As 
discussed in section 1.2b, amplification of CCND1, located at 11q13, occurs in a subset 
of breast cancer patients and the 11q12-q14 amplicon often co-occurs with the 8p11-p12 
amplicon (Still et al. 1999, Reis-Filho et al. 2006, Kwek et al. 2009, Karlsson et al. 2011, 
Sircoulomb et al. 2011, Bilal et al. 2012, Cornen et al. 2014). Cooperation of 11q14 
oncogenes with oncogenes from the 8p11-p12 amplicon has been suggested (Kwek et 
al. 2009, Karlsson et al. 2011) and the data presented here supports this hypothesis. 
The CDK4/6 inhibitor palbociclib is in clinical trials in ER+ breast cancer and is 
demonstrating increased progression free survival in conjunction with endocrine therapy 
in luminal breast cancers (Nagaraj and Ma 2015, Turner et al. 2015, Angus et al. 2016, 
Knudsen and Witkiewicz 2016, Mancuso and Massarweh 2016). Genes with reduced 
H3K4me3 promoter peaks and transcript expression following ASH2L knockdown in 
SUM-44 cells annotated to the “palbociclib response” with a p-value of 5.7E-7, 
suggesting that knockdown of ASH2L reduces the expression of a suite of genes that 
sensitize cells to palbociclib (Figure 3.4-E). We tested response to palbociclib in the 
SUM-44 and MCF7 cell lines following knockdown of ASH2L and validated that ASH2L 
knockdown reduces palbociclib response in SUM-44 cells (Figure 3.6-E). MCF7 cells 
were more sensitive to palbociclib than SUM-44 cells and ASH2L knockdown did not 
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alter sensitivity. Interestingly, CCND1 was identified as downregulated by knockdown of 
ASH2L (Table 3.2), yet immunoblot for cyclin D1 expression demonstrated increased 
cyclin D1 protein levels in SUM-44 cells and no change in MCF7 following knockdown of 
ASH2L (Figure 3.4-C). MCF7 cells do not have either the 8p11-p12 or 11q12-q14 
amplicons present in SUM-44 cells, underscoring the complexity of luminal B breast 
cancer genomic alterations and the potential interaction between multiple oncogenes 
affecting the biology and drug sensitivities of these tumors. 
 Although therapies targeting signaling pathways that complement ERα activity 
have demonstrated some improvement in the treatment of ER+ breast cancer, 
resistance and lack of biomarkers are still common clinical challenges. The work 
presented here identified NSD3 as a potential biomarker for SERD response and ASH2L 
as a potential biomarker for palbociclib response in endocrine-resistant tumors. The 
8p11-p12 amplicon represents not only a source of therapy response markers, but 
understanding the mechanism of action of the oncogenes present in this genomic region 
provides the potential for development of novel therapies that will affect the genomic and 
epigenomic events responsible for tumorigenesis. Indeed, epigenetic therapies are 
under clinical investigation and have demonstrated some success in the treatment of 
breast and other cancer types (Kerdivel et al. 2013, Ades et al. 2014). This work on 
NSD3 and ASH2L provides additional evidence that can be utilized for the development 
and novel therapies and improvement of those already under clinical investigation. 
c. Epigenetic therapies for ER+ breast cancer 
 Unlike genetic alterations, epigenetic changes leading to cancer are reversible 
(Lo and Sukumar 2008, Simon and Lange 2008, Kristensen et al. 2009). Coupled with 
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increased understanding of the histone modifying enzymes dysregulated in cancer and 
their downstream effects, the potential therapeutic benefits of targeting these factors is 
becoming apparent (Morishita and di Luccio 2011). Of the epigenetic drugs, DNMT and 
HDAC inhibitors are the best-studied. Use of these drugs has identified the need to 
better understand optimal timing of epigenetic therapy, appropriate biomarkers, and 
specificity of chromatin-modifying enzymes for tailored therapeutic benefit (Lustberg and 
Ramaswamy 2009, Pathiraja et al. 2010, Cai et al. 2011).  
 HDAC inhibitors (HDACi) have been explored in several disease states, including 
ER+ breast cancer (Thomas and Munster 2009). HDACi are implicated in cell cycle 
arrest by nuclear export of cyclin D1, which interacts with histone modifying enzymes to 
execute its transcriptional program, and by favoring hyperacetylation of genes, including 
pro-apoptotic genes, leading to their expression (Alao et al. 2004, Inoue and Fry 2015). 
HDACi themselves do not discriminate transcription of pro- versus anti-apoptotic genes, 
leaving certain tumors exposed to the possibility of HDACi-induced accelerated growth 
until biomarkers can be established to predict this differential response (Lo and Sukumar 
2008, Lustberg and Ramaswamy 2009). HDAC inhibition also re-sensitizes cells to 
endocrine therapies by interrupting the interaction of HDACs with DNMTs, reversing the 
DNA methylation-induced silencing of ESR1 (Allred et al. 2004, Kristensen et al. 2009, 
Thomas and Munster 2009, Abdel-Hafiz and Horwitz 2015). This mechanism, however, 
only affects tumors where the mechanism of endocrine resistance is loss of ERα 
expression. Alternatively, HDACi have been implicated in hyperacetylation of the 
chaperone protein HSP90 (Lo and Sukumar 2008, Lustberg and Ramaswamy 2009). 
ERα is one of the many client proteins of HSP90, so hyperacetylation that destabilizes 
HSP90 results in degradation of ERα. HDACi, however, can also alter the chromatin 
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structure, allowing histone acetylation-mediated opening of genetic material for 
increased transcription by ERα (Margueron et al. 2004).The multiple and potentially 
conflicting mechanisms by which HDACi function highlight the need to better understand 
epigenetic factors and tailor inhibition toward remedy of specific dysregulated processes. 
 Clinical investigation of HDACi has provided an important step forward in the use 
of epigenetic therapy to treat cancer (Lustberg and Ramaswamy 2011, Connolly and 
Stearns 2012, Walsh et al. 2016). Since histone methylation is not as well-understood as 
DNA methylation and histone acetylation, HMT inhibition (HMTi) is not as developed as 
inhibition of other epigenetic enzymes (Morishita and di Luccio 2011). As the field of 
epigenomics progresses, however, the importance of this mechanism of gene regulation 
has become clear and HMTi is advancing (Morishita and di Luccio 2011, French et al. 
2014, Liu et al. 2014). Several groups have used large databases such as GISTIC and 
TCGA to determine optimal factors for drug targeting and EZH2, MLL, and the NSD 
family of HMTs have been identified as some of the most ideal candidates (Liu et al. 
2014, Michalak and Visvader 2016). EZH2 inhibitors have progressed furthest of the 
HMTi class, but even these drugs have only reached early stage clinical trials (Garapaty-
Rao et al. 2013, Curry et al. 2015, Michalak and Visvader 2016, Sato et al. 2017). Other 
HMTi remain under preclinical investigation and require additional in vitro studies of HMT 
activity and mechanisms of action, such as those described in this work, for continued 
advancement of this field (Liu et al. 2014, Katoh 2016, Michalak and Visvader 2016). 
 EZH2 is a PcG protein implicated in H3K27 methylation-mediated transcriptional 
repression and is one of the best-studied HMT enzymes to date (Lo and Sukumar 2008, 
Pathiraja et al. 2010, Grzenda et al. 2011). It functions in polycomb repressive 
complexes (PRC) and is antagonized by the Trx group proteins such as ASH2L and the 
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MLL complexes (Simon and Lange 2008, Grzenda et al. 2011, Huang et al. 2011). HMT 
inhibitors (HMTi) have been primarily targeted to EZH2 and have been designed based 
on the paradigm that histone methylation is a negative regulator of tumor suppressors, 
and therefore inhibition of EZH2 and other PcG factors will alleviate this repression and 
halt cell cycle progression (Curry et al. 2015, Sato et al. 2017). There is some evidence 
to indicate that this strategy may be efficacious as EZH2 inhibitors indeed demonstrate 
reduced growth in tumor cell lines in vitro (Garapaty-Rao et al. 2013). Unfortunately, 
these therapies are highly dose-dependent and require further investigation to determine 
the precise timing for optimal treatment (Lustberg and Ramaswamy 2009, Garapaty-Rao 
et al. 2013). Several combination therapies have been tested in an attempt to circumvent 
these issues and have displayed more success than individual compounds, however 
these studies have also revealed the need to better understand the histone modifications 
at particular loci to optimize HMTi therapies as global inhibition is not necessarily the 
best strategy in all cases (Lo and Sukumar 2008, Curry et al. 2015, Sato et al. 2017). 
Several companies are developing additional HMT inhibitors currently, including specific 
EZH2 inhibitors as well as generalized SET domain inhibitors, which would not only 
target repressive histone methyltransferases but also transcriptional activators such as 
NSD3 and the MLL family proteins (Michalak and Visvader 2016). 
 Another strategy by which HMT activity can be targeted is via chromatin-
interacting proteins such as those of the chromatin-reader bromodomain and 
chromodomain families. Many HMT enzymes, NSD3 and ASH2L included, rely on these 
reader proteins for recruitment to directed sites on the chromatin. Bromodomain 
inhibitors have been under development and testing and have shown promising results 
in the clinic (French et al. 2014, Borbely et al. 2015). These chromatin readers, however, 
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are promiscuous and broad inhibition of their activity has unknown implications. One 
advantage to this strategy of epigenetic inhibition is that non-SET domain-containing 
proteins, such as ASH2L and NSD3-S, are also inhibited in the manner. NSD3-S is 
known to rely on the BRD family of bromodomain proteins for chromatin tethering, and 
inhibition of BRD4 has demonstrated abrogated NSD3-S interaction with chromatin 
(Shen et al. 2015). NSD3-S bound to BRD4 also binds other factors, such as the 
chromodomain protein CHD8, a potential novel drug target in cancer (Shen et al. 2015). 
Another bromodomain protein, ANCCA, is implicated in recruitment of MLL complexes to 
histones (Zou et al. 2014). These chromatin-reading protein families are candidates for 
drug development and understanding their mechanism of action and effects on the 
epigenomic state of cancer cells is essential to optimizing their therapeutic benefits. 
 Epigenetic therapies represent a novel arm of therapeutic investigation and, 
though still in the early stages of development compared to many other cancer treatment 
strategies, comprise a promising source of compounds with the potential to revolutionize 
cancer treatment. The work presented here on NSD3 and ASH2L, both associated with 
transcriptional activation by histone methylation activity, challenges the current paradigm 
that epigenetic factors function as oncogenes by transcriptional repression of tumor 
suppressors. The antagonistic relationship of these trithorax group proteins on the 
polycomb group counterparts such as EZH2 is an interesting and extremely complicated 
topic of future investigation. Overall, it is clear that further investigation of the specific 
actions of epigenetic factors dysregulated in cancer is necessary in order to advance the 
field of epigenomics and identify efficacious strategies for targeting the biological effects 
of these alterations in patients. 
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4.3. Concluding Remarks 
 Breast cancer is the most common cancer in women and second leading cause 
of cancer death in women in the United States, resulting in the loss of 40,000 lives each 
year (Morris and Carey 2007, Chang 2012, 2014, Lumachi et al. 2015, Selli et al. 2016). 
Great strides have been made over the last four decades in the diagnosis and treatment 
of breast cancer patients, however there remains much progress to be made. 
Resistance to endocrine therapies is still a major clinical challenge in ER+ breast cancer 
and the need to understand mechanisms of resistance and develop novel therapeutics is 
urgent. Identification of intrinsic subtypes of breast cancer, classification of tumors based 
on expression profiles, and technological advancements coupled with the development 
of large databases tracking genomic alterations in primary breast tumors has allowed 
novel biological mechanisms of tumorigenesis to be elucidated and investigated. 
Similarly, the field of epigenomics has opened a novel avenue of investigation into tumor 
biology and identified a suite of potential therapeutic candidates and biomarkers in 
histone methyltransferase enzymes. 
 At the cross-road between genomic and epigenomic alterations in cancer lies 
amplification-induced overexpression of oncogenes that modify the histone code. The 
8p11-p12 amplicon is found in 15% of primary breast tumors and harbors three 
epigenetic modifiers of chromatin, two of which, NSD3 and ASH2L, are implicated in 
regulation of histone methylation and transcriptional activation. NSD3 has been 
previously validated as an oncogene (Yang et al. 2010, Mahmood et al. 2013), however 
little was known about the biological role of the two isoforms of NSD3. This work 
established a link between amplification and overexpression NSD3 and overexpression 
and estrogen-independent activation of ERα (Figure 4.3). We have identified and 
Chapter 4: Discussion  Page | 121  
 
described here a novel mechanism of endocrine resistance in luminal B breast cancer 
and demonstrated a need for improved therapies that reduce receptor activity 
irrespective of estrogen status. Additional work is required to fully understand the 
implications of the non-catalytic short isoform of NSD3 and the mechanism behind 
NSD3-induced overexpression and activation of ERα. 
 ASH2L has been identified by several groups as a candidate oncogene from the 
8p11-p12 region (Ray et al. 2004, Garcia et al. 2005, Gelsi-Boyer et al. 2005, Cornen et 
al. 2014), however this epigenetic factor has been understudied in cancer to date. The 
data presented here identify a role for ASH2L in regulation of H3K4me3 specifically in 
the promoter regions of genes associated with cell cycle progression, epigenetic 
regulation of chromatin, and palbociclib response. We also demonstrated that 
knockdown of ASH2L reduced expression of NSD3 and ERα, extending our 
understanding of the relationship between these oncogenes (Figure 4.3). It is clear from 
the data presented in this work and the unanswered questions that remain that the 
underlying biology of 8p11-p12 amplicon oncogene-mediated epigenetic dysregulation is 
complex. Further investigation of the transcriptional regulation of gene expression by 
NSD3 and ASH2L, cooperation between these oncogenes, effects on the proteome, and 
the mechanism of estrogen-independent ERα activation will provide insight into the 
essential biology of a significant subset of breast cancer patients at risk of succumbing 
to their disease due to endocrine therapy resistance. 
 Histone methyltransferases are increasingly recognized not just for their potential 
as drug targets but also as biomarkers for therapeutic response (Connolly and Stearns 
2012, Chen et al. 2014, Michalak and Visvader 2016). NSD3 and ASH2L both have the 
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potential to be direct drug targets due to their oncogenic effects on transcription and cell 
behavior, and these oncogenes and the 8p11-p12 amplicon also have the potential to be 
utilized as biomarkers to predict treatment response to SERD and cell cycle therapies. 
The work presented here provides a rationale to include survey of NSD3 and ASH2L 
expression in clinical trials investigating these types of compounds. The downstream 
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processes and pathways under control of these two epigenetic oncogenes can be 
targeted therapeutically, extending the future implications of this study. The work 
presented here provides the foundation for a multitude of additional lines of investigation 
and has the potential to be translated into novel therapeutic strategies to improve 
survival for an important group of patients with ER+ breast cancer.  
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CHAPTER 5: Materials and Methods 
5.1. Cell culture 
All cells were cultured at 37°C in 10% CO2. 
5.1a. SUM-44. Cells were cultured in serum-free Ham’s F-12 medium supplemented 
with 1 μg/ml hydrocortisone, 1 mg/ml bovine serum albumin, 10 mM HEPES, 5mM 
ethanolamine, 5 μg/ml transferrin, 10 nM tiiodothyronine, 50 nm sodium selenite, 25 
μg/ml gentamicin, 2.5 μg/ml fungizone, and 5 μg/ml insulin. For estrogen-free culture 
conditions, phenol red-free Ham’s F-12 media was substituted for normal Ham’s F-12 
with all the above supplements. 3 μg/ml puromycin was used for selection and 
maintenance of shRNA-transduced SUM-44 cells. 
5.1b. SUM-52. Cells were cultured in Ham’s F-12 medium supplemented with 5% fetal 
bovine serum, 1 μg/ml hydrocortisone, 25 μg/ml gentamicin, 2.5 μg/ml fungizone, and 5 
μg/ml insulin. 2 μg/ml puromycin was used for selection and maintenance of sRNA-
transduced SUM-52 cells. 
5.1c. MCF-7 and CAMA-1. Cells were cultured in DMEM supplemented with 10% fetal 
bovine serum, 25 μg/ml gentamicin, and 2.5 μg/ml fungizone. 2 μg/ml puromycin was 
used for selection and maintenance of sRNA-transduced MCF-7 and CAMA-1 cells. 
5.1d. MCF10A. Cells were cultured in serum-free Ham’s F-12 medium supplemented 
with 1 μg/ml hydrocortisone, 1 mg/ml bovine serum albumin, 10 mM HEPES, 5mM 
ethanolamine, 5 μg/ml transferrin, 10 nM tiiodothyronine, 50 nm sodium selenite, 25 
μg/ml gentamicin, 2.5 μg/ml fungizone, 10 ng/ml EGF and 5 μg/ml insulin. 1 μg/ml 
puromycin was used for selection and maintenance of sRNA-transduced MCF10A cells. 
5.1e. ZR-75-1. Cells were cultured in RPMI supplemented with 10% fetal bovine serum, 
25 μg/ml gentamicin, and 2.5 μg/ml fungizone.  
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5.2 Antibodies 
Antibodies used in these studies were diluted in 5% milk and used at a dilution of 1:1000 
for immunoblot unless otherwise stated. Antibodies include:  
NSD3 (WHSC1L1): Proteintech 11345-1-AP; Vakoc Lab antibody (Shen et al. 2015) 
ERα: Cell Signaling 8644S, Santa Cruz HC-20 (1:50 dilution for ERα ChIP-PCR 
cocktail); NeoMarkers ER Ab-10 (TE111.5D11) (1:50 dilution for ERα ChIP-PCR 
cocktail) 
pS167 ERα: Cell Signaling 5587S 
ASH2L: Bethyl A300-489A; 1:1000 for immunoblot and 1:50 for IP 
H3K4me3: Abcam ab8580; 1:1000 for immunoblot and 1:50 for ChIP-seq 
FOXA1: Abcam ab109760 
AKT1: Cell Signaling 2938S 
BRD2: Cell Signaling 5848S 
BRD4: Cell Signaling 13440S 
Cyclin D1: Cell Signaling 2926P (courtesy Dr. Carroll Lab) 
Ki-67: Dako A0047 (courtesy Dr. Carroll Lab) 
PI3 Kinase: Abcam ab137815 
PLK1: Abcam ab47867 
IgG: Cell Signaling 3900S 
β-actin: Cell Signaling 3700S 
5.3. shRNA constructs  
Lentiviral shRNA expression vectors from the pLKO shRNA catalog were purchased 
from Sigma. The vectors used were the NSD3-short vector TRCN0000415241, NSD3-
total vectors TRCN000425711, TRCN0000015615, and TRCN0000015616, ASH2L 
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vectors TRC0000019275 and TRC0000019276, ESR1 vector TRCN0000003301 and 
LacZ control vector. Plasmid DNA for all constructs was obtained using the Promega 
PureYield plasmid midiprep system (A2495) according to manufacturer’s instructions. 
5.4. Lentiviral production and transformation 
Lentivirus was prepared using Sigma Mission lentiviral packaging system (Sigma, shp-
001) in 293FT packaging cells following manufacturer’s instructions. Briefly, each 
construct was co-transfected into 293FT cells with Sigma pLKO shRNA vectors and 
Lipofectamine 2000 in antibiotic-free media. Virus was harvested 48 hours after 
transfection, filtered, aliquoted, and stored at -80°C until use. Target cells were 
transduced with virus in growth media supplemented with 5 μg/ml polybrene using 0.5-
1.0 ml virus per 1 million cells. Cells were selected for resistance marker expression and 
maintained in puromycin-containing growth media (1-3 μg/ml as listed above) beginning 
24-48 hours after infection. Cells were cultured at least 5 days to allow expression of the 
construct. 
5.5. Immunoblotting 
Cells were plated and growth to 75-90% confluency. Cells were treated as indicated, 
either with drug compounds or shRNA infection, for the specified timepoints. Cells were 
lysed in buffer containing 20mM Tris-HCl (pH 8.0), 137 mM NaCl, 1% NP40, 10% 
glucerol, 1 mM Na3VO4, and 1x protease inhibitor cocktail (Calbiochem 539131). Protein 
concentrations were measured by Bradford assay (Bio-Rad). Laemmli sample buffer 
was added to the lysates and the samples were boiled for 5 min before being separated 
by electrophoresis on SDS-polyacrylamide gels (Bio-Rad). After transferring the proteins 
to polyvinylidene difluoride (PVDF) membranes, blots were probed overnight at 4°C with 
the indicated antibodies. Blots were washed 3x10 min in 1x tris-buffered saline with 
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tween 20 (TBST), probed 1 hour with the appropriate secondary antibody, incubated 1 
min in ECL and developed on a Konica SRX-101A medical film processor. After 
developing, membranes were re-probed with a new primary antibody or discarded.  
5.6. Proliferation assays 
Proliferation assays were performed in 6-well culture plates seeded in triplicate with 
200,000 cells per well. At each timepoint, cells were washed once with PBS and agitated 
on a rocker table with 0.5 ml HEPES/MgCl2 buffer (0.01 M HEPES and 0.015 M MgCl2) 
for 5 min. Cells were then lysed for 10 min with addition of 50 μl of an ethyl 
hexadecyldimethylammonium solution and nuclei were counted using a Z1 Coulter 
Counter (Beckman Coulter, Brea, CA, USA) according to manufacturer’s instructions. 
Data are reported as averages where error bars represent +/- one standard deviation.  
5.7. Drug treatment proliferation assays 
Drug treatment assays were performed in 6-well culture plates seeded in triplicate with 
250,000 - 500,000 cells per well. Cells were treated every 24 or 48 hours (2-5 treatments 
total) with the indicated drug compound and concentration. When control wells reached 
90% confluence, cells were washed once with PBS and agitated on a rocker table with 
0.5 ml HEPES/MgCl2 buffer (0.01 M HEPES and 0.015 M MgCl2) for 5 min. Cells were 
then lysed for 10 min with addition of 50 μl of an ethyl hexadecyldimethylammonium 
solution and nuclei were counted using a Z1 Coulter Counter (Beckman Coulter, Brea, 
CA, USA) according to manufacturer’s instructions. Counts were normalized to the 
average of the untreated samples and are reported as averages where error bars 
represent +/- one standard deviation. 
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5.8. Colony forming assay 
Cells were plated in triplicate in 6-well plates at varying clonal cell densities. MCF7 cells 
were plated at 5,000 cells per well and SUM-44 cells at 15,000 cells per well. MCF7 cells 
were cultured as normal. SUM-44 cells required 1:1 ratio of regular media to conditioned 
media from SUM-44 cells growing at high density. Puromycin-supplemented media was 
used in these assays to maintain selection of infected cells. Media was changed 24 
hours after plating and then 7 days later. Colonies formed for two weeks and then were 
fixed with 1 ml/well 3.7% paraformaldehyde for 20 minutes at RT. Colonies were stained 
with 1 ml/well 0.2% crystal violet for 15 minutes at RT and de-stained with dH2O. 
Colonies were allowed to dry prior to imaging, counting, and quantification on the 
GelCount System from Oxford Optronix.  
5.9. qRT-PCR 
Total RNA was harvested using a Qiagen RNeasy Plus Mini Kit (74136) according to 
manufacturer’s instructions. RNA was quantified on the NanoDrop 2000c 
spectrophotometer and 2 ug RNA utilized for each cDNA reaction using the iScript Adv 
cDNA Kit for RT-qPCR (172-5038) according to manufacturer’s instructions. Quantitative 
RT-PCR was then performed using 5 ng of cDNA per reaction in triplicate for each 
primer and sample pair in Roche FastStart Universal SYBR Green Master (Rox) mix 
(04913914001). Cycling conditions were 95°C for 10 min, then 40 cycles of 95°C 10 sec, 
51°C 10 sec, 68°C 40 sec. GAPDH primers (IDT PrimeTime qPCR Primer set 
Hs.PT.39a.22214836) were used as control for each sample, analyzed by the Ct 
method (Livak and Schmittgen 2001). Values are reported as averages of triplicate wells 
where error bars represent +/- one standard deviation. Primer sets were designed using 
IDT custom parameters and conditions for each primer pair are as reported below. 











Whole cell lysate was harvested using the buffer and protocol described under section 
5.6 or in FAK buffer supplemented with 1 mM Na3VO4, and 1x protease inhibitor cocktail. 
Samples were measured by Bradford assay (Bio-Rad) and diluted with lysis buffer to 
1000 μg protein per reaction. Antibodies were added at 1:50 dilution and samples 
incubated overnight at 4°C with rotation. Protein A/G beads were incubated with 
lysate/antibody samples for 1 hour at RT with rotation prior to washing 3x in TBST with 
1x protease inhibitor cocktail. Protein was eluted in 50 μl 1x laemmli sample buffer 
(diluted to 1x with lysis buffer), boiled 5 min, and 25 μl loaded per lane on SDS-
polyacrylamide gels (Bio-Rad). Whole cell lysate samples were created in parallel from 
the same samples prior to incubation with antibody and flow through was collected prior 
to wash steps. IgG as well as targeted antibodies were used. Gels were transferred, 
probed, and developed as described in section 5.5.  
5.11. Microarray 
RNA integrity was verified on an Agilent 2200 TapeStation (Agilent Technologies, Palo 
Alto, CA). 100-200 ng of total RNA will be used to prepare cRNA utilizing Ambion 
Name Sequence 5’-3’ Tm (°C) %GC 
ASH2L – F CTCCGTGGATGAAGAGAA 51.1 50.0 
ASH2L – R  GGTAGACAGGATGAGGTATC 51.2 50.0 
ESR1 – F  GCTTCGATGATGGGCTTACT 54.9 50.0 
ESR1 – R  CCTGATCATGGAGGGTCAAATC 55.3 50.0 
FBXO5 – F  GCCTCAAAGCCTGTATTC 50.8 50.0 
FBXO5 – R  CAAATCCACAGCCTTCTC 50.7 50.0 
EZH2 – F  TGACTGCTTCCTACATCC 51.1 50.0 
EZH2 – R  CTTTGCTCCCTCCAAATG 51.0 50.0 
TTK – F GTTGTGCCTGGATCTAAAC 51.0 47.4 
TTK – R  CCAGAGGTTCCTTGAAATG 50.7 47.4 
BUB1 – F  GGTTAATCCAGCACGTATG 50.8 47.4 
BUB1 – R  ACTGGTGTCTGCTGATAG 51.1 50.0 
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Illumina TotalPrep RNA Amplification Kit (Thermo Fisher Scientific, MA). 0.75 µg of 
cRNA per sample was hybridized to Illumina’s (HumanHT-12 v4.0 Expression BeadChip 
following the manufacturer’s WGGEX Direct Hybridization protocol (Illumina, CA). 
Processed array were scanned on an Illumina HiScan. Raw data was produced using 
Illumina Genome Studio followed by differential gene expression analysis utilizing Partek 
Genomics Suite (St. Louis, MO). 
5.12. RNA-seq 
Total RNA was prepared using a Qiagen RNeasy Plus Mini Kit and processed by the 
MUSC Genomics core for 2 x 125 cycles, paired-end RNA sequencing on an Illumina 
HiSeq 2500. RNA integrity was verified on an Agilent 2200 TapeStation (Agilent 
Technologies, Palo Alto, CA). A total of 100-200 ng of total RNA was used to prepare 
RNA-seq libraries using the TruSeq RNA Sample Prep kit following the manufacturer’s 
instructions (Illumina, San Diego, CA). Sequencing was performed on an Illumina HiSeq 
2500. Samples were demultiplexed using CASAVA (Illumina, San Diego, CA). Fastq files 
were used to map reads to the human genome (hg19, UCSC) utilizing Tophat2 with 
default settings. Samples were prepared in triplicate as biological replicates and 
sequenced simultaneously. 
5.13. Chromatin immunoprecipitation (ChIP) 
5.13a. Chromatin isolation and shearing. For each ChIP, 8-15 million cells (1-2 15 cm 
dishes) per treatment condition were used as starting material and processed with the 
Covaris truChIP chromatin shearing reagent kit (Covaris, 520154) according to 
manufacturer’s instructions. Briefly, cells were first washed with RT PBS then 
crosslinked using 2 mM disuccinyl-glutamate in PBS at RT for 30 min followed by 
fixation in 1x Covaris fixing buffer with 1% formaldehyde for 5 min (MCF-7) or 2.5 min 
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(SUM-44). After quenching 5 min in Covaris quenching buffer, cells were washed and 
scraped in 5 ml/plate cold 1x PBS, spun at 7,500xg for 5 min at 4°C, washed in PBS, 
then resuspended in 1x lysis buffer and transferred to a microfuge tube. The samples 
were incubated 10 min with rotation at 4°C, spun at 1,700xg for 5 min at 4°C, 
resuspended in 1x wash buffer, incubated 10 min with rotation at 4°C, and spun at 
1,700xg 5 min at 4°C. The pellets were then washed twice in 1x shearing buffer without 
resuspension using the same pelleting conditions as above. Upon final wash, pellets 
were resuspended in 1 ml shearing buffer and transferred to a Covaris glass sonication 
tube. Pellets of duplicate samples were combined at this step to 1 ml total volume for 
shearing. Each sample was sheared on the Covaris S220 series sonicator under high 
cell ChIP standard conditions for 10 min (MCF-7) or 8 min (SUM-44). Sheared chromatin 
was then transferred to a DNA LoBind tube, centrifuged at 10,000xg for 10 min at 4°C, 
and transferred to a clean DNA LoBind tube for storage at 4°C (up to 72 hours).  
5.13b. ChIP reaction setup. ChIP reactions were set up in duplicate (IgG control, 
H3K4me3), triplicate (ERα), or quadruplicate (NSD3) according to antibody efficiency. 
Reactions included 900 μl ChIP dilution buffer (0.01% SDS, 1.10% Triton X-100, 1x TE 
buffer pH 8.0, 167 mM NaCl), 100 μl sheared chromatin, 10 μl (1x) protease inhibitor 
cocktail (Thermo, 78442), and 4 μg antibody as indicated. Reactions were incubated at 
4°C with end-to-end rotation overnight. 
5.13c. Epitope verification. Upon first use of a new ChIP antibody, a 10 ul aliquot of 
each sheared chromatin sample was mixed with 10 ul of laemmli sample buffer, and run 
as a normal western blot (see section 5.5) to verify that the shearing process did not 
disrupt the epitope to be used in the ChIP process. 
Chapter 5: Methods  Page | 132  
 
5.13d. Size fragment verification. Upon first use of a new cell line, including 
knockdown cells of a previously used cell line, a 25 ul aliquot of each sheared chromatin 
sample was analyzed by Agilent 2200 TapeStation (Agilent Technologies, Palo Alto, CA) 
according to manufacturer’s instructions. 
5.13e. Chromatin washing and DNA elution. Protein A/G beads were pre-blocked with 
0.5% BSA in PBS and 20 μl beads with 10 μl protease inhibitor cocktail added to each 
ChIP reaction at 4°C for 1 hour with end-to-end rotation. Supernatant was removed and 
beads were washed 4x in wash buffer (1x TE buffer pH 8.0, 0,5 M LiCl, 100 mM NaCl, 
0.10% sodium deoxycholate, 1% Triton X-100; recipe courtesy of the Brown Lab) and 2x 
in 1x TE pH 8.0. Beads were resuspended in 50 μl 1x TE buffer pH 8.0 with 2 μl RNase 
and incubated with input samples (10 μl non-ChIP’d sheared chromatin, 40 μl 1x TE, 2 μl 
RNase) for 30 min at 37°C. 50 μl elution buffer (0.2 M sodium bicarbonate, 2% SDS) 
and 2.5 μl proteinase K were added to each sample and incubated at 65°C overnight 
with shaking (1400 rpm). DNA was then purified using AMPure XP beads (Beckman 
Coulter, A6381) according to manufacturer’s instructions and quantified by PicoGreen 
DNA kit (Thermo, 7605).  
5.13f. Preparation for sequencing. Sequencing libraries were prepared from ChIP 
DNA by the MUSC Genomics Core Facility with Rubicon ThruPLEX library preparation 
kits and sequenced as 35 bp single-end reads on an Illumina HiSeq 2500. Libraries for 
three biological replicates were prepared and sequenced for each sample type. 
5.14 Bioinformatics and Statistical Analysis 
5.14a. Microarray. Data were normalized using the linear and LOWESS (LOcally 
WEighted Scatterplot Smoothing) method (Yang et al. 2002). Normalized data were 
imported into GeneSpring for analysis. Statistical significance of differentially expressed 
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genes was determined using four replicate measurements for each probe (gene). A t-
test was performed with the null hypothesis that the normalized log fold changes 
reflecting the change in gene expression (44/NS) equal zero. The Benjamini and 
Hochberg multiple test correction was used to determine the false discovery rate (FDR) 
(Benjamini and Hochberg 1995). 
5.14b. RNA-seq. Paired end sequencing was performed on RNA samples using an 
Illumina HiSeq 2500 with each sample sequenced to a depth of ~50 million reads. Data 
was subjected to Illumina quality control (QC) procedures (>80% of the data yielded a 
Phred score of 30), and preprocessing using Trimmomatic, which removed adapter 
sequences and filtered low quality reads (Bolger et al. 2014). Further data QC was 
performed using FastQC prior to aligning the reads to the human genome hg19 using 
Tophat2 (Kim et al. 2013). The resulting SAM files were sorted and inputted into the 
Python package HTSeq to generate count data for gene-level differential expression 
analyses.  In order to infer differential signal within the data sets with robust statistical 
power, we utilized DEseq2 (Love et al. 2014). Transcript count data from DESeq2 
analysis of the samples were sorted according to their adjusted p-value or q-value, 
which is the smallest false discovery rate (FDR) at which a transcript is called significant. 
FDR adjustment is needed with large data sets such as RNAseq. FDR is the expected 
fraction of false positive tests among significant tests and was calculated using the 
Benjamini-Hochberg multiple testing adjustment procedure (Benjamini and Hochberg 
1995). Using the transcript count data from DESeq2 analysis, we selected transcripts 
with negative log fold change values, indicating decreased expression in test versus 
control samples, and p<0.1. This consensus gene set was then used for downstream 
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analysis, including comparison between different shRNA constructs to generate a more 
statistically stringent list of genes. 
5.14c. ChIP-seq. Single end sequencing was performed on ChIP DNA using an Illumina 
HiSeq 2500 with each sample sequenced to a depth of ~50 million reads. Data was 
subjected to Illumina quality control (QC) procedures (data yielded Phred scores >30). 
Further data QC was performed using FastQC prior to aligning the reads to the human 
genome hg19 using Bowtie2. Aligned reads were converted from SAM to BAM format, 
sorted, and indexed. BED format files were obtained from BAM files. Peaks were called 
with the MACS version 2 peak caller (Zhang et al. 2008). ChIP samples were compared 
to matched input samples to generate peak sets for each replicate, which were then 
compared to matched condition biological replicates as described in Chapter 3, section 2 
using an FDR cutoff of 0.4. Consensus peak sets generated by replicate overlap were 
used for downstream analysis, including comparison between treatment conditions. 
5.14d. Gene Ontology and Pathway Analysis. Various data comparisons were 
performed between ChIP-seq, RNA-seq, and microarray gene lists as described in 
Chapters 2 and 3. Statistical analysis of Gene Ontology and other processes, pathways, 
and interactions was performed on these gene lists by gene list enrichment analysis 
using the ToppGene suite (Chen et al. 2009). P-values and percentage of genes in input 
compared to annotated gene lists in ToppFun are reported in results sections with 
Bonferroni corrected p-values and absolute number of genes aligning to each process 
reported in Appendices according to gene set (See List of Appendices on page v.). 
5.14e. General Statistics. Statistical analysis was performed in Microsoft excel. 
Student’s t-test was used and two-tail p-values reported. Graphs with error bars 
represent +/- one standard deviation unless otherwise reported. 
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5.15. Patient tumor cell culture 
Samples were obtained according to IRB protocol (Pro00048028). Using sterile 
technique, samples were aliquoted to 50 ml falcon tubes, spun at 1,000 rpm for 5 min at 
RT, and the supernatant removed and properly discarded. Cells were resuspended in 1x 
Hank’s Buffered Saline Solution (HBSS), consolidated, and spun again at 1,000 rpm for 
5 min at RT. Supernatant was removed and resuspension and spin step was repeated. 
To lyse red blood cells, 9 ml sterile water was added to the tubes followed immediately 
by 1 ml 10x HBSS. Tubes were spun again at 1,000 rpm for 5 min at RT. Supernatant 
was removed and cells were resuspended in Ham’s F-12 media supplemented with 
insulin, hydrocortisone, and 5% FBS (see section 5.1b). Cells were counted and plated 
in 6-well plates at a density of 1 million cells/well. Cells were cultured in various media 
types and supplements of estradiol but could not be cultured more than a few weeks. 
One well was lysed for western blotting after 2.5 weeks in culture and blotted for NSD3 
and ERα expression according to section 5.5. 
  




"<a systematic evaluation of miRNA mRNA interactions involved in the migration and 
invasion of breast cancer cells.pdf>." 
(2012). "Comprehensive molecular portraits of human breast tumours." Nature 
490(7418): 61-70. 
(2014). "SEER Cancer Statistics Factsheets: Lung Cancer."   Retrieved February 13, 
2014, from http://seer.cancer.gov/statfacts/html/lungb.html. 
Abdel-Hafiz, H. A. and K. B. Horwitz (2015). "Role of epigenetic modifications in luminal 
breast cancer." Epigenomics 7(5): 847-862. 
Ades, F., D. Zardavas, I. Bozovic-Spasojevic, L. Pugliano, D. Fumagalli, E. de 
Azambuja, G. Viale, C. Sotiriou and M. Piccart (2014). "Luminal B breast cancer: 
molecular characterization, clinical management, and future perspectives." J Clin Oncol 
32(25): 2794-2803. 
Alao, J. P., E. W. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. 
Stavropoulou, R. C. Coombes and D. M. Vigushin (2004). "Histone deacetylase inhibitor 
trichostatin A represses estrogen receptor alpha-dependent transcription and promotes 
proteasomal degradation of cyclin D1 in human breast carcinoma cell lines." Clin Cancer 
Res 10(23): 8094-8104. 
Ali, A. and S. Tyagi (2017). "Diverse roles of WDR5-RbBP5-ASH2L-DPY30 (WRAD) 
complex in the functions of the SET1 histone methyltransferase family." J Biosci 42(1): 
155-159. 
Ali, A., S. N. Veeranki and S. Tyagi (2014). "A SET-domain-independent role of WRAD 
complex in cell-cycle regulatory function of mixed lineage leukemia." Nucleic Acids Res 
42(12): 7611-7624. 
Allali-Hassani, A., E. Kuznetsova, T. Hajian, H. Wu, L. Dombrovski, Y. Li, S. Graslund, 
C. H. Arrowsmith, M. Schapira and M. Vedadi (2014). "A Basic Post-SET Extension of 
NSDs Is Essential for Nucleosome Binding In Vitro." J Biomol Screen 19(6): 928-935. 
Allred, D. C., P. Brown and D. Medina (2004). "The origins of estrogen receptor alpha-
positive and estrogen receptor alpha-negative human breast cancer." Breast Cancer 
Res 6(6): 240-245. 
References Cited  Page | 137  
 
Angrand, P. O., F. Apiou, A. F. Stewart, B. Dutrillaux, R. Losson and P. Chambon 
(2001). "NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in 
human breast cancer cell lines." Genomics 74(1): 79-88. 
Angus, L., N. Beije, A. Jager, J. W. Martens and S. Sleijfer (2016). "ESR1 mutations: 
Moving towards guiding treatment decision-making in metastatic breast cancer patients." 
Cancer Treat Rev 52: 33-40. 
Ariazi, E. A., J. L. Ariazi, F. Cordera and V. C. Jordan (2006). "Estrogen receptors as 
therapeutic targets in breast cancer." Curr Top Med Chem 6(3): 181-202. 
Atlas, T. C. G. (2015). "cBioPortal."   Retrieved Feb 2, 2015, 2015, from 
http://www.cbioportal.org/index.do. 
Avdic, V., P. Zhang, S. Lanouette, A. Voronova, I. Skerjanc and J. F. Couture (2011). 
"Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based 
peptide mimetic." FASEB J 25(3): 960-967. 
Azim, H. A., L. Kassem, I. Treilleux, Q. Wang, M. A. El Enein, S. E. Anis and T. Bachelot 
(2016). "Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in 
Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer." Transl 
Oncol 9(2): 114-123. 
Benjamini, Y. and Y. Hochberg (1995). "Controlling the False Discovery Rate: A 
Practical and Powerful Approach to Multiple Testing." Journal of the Royal Statistical 
Society. Series B (Methological) 57(1): 289-300. 
Bennett, R. L., A. Swaroop, C. Troche and J. D. Licht (2017). "The Role of Nuclear 
Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer." 
Cold Spring Harb Perspect Med. 
Bergamaschi, A., Y. H. Kim, P. Wang, T. Sorlie, T. Hernandez-Boussard, P. E. Lonning, 
R. Tibshirani, A. L. Borresen-Dale and J. R. Pollack (2006). "Distinct patterns of DNA 
copy number alteration are associated with different clinicopathological features and 
gene-expression subtypes of breast cancer." Genes Chromosomes Cancer 45(11): 
1033-1040. 
Bernard-Pierrot, I., N. Gruel, N. Stransky, A. Vincent-Salomon, F. Reyal, V. Raynal, C. 
Vallot, G. Pierron, F. Radvanyi and O. Delattre (2008). "Characterization of the recurrent 
References Cited  Page | 138  
 
8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic 
target in breast cancer." Cancer Res 68(17): 7165-7175. 
Bhan, A., I. Hussain, K. I. Ansari, S. A. Bobzean, L. I. Perrotti and S. S. Mandal (2014). 
"Histone methyltransferase EZH2 is transcriptionally induced by estradiol as well as 
estrogenic endocrine disruptors bisphenol-A and diethylstilbestrol." J Mol Biol 426(20): 
3426-3441. 
Bilal, E., K. Vassallo, D. Toppmeyer, N. Barnard, I. H. Rye, V. Almendro, H. Russnes, A. 
L. Borresen-Dale, A. J. Levine, G. Bhanot and S. Ganesan (2012). "Amplified loci on 
chromosomes 8 and 17 predict early relapse in ER-positive breast cancers." PLoS One 
7(6): e38575. 
Blobel, G. A., S. Kadauke, E. Wang, A. W. Lau, J. Zuber, M. M. Chou and C. R. Vakoc 
(2009). "A reconfigured pattern of MLL occupancy within mitotic chromatin promotes 
rapid transcriptional reactivation following mitotic exit." Mol Cell 36(6): 970-983. 
Bolger, A. M., M. Lohse and B. Usadel (2014). "Trimmomatic: a flexible trimmer for 
Illumina sequence data." Bioinformatics 30(15): 2114-2120. 
Borbely, G., L. A. Haldosen, K. Dahlman-Wright and C. Zhao (2015). "Induction of 
USP17 by combining BET and HDAC inhibitors in breast cancer cells." Oncotarget 
6(32): 33623-33635. 
Butler, J. S., Y. H. Qiu, N. Zhang, S. Y. Yoo, K. R. Coombes, S. Y. Dent and S. M. 
Kornblau (2017). "Low expression of ASH2L protein correlates with a favorable outcome 
in acute myeloid leukemia." Leuk Lymphoma 58(5): 1207-1218. 
Butler, J. S., C. I. Zurita-Lopez, S. G. Clarke, M. T. Bedford and S. Y. Dent (2011). 
"Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component 
of mammalian histone H3K4 methyltransferase complexes." J Biol Chem 286(14): 
12234-12244. 
Cadoo, K. A., M. N. Fornier and P. G. Morris (2013). "Biological subtypes of breast 
cancer: current concepts and implications for recurrence patterns." Q J Nucl Med Mol 
Imaging 57(4): 312-321. 
Cai, F. F., C. Kohler, B. Zhang, M. H. Wang, W. J. Chen and X. Y. Zhong (2011). 
"Epigenetic therapy for breast cancer." Int J Mol Sci 12(7): 4465-4487. 
References Cited  Page | 139  
 
Caldon, C. E., C. M. Sergio, J. Kang, A. Muthukaruppan, M. N. Boersma, A. Stone, J. 
Barraclough, C. S. Lee, M. A. Black, L. D. Miller, J. M. Gee, R. I. Nicholson, R. L. 
Sutherland, C. G. Print and E. A. Musgrove (2012). "Cyclin E2 overexpression is 
associated with endocrine resistance but not insensitivity to CDK2 inhibition in human 
breast cancer cells." Mol Cancer Ther 11(7): 1488-1499. 
Cao, F., Y. Chen, T. Cierpicki, Y. Liu, V. Basrur, M. Lei and Y. Dou (2010). "An 
Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through 
coordinated substrate interactions with the MLL1 SET domain." PLoS One 5(11): 
e14102. 
Carey, L. A., C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, G. 
Karaca, M. A. Troester, C. K. Tse, S. Edmiston, S. L. Deming, J. Geradts, M. C. Cheang, 
T. O. Nielsen, P. G. Moorman, H. S. Earp and R. C. Millikan (2006). "Race, breast 
cancer subtypes, and survival in the Carolina Breast Cancer Study." JAMA 295(21): 
2492-2502. 
Chang, M. (2012). "Tamoxifen resistance in breast cancer." Biomol Ther (Seoul) 20(3): 
256-267. 
Chanrion, M., V. Negre, H. Fontaine, N. Salvetat, F. Bibeau, G. Mac Grogan, L. Mauriac, 
D. Katsaros, F. Molina, C. Theillet and J. M. Darbon (2008). "A gene expression 
signature that can predict the recurrence of tamoxifen-treated primary breast cancer." 
Clin Cancer Res 14(6): 1744-1752. 
Cheang, M. C., S. K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. 
Davies, P. S. Bernard, J. S. Parker, C. M. Perou, M. J. Ellis and T. O. Nielsen (2009). 
"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer." J Natl 
Cancer Inst 101(10): 736-750. 
Chen, J., E. E. Bardes, B. J. Aronow and A. G. Jegga (2009). "ToppGene Suite for gene 
list enrichment analysis and candidate gene prioritization." Nucleic Acids Res 37(Web 
Server issue): W305-311. 
Chen, Y., F. Cao, B. Wan, Y. Dou and M. Lei (2012). "Structure of the SPRY domain of 
human Ash2L and its interactions with RbBP5 and DPY30." Cell Res 22(3): 598-602. 
Chen, Y., J. McGee, X. Chen, T. N. Doman, X. Gong, Y. Zhang, N. Hamm, X. Ma, R. E. 
Higgs, S. V. Bhagwat, S. Buchanan, S. B. Peng, K. A. Staschke, V. Yadav, Y. Yue and 
H. Kouros-Mehr (2014). "Identification of druggable cancer driver genes amplified across 
TCGA datasets." PLoS One 9(5): e98293. 
References Cited  Page | 140  
 
Cobain, E. F. and D. F. Hayes (2015). "Indications for prognostic gene expression 
profiling in early breast cancer." Curr Treat Options Oncol 16(5): 23. 
Comsa, S., A. M. Cimpean and M. Raica (2015). "The Story of MCF-7 Breast Cancer 
Cell Line: 40 years of Experience in Research." Anticancer Res 35(6): 3147-3154. 
Connolly, R., H. Li, R. C. Jankowitz, Z. Zhang, M. A. Rudek, S. C. Jeter, S. Slater, P. 
Powers, A. C. Wolff, J. H. Fetting, A. M. Brufsky, R. Piekarz, N. Ahuja, P. W. Laird, H. 
Shen, D. J. Weisenberger, L. Cope, J. G. Herman, G. Somlo, A. Garcia, P. A. Jones, S. 
B. Baylin, N. E. Davidson, C. Zahnow and V. Stearns (2016). "Combination Epigenetic 
Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II 
National Cancer Institute/Stand Up to Cancer Study." Clin Cancer Res. 
Connolly, R. and V. Stearns (2012). "Epigenetics as a therapeutic target in breast 
cancer." J Mammary Gland Biol Neoplasia 17(3-4): 191-204. 
Cooke, S. L., J. C. Pole, S. F. Chin, I. O. Ellis, C. Caldas and P. A. Edwards (2008). 
"High-resolution array CGH clarifies events occurring on 8p in carcinogenesis." BMC 
Cancer 8: 288. 
Cornen, S., A. Guille, J. Adelaide, L. Addou-Klouche, P. Finetti, M. R. Saade, M. Manai, 
N. Carbuccia, I. Bekhouche, A. Letessier, S. Raynaud, E. Charafe-Jauffret, J. 
Jacquemier, S. Spicuglia, H. de The, P. Viens, F. Bertucci, D. Birnbaum and M. 
Chaffanet (2014). "Candidate luminal B breast cancer genes identified by genome, gene 
expression and DNA methylation profiling." PLoS One 9(1): e81843. 
Crowe, B. L., R. C. Larue, C. Yuan, S. Hess, M. Kvaratskhelia and M. P. Foster (2016). 
"Structure of the Brd4 ET domain bound to a C-terminal motif from gamma-retroviral 
integrases reveals a conserved mechanism of interaction." Proc Natl Acad Sci U S A 
113(8): 2086-2091. 
Cui, X., R. Schiff, G. Arpino, C. K. Osborne and A. V. Lee (2005). "Biology of 
progesterone receptor loss in breast cancer and its implications for endocrine therapy." J 
Clin Oncol 23(30): 7721-7735. 
Curry, E., I. Green, N. Chapman-Rothe, E. Shamsaei, S. Kandil, F. L. Cherblanc, L. 
Payne, E. Bell, T. Ganesh, N. Srimongkolpithak, J. Caron, F. Li, A. G. Uren, J. P. 
Snyder, M. Vedadi, M. J. Fuchter and R. Brown (2015). "Dual EZH2 and EHMT2 histone 
methyltransferase inhibition increases biological efficacy in breast cancer cells." Clin 
Epigenetics 7: 84. 
References Cited  Page | 141  
 
Dabydeen, S. A. and P. A. Furth (2014). "Genetically engineered ERalpha-positive 
breast cancer mouse models." Endocr Relat Cancer 21(3): R195-208. 
Damaskos, C., S. Valsami, M. Kontos, E. Spartalis, T. Kalampokas, E. Kalampokas, A. 
Athanasiou, D. Moris, A. Daskalopoulou, S. Davakis, G. Tsourouflis, K. Kontzoglou, D. 
Perrea, N. Nikiteas and D. Dimitroulis (2017). "Histone Deacetylase Inhibitors: An 
Attractive Therapeutic Strategy Against Breast Cancer." Anticancer Res 37(1): 35-46. 
De Marchi, T., J. A. Foekens, A. Umar and J. W. Martens (2016). "Endocrine therapy 
resistance in estrogen receptor (ER)-positive breast cancer." Drug Discov Today 21(7): 
1181-1188. 
Demers, C., C. P. Chaturvedi, J. A. Ranish, G. Juban, P. Lai, F. Morle, R. Aebersold, F. 
J. Dilworth, M. Groudine and M. Brand (2007). "Activator-mediated recruitment of the 
MLL2 methyltransferase complex to the beta-globin locus." Mol Cell 27(4): 573-584. 
Demircan, B., L. M. Dyer, M. Gerace, E. K. Lobenhofer, K. D. Robertson and K. D. 
Brown (2009). "Comparative epigenomics of human and mouse mammary tumors." 
Genes Chromosomes Cancer 48(1): 83-97. 
Dou, Y., T. A. Milne, A. J. Ruthenburg, S. Lee, J. W. Lee, G. L. Verdine, C. D. Allis and 
R. G. Roeder (2006). "Regulation of MLL1 H3K4 methyltransferase activity by its core 
components." Nat Struct Mol Biol 13(8): 713-719. 
Douglas, J., K. Coleman, K. Tatton-Brown, H. E. Hughes, I. K. Temple, T. R. Cole and 
N. Rahman (2005). "Evaluation of NSD2 and NSD3 in overgrowth syndromes." Eur J 
Hum Genet 13(2): 150-153. 
Dowsett, M., R. I. Nicholson and R. J. Pietras (2005). "Biological characteristics of the 
pure antiestrogen fulvestrant: overcoming endocrine resistance." Breast Cancer Res 
Treat 93 Suppl 1: S11-18. 
Dutt, A., A. H. Ramos, P. S. Hammerman, C. Mermel, J. Cho, T. Sharifnia, A. Chande, 
K. E. Tanaka, N. Stransky, H. Greulich, N. S. Gray and M. Meyerson (2011). "Inhibitor-
sensitive FGFR1 amplification in human non-small cell lung cancer." PLoS One 6(6): 
e20351. 
Ellis, M. J., L. Ding, D. Shen, J. Luo, V. J. Suman, J. W. Wallis, B. A. Van Tine, J. Hoog, 
R. J. Goiffon, T. C. Goldstein, S. Ng, L. Lin, R. Crowder, J. Snider, K. Ballman, J. Weber, 
K. Chen, D. C. Koboldt, C. Kandoth, W. S. Schierding, J. F. McMichael, C. A. Miller, C. 
References Cited  Page | 142  
 
Lu, C. C. Harris, M. D. McLellan, M. C. Wendl, K. DeSchryver, D. C. Allred, L. 
Esserman, G. Unzeitig, J. Margenthaler, G. V. Babiera, P. K. Marcom, J. M. Guenther, 
M. Leitch, K. Hunt, J. Olson, Y. Tao, C. A. Maher, L. L. Fulton, R. S. Fulton, M. Harrison, 
B. Oberkfell, F. Du, R. Demeter, T. L. Vickery, A. Elhammali, H. Piwnica-Worms, S. 
McDonald, M. Watson, D. J. Dooling, D. Ota, L. W. Chang, R. Bose, T. J. Ley, D. 
Piwnica-Worms, J. M. Stuart, R. K. Wilson and E. R. Mardis (2012). "Whole-genome 
analysis informs breast cancer response to aromatase inhibition." Nature 486(7403): 
353-360. 
Ellis, M. J., M. Dixon, M. Dowsett, R. Nagarajan and E. Mardis (2007). "A luminal breast 
cancer genome atlas: progress and barriers." J Steroid Biochem Mol Biol 106(1-5): 125-
129. 
Elsheikh, S. E., A. R. Green, E. A. Rakha, D. G. Powe, R. A. Ahmed, H. M. Collins, D. 
Soria, J. M. Garibaldi, C. E. Paish, A. A. Ammar, M. J. Grainge, G. R. Ball, M. K. 
Abdelghany, L. Martinez-Pomares, D. M. Heery and I. O. Ellis (2009). "Global histone 
modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and 
patient outcome." Cancer Res 69(9): 3802-3809. 
Erfani, P., J. Tome-Garcia, P. Canoll, F. Doetsch and N. M. Tsankova (2015). "EGFR 
promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in 
human germinal matrix and gliomas." Epigenetics 10(6): 496-507. 
Ernst, P. and C. R. Vakoc (2012). "WRAD: enabler of the SET1-family of H3K4 
methyltransferases." Brief Funct Genomics 11(3): 217-226. 
Eroles, P., A. Bosch, J. A. Perez-Fidalgo and A. Lluch (2012). "Molecular biology in 
breast cancer: intrinsic subtypes and signaling pathways." Cancer Treat Rev 38(6): 698-
707. 
Ethier, S. P. (1996). "Human breast cancer cell lines as models of growth regulation and 
disease progression." J Mammary Gland Biol Neoplasia 1(1): 111-121. 
Ethier, S. P., M. L. Mahacek, W. J. Gullick, T. S. Frank and B. L. Weber (1993). 
"Differential isolation of normal luminal mammary epithelial cells and breast cancer cells 
from primary and metastatic sites using selective media." Cancer Res 53(3): 627-635. 
Falahi, F., M. van Kruchten, N. Martinet, G. A. Hospers and M. G. Rots (2014). "Current 
and upcoming approaches to exploit the reversibility of epigenetic mutations in breast 
cancer." Breast Cancer Res 16(4): 412. 
References Cited  Page | 143  
 
Fang, R., A. J. Barbera, Y. Xu, M. Rutenberg, T. Leonor, Q. Bi, F. Lan, P. Mei, G. C. 
Yuan, C. Lian, J. Peng, D. Cheng, G. Sui, U. B. Kaiser, Y. Shi and Y. G. Shi (2010). 
"Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic 
H3K4me2 methylation." Mol Cell 39(2): 222-233. 
Fedele, P., N. Calvani, A. Marino, L. Orlando, P. Schiavone, A. Quaranta and S. Cinieri 
(2012). "Targeted agents to reverse resistance to endocrine therapy in metastatic breast 
cancer: where are we now and where are we going?" Crit Rev Oncol Hematol 84(2): 
243-251. 
Feng, Q., Z. Zhang, M. J. Shea, C. J. Creighton, C. Coarfa, S. G. Hilsenbeck, R. Lanz, 
B. He, L. Wang, X. Fu, A. Nardone, Y. Song, J. Bradner, N. Mitsiades, C. S. Mitsiades, 
C. K. Osborne, R. Schiff and B. W. O'Malley (2014). "An epigenomic approach to 
therapy for tamoxifen-resistant breast cancer." Cell Res 24(7): 809-819. 
Fossati, A., D. Dolfini, G. Donati and R. Mantovani (2011). "NF-Y recruits Ash2L to 
impart H3K4 trimethylation on CCAAT promoters." PLoS One 6(3): e17220. 
French, C. A., S. Rahman, E. M. Walsh, S. Kuhnle, A. R. Grayson, M. E. Lemieux, N. 
Grunfeld, B. P. Rubin, C. R. Antonescu, S. Zhang, R. Venkatramani, P. Dal Cin and P. 
M. Howley (2014). "NSD3-NUT fusion oncoprotein in NUT midline carcinoma: 
implications for a novel oncogenic mechanism." Cancer Discov 4(8): 928-941. 
Gao, J., B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, Y. Sun, A. 
Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander and N. Schultz (2013). 
"Integrative analysis of complex cancer genomics and clinical profiles using the 
cBioPortal." Sci Signal 6(269): pl1. 
Garapaty-Rao, S., C. Nasveschuk, A. Gagnon, E. Y. Chan, P. Sandy, J. Busby, S. 
Balasubramanian, R. Campbell, F. Zhao, L. Bergeron, J. E. Audia, B. K. Albrecht, J. C. 
Harmange, R. Cummings and P. Trojer (2013). "Identification of EZH2 and EZH1 small 
molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth." 
Chem Biol 20(11): 1329-1339. 
Garapaty, S., C. F. Xu, P. Trojer, M. A. Mahajan, T. A. Neubert and H. H. Samuels 
(2009). "Identification and characterization of a novel nuclear protein complex involved in 
nuclear hormone receptor-mediated gene regulation." J Biol Chem 284(12): 7542-7552. 
Garcia, M. J., J. C. Pole, S. F. Chin, A. Teschendorff, A. Naderi, H. Ozdag, M. Vias, T. 
Kranjac, T. Subkhankulova, C. Paish, I. Ellis, J. D. Brenton, P. A. Edwards and C. 
References Cited  Page | 144  
 
Caldas (2005). "A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new 
candidate oncogenes." Oncogene 24(33): 5235-5245. 
Gelsi-Boyer, V., B. Orsetti, N. Cervera, P. Finetti, F. Sircoulomb, C. Rouge, L. Lasorsa, 
A. Letessier, C. Ginestier, F. Monville, S. Esteyries, J. Adelaide, B. Esterni, C. Henry, S. 
P. Ethier, F. Bibeau, M. J. Mozziconacci, E. Charafe-Jauffret, J. Jacquemier, F. Bertucci, 
D. Birnbaum, C. Theillet and M. Chaffanet (2005). "Comprehensive profiling of 8p11-12 
amplification in breast cancer." Mol Cancer Res 3(12): 655-667. 
Geyer, F. C., D. N. Rodrigues, B. Weigelt and J. S. Reis-Filho (2012). "Molecular 
classification of estrogen receptor-positive/luminal breast cancers." Adv Anat Pathol 
19(1): 39-53. 
Grzenda, A., T. Ordog and R. Urrutia (2011). "Polycomb and the emerging epigenetics 
of pancreatic cancer." J Gastrointest Cancer 42(2): 100-111. 
Guccione, E., C. Bassi, F. Casadio, F. Martinato, M. Cesaroni, H. Schuchlautz, B. 
Luscher and B. Amati (2007). "Methylation of histone H3R2 by PRMT6 and H3K4 by an 
MLL complex are mutually exclusive." Nature 449(7164): 933-937. 
Guertin, D. A., K. V. Guntur, G. W. Bell, C. C. Thoreen and D. M. Sabatini (2006). 
"Functional genomics identifies TOR-regulated genes that control growth and division." 
Curr Biol 16(10): 958-970. 
Habashy, H. O., D. G. Powe, T. M. Abdel-Fatah, J. M. Gee, R. I. Nicholson, A. R. Green, 
E. A. Rakha and I. O. Ellis (2012). "A review of the biological and clinical characteristics 
of luminal-like oestrogen receptor-positive breast cancer." Histopathology 60(6): 854-
863. 
Hartman, J., A. Strom and J. A. Gustafsson (2009). "Estrogen receptor beta in breast 
cancer--diagnostic and therapeutic implications." Steroids 74(8): 635-641. 
Haverty, P. M., J. Fridlyand, L. Li, G. Getz, R. Beroukhim, S. Lohr, T. D. Wu, G. Cavet, 
Z. Zhang and J. Chant (2008). "High-resolution genomic and expression analyses of 
copy number alterations in breast tumors." Genes Chromosomes Cancer 47(6): 530-
542. 
He, C., F. Li, J. Zhang, J. Wu and Y. Shi (2013). "The methyltransferase NSD3 has 
chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear 
References Cited  Page | 145  
 
receptor SET domain) family members in their histone H3 recognition." J Biol Chem 
288(7): 4692-4703. 
Hervouet, E., P. F. Cartron, M. Jouvenot and R. Delage-Mourroux (2013). "Epigenetic 
regulation of estrogen signaling in breast cancer." Epigenetics 8(3): 237-245. 
Holland, D. G., A. Burleigh, A. Git, M. A. Goldgraben, P. A. Perez-Mancera, S. F. Chin, 
A. Hurtado, A. Bruna, H. R. Ali, W. Greenwood, M. J. Dunning, S. Samarajiwa, S. 
Menon, O. M. Rueda, A. G. Lynch, S. McKinney, I. O. Ellis, C. J. Eaves, J. S. Carroll, C. 
Curtis, S. Aparicio and C. Caldas (2011). "ZNF703 is a common Luminal B breast 
cancer oncogene that differentially regulates luminal and basal progenitors in human 
mammary epithelium." EMBO Mol Med 3(3): 167-180. 
Howell, A. (2006). "Pure oestrogen antagonists for the treatment of advanced breast 
cancer." Endocr Relat Cancer 13(3): 689-706. 
Huang, L., S. Zhao, J. M. Frasor and Y. Dai (2011). "An integrated bioinformatics 
approach identifies elevated cyclin E2 expression and E2F activity as distinct features of 
tamoxifen resistant breast tumors." PLoS One 6(7): e22274. 
Huang, N., E. vom Baur, J. M. Garnier, T. Lerouge, J. L. Vonesch, Y. Lutz, P. Chambon 
and R. Losson (1998). "Two distinct nuclear receptor interaction domains in NSD1, a 
novel SET protein that exhibits characteristics of both corepressors and coactivators." 
EMBO J 17(12): 3398-3412. 
Huang, Y., S. Nayak, R. Jankowitz, N. E. Davidson and S. Oesterreich (2011). 
"Epigenetics in breast cancer: what's new?" Breast Cancer Res 13(6): 225. 
Ignatiadis, M. and C. Sotiriou (2013). "Luminal breast cancer: from biology to treatment." 
Nat Rev Clin Oncol 10(9): 494-506. 
Ikegawa, S., M. Isomura, Y. Koshizuka and Y. Nakamura (1999). "Cloning and 
characterization of ASH2L and Ash2l, human and mouse homologs of the Drosophila 
ash2 gene." Cytogenet Cell Genet 84(3-4): 167-172. 
Inoue, K. and E. A. Fry (2015). "Aberrant expression of cyclin D1 in cancer." Sign 
Transduct Insights 4: 1-13. 
References Cited  Page | 146  
 
Irish, J. C., J. N. Mills, B. Turner-Ivey, R. C. Wilson, S. T. Guest, A. Rutkovsky, A. 
Dombkowski, C. S. Kappler, G. Hardiman and S. P. Ethier (2016). "Amplification of 
WHSC1L1 regulates expression and estrogen-independent activation of ERalpha in 
SUM-44 breast cancer cells and is associated with ERalpha over-expression in breast 
cancer." Mol Oncol. 
Jacques-Fricke, B. T. and L. S. Gammill (2014). "Neural crest specification and migration 
independently require NSD3-related lysine methyltransferase activity." Mol Biol Cell 
25(25): 4174-4186. 
Johnston, S. J. and K. L. Cheung (2010). "Fulvestrant - a novel endocrine therapy for 
breast cancer." Curr Med Chem 17(10): 902-914. 
Johnston, S. R., L. A. Martin, J. Head, I. Smith and M. Dowsett (2005). "Aromatase 
inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to 
overcome endocrine resistance." J Steroid Biochem Mol Biol 95(1-5): 173-181. 
Jovanovic, J., J. A. Ronneberg, J. Tost and V. Kristensen (2010). "The epigenetics of 
breast cancer." Mol Oncol 4(3): 242-254. 
Judes, G., A. Dagdemir, S. Karsli-Ceppioglu, A. Lebert, M. Echegut, M. Ngollo, Y. J. 
Bignon, F. Penault-Llorca and D. Bernard-Gallon (2016). "H3K4 acetylation, H3K9 
acetylation and H3K27 methylation in breast tumor molecular subtypes." Epigenomics 
8(7): 909-924. 
Kang, D., H. S. Cho, G. Toyokawa, M. Kogure, Y. Yamane, Y. Iwai, S. Hayami, T. 
Tsunoda, H. I. Field, K. Matsuda, D. E. Neal, B. A. Ponder, Y. Maehara, Y. Nakamura 
and R. Hamamoto (2013). "The histone methyltransferase Wolf-Hirschhorn syndrome 
candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis." Genes 
Chromosomes Cancer 52(2): 126-139. 
Kao, J., K. Salari, M. Bocanegra, Y. L. Choi, L. Girard, J. Gandhi, K. A. Kwei, T. 
Hernandez-Boussard, P. Wang, A. F. Gazdar, J. D. Minna and J. R. Pollack (2009). 
"Molecular profiling of breast cancer cell lines defines relevant tumor models and 
provides a resource for cancer gene discovery." PLoS One 4(7): e6146. 
Karlsson, E., M. A. Waltersson, J. Bostner, G. Perez-Tenorio, B. Olsson, A. L. Hallbeck 
and O. Stal (2011). "High-resolution genomic analysis of the 11q13 amplicon in breast 
cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 
4EBP1." Genes Chromosomes Cancer 50(10): 775-787. 
References Cited  Page | 147  
 
Katoh, M. (2016). "Mutation spectra of histone methyltransferases with canonical SET 
domains and EZH2-targeted therapy." Epigenomics 8(2): 285-305. 
Kawabe, Y., Y. X. Wang, I. W. McKinnell, M. T. Bedford and M. A. Rudnicki (2012). 
"Carm1 regulates Pax7 transcriptional activity through MLL1/2 recruitment during 
asymmetric satellite stem cell divisions." Cell Stem Cell 11(3): 333-345. 
Kerdivel, G., G. Flouriot and F. Pakdel (2013). "Modulation of estrogen receptor alpha 
activity and expression during breast cancer progression." Vitam Horm 93: 135-160. 
Kim, D., G. Pertea, C. Trapnell, H. Pimentel, R. Kelley and S. L. Salzberg (2013). 
"TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions 
and gene fusions." Genome Biol 14(4): R36. 
Kim, J. H., A. Sharma, S. S. Dhar, S. H. Lee, B. Gu, C. H. Chan, H. K. Lin and M. G. Lee 
(2014). "UTX and MLL4 coordinately regulate transcriptional programs for cell 
proliferation and invasiveness in breast cancer cells." Cancer Res 74(6): 1705-1717. 
Kim, S., S. Natesan, G. Cornilescu, S. Carlson, M. Tonelli, U. L. McClurg, O. Binda, C. 
N. Robson, J. L. Markley, S. Balaz and K. C. Glass (2016). "Mechanism of Histone 
H3K4me3 Recognition by the Plant Homeodomain of Inhibitor of Growth 3." J Biol Chem 
291(35): 18326-18341. 
Kim, S. M., H. J. Kee, N. Choe, J. Y. Kim, H. Kook, H. Kook and S. B. Seo (2007). "The 
histone methyltransferase activity of WHISTLE is important for the induction of apoptosis 
and HDAC1-mediated transcriptional repression." Exp Cell Res 313(5): 975-983. 
Knudsen, E. S. and A. K. Witkiewicz (2016). "Defining the transcriptional and biological 
response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer." Oncotarget 
7(43): 69111-69123. 
Kristensen, L. S., H. M. Nielsen and L. L. Hansen (2009). "Epigenetics and cancer 
treatment." Eur J Pharmacol 625(1-3): 131-142. 
Kristensen, V. N., T. Sorlie, J. Geisler, A. Langerod, N. Yoshimura, R. Karesen, N. 
Harada, P. E. Lonning and A. L. Borresen-Dale (2005). "Gene expression profiling of 
breast cancer in relation to estrogen receptor status and estrogen-metabolizing 
enzymes: clinical implications." Clin Cancer Res 11(2 Pt 2): 878s-883s. 
References Cited  Page | 148  
 
Kumar, R., D. Q. Li, S. Muller and S. Knapp (2016). "Epigenomic regulation of 
oncogenesis by chromatin remodeling." Oncogene 35(34): 4423-4436. 
Kumler, I., A. S. Knoop, C. A. Jessing, B. Ejlertsen and D. L. Nielsen (2016). "Review of 
hormone-based treatments in postmenopausal patients with advanced breast cancer 
focusing on aromatase inhibitors and fulvestrant." ESMO Open 1(4): e000062. 
Kuo, A. J., P. Cheung, K. Chen, B. M. Zee, M. Kioi, J. Lauring, Y. Xi, B. H. Park, X. Shi, 
B. A. Garcia, W. Li and O. Gozani (2011). "NSD2 links dimethylation of histone H3 at 
lysine 36 to oncogenic programming." Mol Cell 44(4): 609-620. 
Kwek, S. S., R. Roy, H. Zhou, J. Climent, J. A. Martinez-Climent, J. Fridlyand and D. G. 
Albertson (2009). "Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate 
with two major pathways in oncogenesis." Oncogene 28(17): 1892-1903. 
Li, Y., J. Han, Y. Zhang, F. Cao, Z. Liu, S. Li, J. Wu, C. Hu, Y. Wang, J. Shuai, J. Chen, 
L. Cao, D. Li, P. Shi, C. Tian, J. Zhang, Y. Dou, G. Li, Y. Chen and M. Lei (2016). 
"Structural basis for activity regulation of MLL family methyltransferases." Nature 
530(7591): 447-452. 
Li, Y., P. Trojer, C. F. Xu, P. Cheung, A. Kuo, W. J. Drury, 3rd, Q. Qiao, T. A. Neubert, 
R. M. Xu, O. Gozani and D. Reinberg (2009). "The target of the NSD family of histone 
lysine methyltransferases depends on the nature of the substrate." J Biol Chem 284(49): 
34283-34295. 
Lim, E., G. Tarulli, N. Portman, T. E. Hickey, W. D. Tilley and C. Palmieri (2016). 
"Pushing estrogen receptor around in breast cancer." Endocr Relat Cancer 23(12): 
T227-T241. 
Lin, I. H., D. T. Chen, Y. F. Chang, Y. L. Lee, C. H. Su, C. Cheng, Y. C. Tsai, S. C. Ng, 
H. T. Chen, M. C. Lee, H. W. Chen, S. H. Suen, Y. C. Chen, T. T. Liu, C. H. Chang and 
M. T. Hsu (2015). "Hierarchical clustering of breast cancer methylomes revealed 
differentially methylated and expressed breast cancer genes." PLoS One 10(2): 
e0118453. 
Liu, G., A. Bollig-Fischer, B. Kreike, M. J. van de Vijver, J. Abrams, S. P. Ethier and Z. 
Q. Yang (2009). "Genomic amplification and oncogenic properties of the GASC1 histone 
demethylase gene in breast cancer." Oncogene 28(50): 4491-4500. 
References Cited  Page | 149  
 
Liu, L., S. Kimball, H. Liu, A. Holowatyj and Z. Q. Yang (2014). "Genetic alterations of 
histone lysine methyltransferases and their significance in breast cancer." Oncotarget. 
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method." Methods 25(4): 
402-408. 
Lo, P. K. and S. Sukumar (2008). "Epigenomics and breast cancer." Pharmacogenomics 
9(12): 1879-1902. 
Locke, W. J., E. Zotenko, C. Stirzaker, M. D. Robinson, R. A. Hinshelwood, A. Stone, R. 
R. Reddel, L. I. Huschtscha and S. J. Clark (2015). "Coordinated epigenetic remodelling 
of transcriptional networks occurs during early breast carcinogenesis." Clin Epigenetics 
7: 52. 
Loi, S., C. Sotiriou, B. Haibe-Kains, F. Lallemand, N. M. Conus, M. J. Piccart, T. P. 
Speed and G. A. McArthur (2009). "Gene expression profiling identifies activated growth 
factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer." 
BMC Med Genomics 2: 37. 
Lonning, P. E., T. Sorlie and A. L. Borresen-Dale (2005). "Genomics in breast cancer-
therapeutic implications." Nat Clin Pract Oncol 2(1): 26-33. 
Love, M. I., W. Huber and S. Anders (2014). "Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2." Genome Biol 15(12): 550. 
Lumachi, F., D. A. Santeufemia and S. M. Basso (2015). "Current medical treatment of 
estrogen receptor-positive breast cancer." World J Biol Chem 6(3): 231-239. 
Luo, J., S. Liu, S. Leung, A. A. Gru, Y. Tao, J. Hoog, J. Ho, S. R. Davies, D. C. Allred, A. 
L. Salavaggione, J. Snider, E. R. Mardis, T. O. Nielsen and M. J. Ellis (2017). "An mRNA 
Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-
Positive Breast Tumors." J Mol Diagn 19(1): 147-161. 
Luscher-Firzlaff, J., I. Gawlista, J. Vervoorts, K. Kapelle, T. Braunschweig, G. 
Walsemann, C. Rodgarkia-Schamberger, H. Schuchlautz, S. Dreschers, E. Kremmer, R. 
Lilischkis, C. Cerni, A. Wellmann and B. Luscher (2008). "The human trithorax protein 
hASH2 functions as an oncoprotein." Cancer Res 68(3): 749-758. 
References Cited  Page | 150  
 
Lustberg, M. B. and B. Ramaswamy (2009). "Epigenetic targeting in breast cancer: 
therapeutic impact and future direction." Drug News Perspect 22(7): 369-381. 
Lustberg, M. B. and B. Ramaswamy (2011). "Epigenetic Therapy in Breast Cancer." 
Curr Breast Cancer Rep 3(1): 34-43. 
Mahmood, S. F., N. Gruel, R. Nicolle, E. Chapeaublanc, O. Delattre, F. Radvanyi and I. 
Bernard-Pierrot (2013). "PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 
amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung 
tumors." Am J Pathol 183(5): 1634-1644. 
Mancuso, M. R. and S. A. Massarweh (2016). "Endocrine therapy and strategies to 
overcome therapeutic resistance in breast cancer." Curr Probl Cancer 40(2-4): 95-105. 
Mann, K. M., J. M. Ward, C. C. Yew, A. Kovochich, D. W. Dawson, M. A. Black, B. T. 
Brett, T. E. Sheetz, A. J. Dupuy, D. K. Chang, A. V. Biankin, N. Waddell, K. S. Kassahn, 
S. M. Grimmond, A. G. Rust, D. J. Adams, N. A. Jenkins and N. G. Copeland (2012). 
"Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in 
pancreatic adenocarcinoma." Proc Natl Acad Sci U S A 109(16): 5934-5941. 
Margueron, R., V. Duong, A. Castet and V. Cavailles (2004). "Histone deacetylase 
inhibition and estrogen signalling in human breast cancer cells." Biochem Pharmacol 
68(6): 1239-1246. 
McKeage, K., M. P. Curran and G. L. Plosker (2004). "Fulvestrant: a review of its use in 
hormone receptor-positive metastatic breast cancer in postmenopausal women with 
disease progression following antiestrogen therapy." Drugs 64(6): 633-648. 
Melchor, L., M. J. Garcia, E. Honrado, J. C. Pole, S. Alvarez, P. A. Edwards, C. Caldas, 
J. D. Brenton and J. Benitez (2007). "Genomic analysis of the 8p11-12 amplicon in 
familial breast cancer." Int J Cancer 120(3): 714-717. 
Messier, T. L., J. A. Gordon, J. R. Boyd, C. E. Tye, G. Browne, J. L. Stein, J. B. Lian and 
G. S. Stein (2016). "Histone H3 lysine 4 acetylation and methylation dynamics define 
breast cancer subtypes." Oncotarget 7(5): 5094-5109. 
Michalak, E. M. and J. E. Visvader (2016). "Dysregulation of histone methyltransferases 
in breast cancer - Opportunities for new targeted therapies?" Mol Oncol 10(10): 1497-
1515. 
References Cited  Page | 151  
 
Miller, W. R., A. Larionov, L. Renshaw, T. J. Anderson, J. R. Walker, A. Krause, T. Sing, 
D. B. Evans and J. M. Dixon (2009). "Gene expression profiles differentiating between 
breast cancers clinically responsive or resistant to letrozole." J Clin Oncol 27(9): 1382-
1387. 
Miyamoto, K. and T. Ushijima (2005). "Diagnostic and therapeutic applications of 
epigenetics." Jpn J Clin Oncol 35(6): 293-301. 
Mohammed, H., I. A. Russell, R. Stark, O. M. Rueda, T. E. Hickey, G. A. Tarulli, A. A. 
Serandour, S. N. Birrell, A. Bruna, A. Saadi, S. Menon, J. Hadfield, M. Pugh, G. V. Raj, 
G. D. Brown, C. D'Santos, J. L. Robinson, G. Silva, R. Launchbury, C. M. Perou, J. 
Stingl, C. Caldas, W. D. Tilley and J. S. Carroll (2015). "Progesterone receptor 
modulates ERalpha action in breast cancer." Nature 523(7560): 313-317. 
Morishita, M. and E. di Luccio (2011). "Cancers and the NSD family of histone lysine 
methyltransferases." Biochim Biophys Acta 1816(2): 158-163. 
Morishita, M. and E. di Luccio (2011). "Structural insights into the regulation and the 
recognition of histone marks by the SET domain of NSD1." Biochem Biophys Res 
Commun 412(2): 214-219. 
Morishita, M., D. Mevius and E. di Luccio (2014). "In vitro histone lysine methylation by 
NSD1, NSD2/MMSET/WHSC1, and NSD3/WHSC1L." BMC Struct Biol 14(1): 25. 
Morris, C. and A. Wakeling (2002). "Fulvestrant ('Faslodex')--a new treatment option for 
patients progressing on prior endocrine therapy." Endocr Relat Cancer 9(4): 267-276. 
Morris, S. R. and L. A. Carey (2007). "Molecular profiling in breast cancer." Rev Endocr 
Metab Disord 8(3): 185-198. 
Mungamuri, S. K., S. Wang, J. J. Manfredi, W. Gu and S. A. Aaronson (2015). "Ash2L 
enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex 
formation on its pro-apoptotic target promoters." Oncogene 34(19): 2461-2470. 
Nagamatsu, G., S. Saito, T. Kosaka, K. Takubo, T. Kinoshita, M. Oya, K. Horimoto and 
T. Suda (2012). "Optimal ratio of transcription factors for somatic cell reprogramming." J 
Biol Chem 287(43): 36273-36282. 
References Cited  Page | 152  
 
Nagaraj, G. and C. Ma (2015). "Revisiting the estrogen receptor pathway and its role in 
endocrine therapy for postmenopausal women with estrogen receptor-positive 
metastatic breast cancer." Breast Cancer Res Treat 150(2): 231-242. 
Nagarajan, S., E. Benito, A. Fischer and S. A. Johnsen (2015). "H4K12ac is regulated by 
estrogen receptor-alpha and is associated with BRD4 function and inducible 
transcription." Oncotarget 6(9): 7305-7317. 
Netanely, D., A. Avraham, A. Ben-Baruch, E. Evron and R. Shamir (2016). "Expression 
and methylation patterns partition luminal-A breast tumors into distinct prognostic 
subgroups." Breast Cancer Res 18(1): 74. 
Nguyen, P., G. Bar-Sela, L. Sun, K. S. Bisht, H. Cui, E. Kohn, A. P. Feinberg and D. 
Gius (2008). "BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 
histone dimethylation and gene expression." Mol Cell Biol 28(21): 6720-6729. 
Nicholson, R. I. and S. R. Johnston (2005). "Endocrine therapy--current benefits and 
limitations." Breast Cancer Res Treat 93 Suppl 1: S3-10. 
Noberini, R. and T. Bonaldi (2017). "A Super-SILAC Strategy for the Accurate and 
Multiplexed Profiling of Histone Posttranslational Modifications." Methods Enzymol 586: 
311-332. 
Osmanbeyoglu, H. U., R. Pelossof, J. F. Bromberg and C. S. Leslie (2014). "Linking 
signaling pathways to transcriptional programs in breast cancer." Genome Res 24(11): 
1869-1880. 
Paska, A. V. and P. Hudler (2015). "Aberrant methylation patterns in cancer: a clinical 
view." Biochem Med (Zagreb) 25(2): 161-176. 
Patel, A., V. Dharmarajan, V. E. Vought and M. S. Cosgrove (2009). "On the mechanism 
of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) 
core complex." J Biol Chem 284(36): 24242-24256. 
Patel, A., V. E. Vought, V. Dharmarajan and M. S. Cosgrove (2011). "A novel non-SET 
domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 
methylation by the mixed lineage leukemia protein-1 (MLL1) core complex." J Biol Chem 
286(5): 3359-3369. 
References Cited  Page | 153  
 
Patel, A., V. E. Vought, S. Swatkoski, S. Viggiano, B. Howard, V. Dharmarajan, K. E. 
Monteith, G. Kupakuwana, K. E. Namitz, S. A. Shinsky, R. J. Cotter and M. S. Cosgrove 
(2014). "Automethylation activities within the mixed lineage leukemia-1 (MLL1) core 
complex reveal evidence supporting a "two-active site" model for multiple histone H3 
lysine 4 methylation." J Biol Chem 289(2): 868-884. 
Pathiraja, T. N., V. Stearns and S. Oesterreich (2010). "Epigenetic regulation in estrogen 
receptor positive breast cancer--role in treatment response." J Mammary Gland Biol 
Neoplasia 15(1): 35-47. 
Perou, C. M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. 
Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. 
Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown and D. Botstein 
(2000). "Molecular portraits of human breast tumours." Nature 406(6797): 747-752. 
Pritchard, K. I. (2013). "Endocrine therapy: is the first generation of targeted drugs the 
last?" J Intern Med 274(2): 144-152. 
Pullirsch, D., R. Hartel, H. Kishimoto, M. Leeb, G. Steiner and A. Wutz (2010). "The 
Trithorax group protein Ash2l and Saf-A are recruited to the inactive X chromosome at 
the onset of stable X inactivation." Development 137(6): 935-943. 
Qi, J., L. Huo, Y. T. Zhu and Y. J. Zhu (2014). "Absent, small or homeotic 2-like protein 
(ASH2L) enhances the transcription of the estrogen receptor alpha gene through GATA-
binding protein 3 (GATA3)." J Biol Chem 289(45): 31373-31381. 
Rahman, S., M. E. Sowa, M. Ottinger, J. A. Smith, Y. Shi, J. W. Harper and P. M. 
Howley (2011). "The Brd4 extraterminal domain confers transcription activation 
independent of pTEFb by recruiting multiple proteins, including NSD3." Mol Cell Biol 
31(13): 2641-2652. 
Raica, M., I. Jung, A. M. Cimpean, C. Suciu and A. M. Muresan (2009). "From 
conventional pathologic diagnosis to the molecular classification of breast carcinoma: 
are we ready for the change?" Rom J Morphol Embryol 50(1): 5-13. 
Rakha, E. A. and A. R. Green (2017). "Molecular classification of breast cancer: what the 
pathologist needs to know." Pathology 49(2): 111-119. 
Rampalli, S., L. Li, E. Mak, K. Ge, M. Brand, S. J. Tapscott and F. J. Dilworth (2007). 
"p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase 
References Cited  Page | 154  
 
complexes to specific genes during differentiation." Nat Struct Mol Biol 14(12): 1150-
1156. 
Ray, M. E., Z. Q. Yang, D. Albertson, C. G. Kleer, J. G. Washburn, J. A. Macoska and S. 
P. Ethier (2004). "Genomic and expression analysis of the 8p11-12 amplicon in human 
breast cancer cell lines." Cancer Res 64(1): 40-47. 
Reis-Filho, J. S. and L. Pusztai (2011). "Gene expression profiling in breast cancer: 
classification, prognostication, and prediction." Lancet 378(9805): 1812-1823. 
Reis-Filho, J. S., P. T. Simpson, N. C. Turner, M. B. Lambros, C. Jones, A. Mackay, A. 
Grigoriadis, D. Sarrio, K. Savage, T. Dexter, M. Iravani, K. Fenwick, B. Weber, D. 
Hardisson, F. C. Schmitt, J. Palacios, S. R. Lakhani and A. Ashworth (2006). "FGFR1 
emerges as a potential therapeutic target for lobular breast carcinomas." Clin Cancer 
Res 12(22): 6652-6662. 
Reynisdottir, I., A. Arason, B. O. Einarsdottir, H. Gunnarsson, J. Staaf, J. Vallon-
Christersson, G. Jonsson, M. Ringner, B. A. Agnarsson, K. Olafsdottir, R. Fagerholm, T. 
Einarsdottir, G. Johannesdottir, O. T. Johannsson, H. Nevanlinna, A. Borg and R. B. 
Barkardottir (2013). "High expression of ZNF703 independent of amplification indicates 
worse prognosis in patients with luminal B breast cancer." Cancer Med 2(4): 437-446. 
Rijnkels, M., E. Kabotyanski, M. B. Montazer-Torbati, C. Hue Beauvais, Y. Vassetzky, J. 
M. Rosen and E. Devinoy (2010). "The epigenetic landscape of mammary gland 
development and functional differentiation." J Mammary Gland Biol Neoplasia 15(1): 85-
100. 
Robertson, J. F. (2007). "Fulvestrant (Faslodex) -- how to make a good drug better." 
Oncologist 12(7): 774-784. 
Robertson, J. F., J. Lindemann, S. Garnett, E. Anderson, R. I. Nicholson, I. Kuter and J. 
M. Gee (2014). "A good drug made better: the fulvestrant dose-response story." Clin 
Breast Cancer 14(6): 381-389. 
Rosati, R., R. La Starza, A. Veronese, A. Aventin, C. Schwienbacher, T. Vallespi, M. 
Negrini, M. F. Martelli and C. Mecucci (2002). "NUP98 is fused to the NSD3 gene in 
acute myeloid leukemia associated with t(8;11)(p11.2;p15)." Blood 99(10): 3857-3860. 
Ross-Innes, C. S., R. Stark, A. E. Teschendorff, K. A. Holmes, H. R. Ali, M. J. Dunning, 
G. D. Brown, O. Gojis, I. O. Ellis, A. R. Green, S. Ali, S. F. Chin, C. Palmieri, C. Caldas 
References Cited  Page | 155  
 
and J. S. Carroll (2012). "Differential oestrogen receptor binding is associated with 
clinical outcome in breast cancer." Nature 481(7381): 389-393. 
Saloura, V., T. Vougiouklakis, M. Zewde, X. Deng, K. Kiyotani, J. H. Park, Y. Matsuo, M. 
Lingen, T. Suzuki, N. Dohmae, R. Hamamoto and Y. Nakamura (2017). "WHSC1L1-
mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic 
activity of EGFR in head and neck cancer." Sci Rep 7: 40664. 
Saloura, V., T. Vougiouklakis, M. Zewde, K. Kiyotani, J. H. Park, G. Gao, T. Karrison, M. 
Lingen, Y. Nakamura and R. Hamamoto (2016). "WHSC1L1 drives cell cycle 
progression through transcriptional regulation of CDC6 and CDK2 in squamous cell 
carcinoma of the head and neck." Oncotarget 7(27): 42527-42538. 
Sato, T., M. Cesaroni, W. Chung, S. Panjarian, A. Tran, J. Madzo, Y. Okamoto, H. 
Zhang, X. Chen, J. Jelinek and J. J. Issa (2017). "Transcriptional Selectivity of 
Epigenetic Therapy in Cancer." Cancer Res 77(2): 470-481. 
Schiff, R., S. Massarweh, J. Shou and C. K. Osborne (2003). "Breast cancer endocrine 
resistance: how growth factor signaling and estrogen receptor coregulators modulate 
response." Clin Cancer Res 9(1 Pt 2): 447S-454S. 
Schram, A. W., R. Baas, P. W. Jansen, A. Riss, L. Tora, M. Vermeulen and H. T. 
Timmers (2013). "A dual role for SAGA-associated factor 29 (SGF29) in ER stress 
survival by coordination of both histone H3 acetylation and histone H3 lysine-4 
trimethylation." PLoS One 8(7): e70035. 
Scott, S. M., M. Brown and S. E. Come (2011). "Emerging data on the efficacy and 
safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer." Expert 
Opin Drug Saf 10(5): 819-826. 
Selli, C., J. M. Dixon and A. H. Sims (2016). "Accurate prediction of response to 
endocrine therapy in breast cancer patients: current and future biomarkers." Breast 
Cancer Res 18(1): 118. 
Shan, L., X. Li, L. Liu, X. Ding, Q. Wang, Y. Zheng, Y. Duan, C. Xuan, Y. Wang, F. 
Yang, Y. Shang and L. Shi (2014). "GATA3 cooperates with PARP1 to regulate CCND1 
transcription through modulating histone H1 incorporation." Oncogene 33(24): 3205-
3216. 
References Cited  Page | 156  
 
Shen, C., J. J. Ipsaro, J. Shi, J. P. Milazzo, E. Wang, J. S. Roe, Y. Suzuki, D. J. Pappin, 
L. Joshua-Tor and C. R. Vakoc (2015). "NSD3-Short Is an Adaptor Protein that Couples 
BRD4 to the CHD8 Chromatin Remodeler." Mol Cell 60(6): 847-859. 
Shiu, K. K., R. Natrajan, F. C. Geyer, A. Ashworth and J. S. Reis-Filho (2010). "DNA 
amplifications in breast cancer: genotypic-phenotypic correlations." Future Oncol 6(6): 
967-984. 
Simon, J. A. and C. A. Lange (2008). "Roles of the EZH2 histone methyltransferase in 
cancer epigenetics." Mutat Res 647(1-2): 21-29. 
Sircoulomb, F., N. Nicolas, A. Ferrari, P. Finetti, I. Bekhouche, E. Rousselet, A. Lonigro, 
J. Adelaide, E. Baudelet, S. Esteyries, J. Wicinski, S. Audebert, E. Charafe-Jauffret, J. 
Jacquemier, M. Lopez, J. P. Borg, C. Sotiriou, C. Popovici, F. Bertucci, D. Birnbaum, M. 
Chaffanet and C. Ginestier (2011). "ZNF703 gene amplification at 8p12 specifies luminal 
B breast cancer." EMBO Mol Med 3(3): 153-166. 
Sorlie, T., C. M. Perou, C. Fan, S. Geisler, T. Aas, A. Nobel, G. Anker, L. A. Akslen, D. 
Botstein, A. L. Borresen-Dale and P. E. Lonning (2006). "Gene expression profiles do 
not consistently predict the clinical treatment response in locally advanced breast 
cancer." Mol Cancer Ther 5(11): 2914-2918. 
Sorlie, T., C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. 
Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. 
Botstein, P. E. Lonning and A. L. Borresen-Dale (2001). "Gene expression patterns of 
breast carcinomas distinguish tumor subclasses with clinical implications." Proc Natl 
Acad Sci U S A 98(19): 10869-10874. 
Sorlie, T., R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. 
Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A. 
L. Borresen-Dale and D. Botstein (2003). "Repeated observation of breast tumor 
subtypes in independent gene expression data sets." Proc Natl Acad Sci U S A 100(14): 
8418-8423. 
Sotiriou, C., S. Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. 
B. Fox, A. L. Harris and E. T. Liu (2003). "Breast cancer classification and prognosis 
based on gene expression profiles from a population-based study." Proc Natl Acad Sci U 
S A 100(18): 10393-10398. 
References Cited  Page | 157  
 
Southall, S. M., P. S. Wong, Z. Odho, S. M. Roe and J. R. Wilson (2009). "Structural 
basis for the requirement of additional factors for MLL1 SET domain activity and 
recognition of epigenetic marks." Mol Cell 33(2): 181-191. 
Souza, P. P., P. Volkel, D. Trinel, J. Vandamme, C. Rosnoblet, L. Heliot and P. O. 
Angrand (2009). "The histone methyltransferase SUV420H2 and Heterochromatin 
Proteins HP1 interact but show different dynamic behaviours." BMC Cell Biol 10: 41. 
Stec, I., G. J. van Ommen and J. T. den Dunnen (2001). "WHSC1L1, on human 
chromosome 8p11.2, closely resembles WHSC1 and maps to a duplicated region 
shared with 4p16.3." Genomics 76(1-3): 5-8. 
Steelman, L. S., A. M. Martelli, L. Cocco, M. Libra, F. Nicoletti, S. L. Abrams and J. A. 
McCubrey (2016). "The therapeutic potential of mTOR inhibitors in breast cancer." Br J 
Clin Pharmacol 82(5): 1189-1212. 
Steward, M. M., J. S. Lee, A. O'Donovan, M. Wyatt, B. E. Bernstein and A. Shilatifard 
(2006). "Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL 
complexes." Nat Struct Mol Biol 13(9): 852-854. 
Still, I. H., M. Hamilton, P. Vince, A. Wolfman and J. K. Cowell (1999). "Cloning of 
TACC1, an embryonically expressed, potentially transforming coiled coil containing 
gene, from the 8p11 breast cancer amplicon." Oncogene 18(27): 4032-4038. 
Streicher, K. L., Z. Q. Yang, S. Draghici and S. P. Ethier (2007). "Transforming function 
of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon." Oncogene 
26(14): 2104-2114. 
Suzuki, S., N. Kurabe, I. Ohnishi, K. Yasuda, Y. Aoshima, M. Naito, F. Tanioka and H. 
Sugimura (2015). "NSD3-NUT-expressing midline carcinoma of the lung: first 
characterization of primary cancer tissue." Pathol Res Pract 211(5): 404-408. 
Tabarestani, S., M. Motallebi and M. E. Akbari (2016). "Are Estrogen Receptor Genomic 
Aberrations Predictive of Hormone Therapy Response in Breast Cancer?" Iran J Cancer 
Prev 9(4): e6565. 
Taketani, T., T. Taki, H. Nakamura, M. Taniwaki, J. Masuda and Y. Hayashi (2009). 
"NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with 
t(8;11)(p11;p15) and expression pattern of NSD family genes." Cancer Genet Cytogenet 
190(2): 108-112. 
References Cited  Page | 158  
 
Tan, C. C., K. V. Sindhu, S. Li, H. Nishio, J. Z. Stoller, K. Oishi, S. Puttreddy, T. J. Lee, 
J. A. Epstein, M. J. Walsh and B. D. Gelb (2008). "Transcription factor Ap2delta 
associates with Ash2l and ALR, a trithorax family histone methyltransferase, to activate 
Hoxc8 transcription." Proc Natl Acad Sci U S A 105(21): 7472-7477. 
Tan, C. C., M. J. Walsh and B. D. Gelb (2009). "Fgfr3 is a transcriptional target of 
Ap2delta and Ash2l-containing histone methyltransferase complexes." PLoS One 4(12): 
e8535. 
Tang, P. and G. M. Tse (2016). "Immunohistochemical Surrogates for Molecular 
Classification of Breast Carcinoma: A 2015 Update." Arch Pathol Lab Med 140(8): 806-
814. 
Thomas, S. and P. N. Munster (2009). "Histone deacetylase inhibitor induced modulation 
of anti-estrogen therapy." Cancer Lett 280(2): 184-191. 
Turner-Ivey, B., S. T. Guest, J. C. Irish, C. S. Kappler, E. Garrett-Mayer, R. C. Wilson 
and S. P. Ethier (2014). "KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a 
candidate oncogene in luminal breast cancer." Neoplasia 16(8): 644-655. 
Turner-Ivey, B., E. L. Smith, A. C. Rutkovsky, L. S. Spruill, J. N. Mills and S. P. Ethier 
(2017). "Development of mammary hyperplasia, dysplasia, and invasive ductal 
carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3." Breast 
Cancer Res Treat. 
Turner, N., A. Pearson, R. Sharpe, M. Lambros, F. Geyer, M. A. Lopez-Garcia, R. 
Natrajan, C. Marchio, E. Iorns, A. Mackay, C. Gillett, A. Grigoriadis, A. Tutt, J. S. Reis-
Filho and A. Ashworth (2010). "FGFR1 amplification drives endocrine therapy resistance 
and is a therapeutic target in breast cancer." Cancer Res 70(5): 2085-2094. 
Turner, N. C., J. Ro, F. Andre, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, C. 
Huang Bartlett, K. Zhang, C. Giorgetti, S. Randolph, M. Koehler and M. Cristofanilli 
(2015). "Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer." N Engl J 
Med 373(3): 209-219. 
Ullius, A., J. Luscher-Firzlaff, I. G. Costa, G. Walsemann, A. H. Forst, E. G. Gusmao, K. 
Kapelle, H. Kleine, E. Kremmer, J. Vervoorts and B. Luscher (2014). "The interaction of 
MYC with the trithorax protein ASH2L promotes gene transcription by regulating H3K27 
modification." Nucleic Acids Res 42(11): 6901-6920. 
References Cited  Page | 159  
 
van 't Veer, L. J., H. Dai, M. J. van de Vijver, Y. D. He, A. A. Hart, M. Mao, H. L. Peterse, 
K. van der Kooy, M. J. Marton, A. T. Witteveen, G. J. Schreiber, R. M. Kerkhoven, C. 
Roberts, P. S. Linsley, R. Bernards and S. H. Friend (2002). "Gene expression profiling 
predicts clinical outcome of breast cancer." Nature 415(6871): 530-536. 
Vedadi, M., L. Blazer, M. S. Eram, D. Barsyte-Lovejoy, C. H. Arrowsmith and T. Hajian 
(2017). "Targeting human SET1/MLL family of proteins." Protein Sci. 
Veeck, J. and M. Esteller (2010). "Breast cancer epigenetics: from DNA methylation to 
microRNAs." J Mammary Gland Biol Neoplasia 15(1): 5-17. 
Wagner, E. J. and P. B. Carpenter (2012). "Understanding the language of Lys36 
methylation at histone H3." Nat Rev Mol Cell Biol 13(2): 115-126. 
Walsh, L., W. M. Gallagher, D. P. O'Connor and T. Ni Chonghaile (2016). "Diagnostic 
and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer." Expert 
Rev Mol Diagn 16(5): 541-551. 
Wan, M., J. Liang, Y. Xiong, F. Shi, Y. Zhang, W. Lu, Q. He, D. Yang, R. Chen, D. Liu, 
M. Barton and Z. Songyang (2013). "The trithorax group protein Ash2l is essential for 
pluripotency and maintaining open chromatin in embryonic stem cells." J Biol Chem 
288(7): 5039-5048. 
Wang, G., G. Liu, X. Wang, S. Sethi, R. Ali-Fehmi, J. Abrams, Z. Zheng, K. Zhang, S. 
Ethier and Z. Q. Yang (2012). "ERLIN2 promotes breast cancer cell survival by 
modulating endoplasmic reticulum stress pathways." BMC Cancer 12: 225. 
Wang, G. G., L. Cai, M. P. Pasillas and M. P. Kamps (2007). "NUP98-NSD1 links H3K36 
methylation to Hox-A gene activation and leukaemogenesis." Nat Cell Biol 9(7): 804-812. 
Wang, J., Y. Zhou, B. Yin, G. Du, X. Huang, G. Li, Y. Shen, J. Yuan and B. Qiang 
(2001). "ASH2L: alternative splicing and downregulation during induced megakaryocytic 
differentiation of multipotential leukemia cell lines." J Mol Med (Berl) 79(7): 399-405. 
Wang, Z. Y. and L. Yin (2015). "Estrogen receptor alpha-36 (ER-alpha36): A new player 
in human breast cancer." Mol Cell Endocrinol 418 Pt 3: 193-206. 
References Cited  Page | 160  
 
Wen, H., Y. Li, Y. Xi, S. Jiang, S. Stratton, D. Peng, K. Tanaka, Y. Ren, Z. Xia, J. Wu, B. 
Li, M. C. Barton, W. Li, H. Li and X. Shi (2014). "ZMYND11 links histone H3.3K36me3 to 
transcription elongation and tumour suppression." Nature 508(7495): 263-268. 
Wesierska-Gadek, J., T. Schreiner, M. Gueorguieva and C. Ranftler (2006). "Phenol red 
reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells." J Cell 
Biochem 98(6): 1367-1379. 
Wu, H., J. Min, V. V. Lunin, T. Antoshenko, L. Dombrovski, H. Zeng, A. Allali-Hassani, V. 
Campagna-Slater, M. Vedadi, C. H. Arrowsmith, A. N. Plotnikov and M. Schapira (2010). 
"Structural biology of human H3K9 methyltransferases." PLoS One 5(1): e8570. 
Wu, J., S. Liu, G. Liu, A. Dombkowski, J. Abrams, R. Martin-Trevino, M. S. Wicha, S. P. 
Ethier and Z. Q. Yang (2012). "Identification and functional analysis of 9p24 amplified 
genes in human breast cancer." Oncogene 31(3): 333-341. 
Xiao, Y., C. Bedet, V. J. Robert, T. Simonet, S. Dunkelbarger, C. Rakotomalala, G. 
Soete, H. C. Korswagen, S. Strome and F. Palladino (2011). "Caenorhabditis elegans 
chromatin-associated proteins SET-2 and ASH-2 are differentially required for histone 
H3 Lys 4 methylation in embryos and adult germ cells." Proc Natl Acad Sci U S A 
108(20): 8305-8310. 
Yang, Y. H., S. Dudoit, P. Luu, D. M. Lin, V. Peng, J. Ngai and T. P. Speed (2002). 
"Normalization for cDNA microarray data: a robust composite method addressing single 
and multiple slide systematic variation." Nucleic Acids Res 30(4): e15. 
Yang, Z. Q., D. Albertson and S. P. Ethier (2004). "Genomic organization of the 8p11-
p12 amplicon in three breast cancer cell lines." Cancer Genet Cytogenet 155(1): 57-62. 
Yang, Z. Q., G. Liu, A. Bollig-Fischer, C. N. Giroux and S. P. Ethier (2010). 
"Transforming properties of 8p11-12 amplified genes in human breast cancer." Cancer 
Res 70(21): 8487-8497. 
Yang, Z. Q., G. Liu, A. Bollig-Fischer, R. Haddad, A. L. Tarca and S. P. Ethier (2009). 
"Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits 
canonical and non-canonical WNT pathways in breast cancers." Int J Cancer 125(7): 
1613-1621. 
References Cited  Page | 161  
 
Yang, Z. Q., K. L. Streicher, M. E. Ray, J. Abrams and S. P. Ethier (2006). "Multiple 
interacting oncogenes on the 8p11-p12 amplicon in human breast cancer." Cancer Res 
66(24): 11632-11643. 
Yates, J. A., T. Menon, B. A. Thompson and D. A. Bochar (2010). "Regulation of HOXA2 
gene expression by the ATP-dependent chromatin remodeling enzyme CHD8." FEBS 
Lett 584(4): 689-693. 
Yuan, W., M. Xu, C. Huang, N. Liu, S. Chen and B. Zhu (2011). "H3K36 methylation 
antagonizes PRC2-mediated H3K27 methylation." J Biol Chem 286(10): 7983-7989. 
Zhang, Q., L. Zeng, C. Shen, Y. Ju, T. Konuma, C. Zhao, C. R. Vakoc and M. M. Zhou 
(2016). "Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET 
Domain of BRD4." Structure 24(7): 1201-1208. 
Zhang, X., X. Mu, O. Huang, Z. Xie, M. Jiang, M. Geng and K. Shen (2013). "Luminal 
breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through 
activation of Akt/mTOR signaling." PLoS One 8(8): e72053. 
Zhang, X., K. Tanaka, J. Yan, J. Li, D. Peng, Y. Jiang, Z. Yang, M. C. Barton, H. Wen 
and X. Shi (2013). "Regulation of estrogen receptor alpha by histone methyltransferase 
SMYD2-mediated protein methylation." Proc Natl Acad Sci U S A 110(43): 17284-17289. 
Zhang, Y., T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson, B. E. Bernstein, C. 
Nusbaum, R. M. Myers, M. Brown, W. Li and X. S. Liu (2008). "Model-based analysis of 
ChIP-Seq (MACS)." Genome Biol 9(9): R137. 
Zhou, Z., R. Thomsen, S. Kahns and A. L. Nielsen (2010). "The NSD3L histone 
methyltransferase regulates cell cycle and cell invasion in breast cancer cells." Biochem 
Biophys Res Commun 398(3): 565-570. 
Zhu, L., Q. Li, S. H. Wong, M. Huang, B. J. Klein, J. Shen, L. Ikenouye, M. Onishi, D. 
Schneidawind, C. Buechele, L. Hansen, J. Duque-Afonso, F. Zhu, G. M. Martin, O. 
Gozani, R. Majeti, T. G. Kutateladze and M. L. Cleary (2016). "ASH1L Links Histone H3 
Lysine 36 Dimethylation to MLL Leukemia." Cancer Discov 6(7): 770-783. 
Zou, J. X., Z. Duan, J. Wang, A. Sokolov, J. Xu, C. Z. Chen, J. J. Li and H. W. Chen 
(2014). "Kinesin family deregulation coordinated by bromodomain protein ANCCA and 
histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen 
resistance." Mol Cancer Res 12(4): 539-549. 
Appendix A      Page | 162  
 
APPENDIX A. NSD3-S and ESR1 knockdown microarray results. 
Immunoblots (lower right) for ERα and NSD3 (WH) following knockdown of ESR1 or 
NSD3, respectively, corresponding to microarray samples appear below. Venn Diagram 
represents genes in the ESR1 knockdown compared to LacZ control (left) or NSD3 
knockdown compared to LacZ control (right). Overlapping (left) or NSD3-unique (right) 
gene sets were analyzed in ToppFun to produce the tables found below the diagram. 
Full gene lists and associated statistical measures can be located 
at https://www.researchgate.net/profile/Jamie_Mills2/publications. File NSD3-short 
knockdown microarray DOI: 10.13140/RG.2.2.13586.25286 and file ESR1 knockdown 
microarray DOI: 10.13140/RG.2.2.11908.53126. 
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APPENDIX B. H3K4me3 ChIP-seq quality control and enrichment reports. 
Output from sequencing quality control measures appears in the table below. The figure 
represents Phred scores for the ChIP-seq sequencing run. All samples are nearly 
identical, therefore only one is presented (shASH2L-A-H3K4me3). Cross-correlation 
plots appear on page 208 and enrichment plots on page 209. 
Sample-Name Total Sequences Type # reads %GC 
2247_shASH2L-A-H3K4me3   28430917 ChIP 28387407 45 
2248_shASH2L-A-input    28847916 Input 28819172 41 
2249_shASH2L-B-H3K4me3   28142484 ChIP 28057625 43 
2250_shASH2L-B-input    35706228 Input 35668119 43 
2251_shASH2L-C-H3K4me3   35126397 ChIP 34986667 51 
2252_shASH2L-C-input    32529399 Input 32449969 43 
2253_shLacZ18-A-H3K4me3  32483014 ChIP 32393402 48 
2254_shLacZ18-A-input   33296775 Input 33219481 44 
2255_shLacZ19-B-H3K4me3  35198935 ChIP 35069303 49 
2256_shLacZ19-B-input   35411340 Input 35328228 43 
2257_shLacZ20-C-H3K4me3  34957285 ChIP 34835920 49 
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APPENDIX C. H3K4me3 ChIP-seq peak datasets: LacZ control and ASH2L knockdown. 
Output lists from MACS2 ChIP-seq analysis can be found 
at https://www.researchgate.net/profile/Jamie_Mills2/publications. File H3K4me3 ChIP-
seq MACS2 shLacZ DOI: 10.13140/RG.2.2.21345.71526 and file H3K4me3 ChIP-seq 
MACS2 shASH2L DOI: 10.13140/RG.2.2.28056.60162. 
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APPENDIX D. Gene Lists: overall H3K4me3 ChIP-seq peaks. 
Output lists from MACS2 ChIP-seq analysis Venn Diagrams comparing LacZ and 
ASH2L overall gene lists appear in this appendix. These lists correspond to Figure 3.2-
D but do not report the 13,090 genes in common.



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix E      Page | 179  
 
APPENDIX E. Gene Lists and ToppFun Analysis: promoter only H3K4me3 ChIP-seq 
peaks. 
Output lists from MACS2 ChIP-seq analysis Venn Diagrams comparing LacZ and 
ASH2L promoter peaks only gene lists appear in this appendix. These lists correspond 
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APPENDIX F. ASH2L knockdown RNA-seq results. 
RNA-seq results following knockdown of ASH2L with two shRNA constructs (275 and 
276). Sequencing read count data for each knockdown sample was compared to read 
count data for LacZ control. Genes were ranked by negative log2 Fold Change from 
control and can be found at 
https://www.researchgate.net/profile/Jamie_Mills2/publications. File ASH2L 275 
knockdown RNA-seq DOI: 10.13140/RG.2.2.36445.20967 and file ASH2L 276 
knockdown RNA-seq DOI: 10.13140/RG2.2.23652.58249.
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APPENDIX G. Gene lists and ToppFun analysis: ASH2L knockdown RNA-seq 
downregulated genes. 
The 3,278 genes in common between the two shRNA constructs, corresponding to 
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APPENDIX H. Gene lists and ToppFun analysis: ASH2L knockdown H3K4me3 ChIP-
seq and RNA-seq. 
The 438 genes in common between the ASH2L knockdown RNA-seq and H3K4me3 
ChIP-seq, corresponding to Figure 3.4-D, are reported below and ToppFun analysis on 
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APPENDIX I. Gene lists and ToppFun analysis: ASH2L, NSD3-S, and ESR1 knockdown 
expression analysis and ASH2L knockdown H3K4me3 ChIP-seq overlap. 
The 44 genes in common between the ASH2L knockdown RNA-seq and H3K4me3 
ChIP-seq and NSD3-S and ESR1 knockdown microarrays, corresponding to Figure 3.5-
C, are reported below and ToppFun analysis on these genes can be found at this 
link: https://toppgene.cchmc.org/output.jsp?userdata_id=be0407ac-a6be-4e45-b138-
28ef7cb260d7. 
The 320 genes that remain unique to the ASH2L knockdown RNA-seq and H3K4me3 
ChIP-seq group following the comparison in Figure 3.5-C also appear below and 
ToppFun analysis on these genes can be found at this 
link: https://toppgene.cchmc.org/output.jsp?userdata_id=69413b86-3639-4bd6-8210-
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AP2A1 
MIR4664 
SUPT5H 
ZNF473 
GPRIN1 
CEP112 
NXF1 
HNRNPUL1 
PPP1R10 
NEK11 
TBC1D5 
ZNF311 
MED16 
ADRB2 
CCDC74B 
DTYMK 
PLEKHH2 
HMG20B 
DCAF16 
ZMYM3 
HNRNPL 
ESCO2 
CECR5 
DLX1 
SEC16A 
TECR 
MIS18A 
ADARB1 
ALYREF 
RRP9 
TRIM32 
VRK3 
ZGRF1 
 
